Amneal Pharmaceuticals (AMRX) 10-K 14 Mar 24 2023 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Feb. 29, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-38485
Entity Registrant Name	Amneal Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	93-4225266
Entity Address, Address Line One	400 Crossing Boulevard
Entity Address, City or Town	Bridgewater
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08807
City Area Code	908
Local Phone Number	947-3120
Title of 12(b) Security	Class A Common Stock, par value $0.01 per share
Trading Symbol	AMRX
Security Exchange Name	NASDAQ
Entity Well-Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction Flag	false
Entity Shell Company	false
Entity Public Float			$ 464
Entity Common Stock, Shares Outstanding (in shares)		307,006,908
Documents Incorporated by Reference	Certain information required to be furnished pursuant to Part III of this Form 10-K will be set forth in, and is hereby incorporated by reference herein from, the registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders, to be filed by the registrant with the Securities and Exchange Commission pursuant to Regulation 14A no later than 120 days after December 31, 2023 (the “2024 Proxy Statement”).
Amendment Flag	false
Document Fiscal Period Focus	FY
Entity Central Index Key	0001723128
Document Fiscal Year Focus	2023

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2023
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Iselin, NJ
Auditor Firm ID	42

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net revenue	$ 2,393,607	$ 2,212,304	$ 2,093,669
Cost of goods sold	1,573,042	1,427,596	1,324,696
Gross profit	820,565	784,708	768,973
Selling, general and administrative	429,675	399,700	365,504
Research and development	163,950	195,688	201,847
In-process research and development impairment charges	30,800	12,970	710
Intellectual property legal development expenses	3,828	4,358	7,716
Acquisition, transaction-related and integration expenses	0	709	8,055
Restructuring and other charges	1,749	1,421	1,857
Change in fair value of contingent consideration	(14,497)	731	200
(Insurance recoveries) charges for property losses and associated expenses, net	0	(1,911)	5,368
Charges related to legal matters, net	1,824	269,930	25,000
Other operating income	(1,138)	(3,960)	0
Operating income (loss)	204,374	(94,928)	152,716
Other (expense) income:
Interest expense, net	(210,629)	(158,377)	(136,325)
Foreign exchange gain (loss), net	1,671	(12,364)	(355)
Loss on refinancing	(40,805)	(291)	0
Other income, net	5,119	17,833	15,330
Total other expense, net	(244,644)	(153,199)	(121,350)
(Loss) income before income taxes	(40,270)	(248,127)	31,366
Provision for income taxes	8,452	6,662	11,196
Net (loss) income	(48,722)	(254,789)	20,170
Less: Net (income) loss attributable to non-controlling interests	(35,271)	125,241	(9,546)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest	(83,993)	(129,548)	10,624
Accretion of redeemable non-controlling interest	0	(438)	0
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.	$ (83,993)	$ (129,986)	$ 10,624
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:
Basic (in dollars per share)	$ (0.48)	$ (0.86)	$ 0.07
Diluted (in dollars per share)	$ (0.48)	$ (0.86)	$ 0.07
Weighted-average common shares outstanding:
Basic (in shares)	176,136	150,944	148,922
Diluted (in shares)	176,136	150,944	151,821

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Other Comprehensive Income [Abstract]
Net (loss) income	$ (48,722)	$ (254,789)	$ 20,170
Less: Net (income) loss attributable to non-controlling interests	(35,271)	125,241	(9,546)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest	(83,993)	(129,548)	10,624
Accretion of redeemable non-controlling interest	0	(438)	0
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.	(83,993)	(129,986)	10,624
Other comprehensive (loss) income:
Foreign currency translation adjustments arising during the period	(1,059)	(26,891)	(8,618)
Unrealized (loss) gain on cash flow hedge, net of tax	(48,497)	97,059	42,430
Reclassification of cash flow hedge to earnings, net of tax	(3,366)	0	0
Less: Other comprehensive loss (income) attributable to non-controlling interests	9,875	(35,292)	(17,095)
Other comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc.	(43,047)	34,876	16,717
Comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc.	$ (127,040)	$ (95,110)	$ 27,341

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 91,542	$ 25,976
Restricted cash	7,565	9,251
Inventories	581,384	530,735
Prepaid expenses and other current assets	82,685	103,565
Total current assets	1,377,863	1,411,818
Property, plant and equipment, net	447,574	469,815
Goodwill	598,629	598,853
Intangible assets, net	890,423	1,096,093
Operating lease right-of-use assets	43,283	56,121
Other assets	55,517	103,217
Total assets	3,472,569	3,799,341
Current liabilities:
Current portion of liabilities for legal matters	76,988	107,483
Revolving credit facility	179,000	60,000
Current portion of long-term debt, net	34,125	29,961
Total current liabilities	846,595	752,800
Long-term debt, net	2,386,004	2,591,981
Note payable - related party	41,447	39,706
Total long-term liabilities	2,564,670	2,837,613
Commitments and contingencies (Notes 5 and 21)
Redeemable non-controlling interests	41,293	24,949
Stockholders’ equity:
Preferred stock, $0.01 par value, 2,000 shares authorized; none issued at both December 31, 2023 and 2022	0	0
Additional paid-in capital	539,240	691,629
Stockholders' accumulated deficit	(490,176)	(406,183)
Accumulated other comprehensive (loss) income	(32,349)	9,939
Total Amneal Pharmaceuticals, Inc. stockholders' equity	19,781	298,421
Non-controlling interests	230	(114,442)
Total stockholders' equity	20,011	183,979
Total liabilities and stockholders' equity	3,472,569	3,799,341
Common Class A
Stockholders’ equity:
Common stock	3,066	1,514
Common Class B
Stockholders’ equity:
Common stock	0	1,522
Nonrelated Party
Current assets:
Trade accounts receivable, net	613,732	741,791
Operating lease right-of-use assets	30,329	38,211
Financing lease right of use assets	59,280	63,424
Current liabilities:
Accounts payable and accrued expenses	534,662	538,199
Current portion of operating lease liabilities	9,207	8,321
Current portion of financing lease liabilities	2,467	3,488
Operating lease liabilities	24,095	32,126
Financing lease liabilities	58,566	60,769
Other long-term liabilities	29,995	87,468
Related Party
Current assets:
Trade accounts receivable, net	955	500
Operating lease right-of-use assets	12,954	17,910
Current liabilities:
Accounts payable and accrued expenses	7,321	2,479
Current portion of operating lease liabilities	2,825	2,869
Operating lease liabilities	12,787	15,914
Other long-term liabilities	$ 11,776	$ 9,649

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Class A Common Stock
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	900,000,000	900,000,000
Common stock, shares issued (in shares)	306,565,000	151,490,000
Class B Common Stock
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	0	152,117,000

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Kashiv Specialty Pharmaceuticals, LLC	Subsequent To Combination	Common Stock Old PubCo, Common Class A	Common Stock Old PubCo, Common Class B	Common Stock Class A Common Stock	Additional Paid-in Capital	Stockholders’ Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Non- Controlling Interests	Non- Controlling Interests Kashiv Specialty Pharmaceuticals, LLC	Non- Controlling Interests Subsequent To Combination
Shares beginning balance (in shares) at Dec. 31, 2020				147,674,000	152,117,000
Stockholders' equity beginning balance at Dec. 31, 2020	$ 344,932			$ 1,475	$ 1,522		$ 628,413	$ (286,821)	$ (41,318)	$ 41,661
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	13,163							10,624		2,539
Foreign currency translation adjustments	(8,618)								(4,255)	(4,363)
Stock-based compensation	$ 28,412						28,412
Exercise of stock options (in shares)	342,350			342,000
Exercise of stock options	$ 853			$ 3			901		(44)	(7)
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)				1,397,000
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	(2,713)			$ 14			624		(182)	(3,169)
Unrealized gain (loss) on cash flow hedge, net of tax	42,430								20,972	21,458
Tax distributions, net			$ (53,486)									$ (53,486)
Reclassification of cash flow hedge to earnings, net of tax	0
Acquisition of non-controlling interest		$ 2,000									$ 2,000
Shares ending balance (in shares) at Dec. 31, 2021				149,413,000	152,117,000
Stockholders' equity ending balance at Dec. 31, 2021	366,973			$ 1,492	$ 1,522		658,350	(276,197)	(24,827)	6,633
Redeemable non-controlling interest, beginning balance at Dec. 31, 2020	11,804
Increase (Decrease) in Temporary Equity [Roll Forward]
Net (loss) income	7,007
Tax distributions, net	(3,646)
Acquisition of non-controlling interest	1,742
Redeemable non-controlling interest, ending balance at Dec. 31, 2021	16,907
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(270,584)							(129,548)		(141,036)
Foreign currency translation adjustments	(26,891)								(13,394)	(13,497)
Stock-based compensation	$ 31,847						31,847
Exercise of stock options (in shares)	207,452			207,000
Exercise of stock options	$ 662			$ 2			615			45
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)				1,870,000
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	(3,562)			$ 20			817		(110)	(4,289)
Unrealized gain (loss) on cash flow hedge, net of tax	97,059								48,270	48,789
Tax distributions, net			(10,642)									(10,642)
Reclassification of cash flow hedge to earnings, net of tax	0
Reclassification of redeemable non-controlling interests	(883)							(438)		(445)
Shares ending balance (in shares) at Dec. 31, 2022				151,490,000	152,117,000
Stockholders' equity ending balance at Dec. 31, 2022	183,979			$ 1,514	$ 1,522		691,629	(406,183)	9,939	(114,442)
Increase (Decrease) in Temporary Equity [Roll Forward]
Net (loss) income	15,795
Tax distributions, net	(6,914)
Reclassification of redeemable non-controlling interests	883
Acquisition of non-controlling interest	(1,722)
Redeemable non-controlling interest, ending balance at Dec. 31, 2022	24,949
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(79,265)							(83,993)		4,728
Foreign currency translation adjustments	(1,059)								(433)	(626)
Stock-based compensation	$ 26,822						26,822
Exercise of stock options (in shares)	163,824			148,000		15,000
Exercise of stock options	$ 451			$ 1		$ 1	447		4	(2)
Restricted stock unit vesting, net of shares withheld to cover payroll taxes (in shares)				2,789,000		6,000
Restricted stock unit vesting, net of shares withheld to cover payroll taxes	(2,370)			$ 28			2,594		77	(5,069)
Unrealized gain (loss) on cash flow hedge, net of tax	(48,497)								(39,248)	(9,249)
Tax distributions, net			$ (56,684)									$ (56,684)
Reclassification of cash flow hedge to earnings, net of tax	(3,366)								(3,366)
Effect of the Reorganization (in shares)				(154,427,000)	(152,117,000)	306,544,000
Effect of the Reorganization	0			$ (1,543)	$ (1,522)	$ 3,065	(182,252)		678	181,574
Shares ending balance (in shares) at Dec. 31, 2023						306,565,000
Stockholders' equity ending balance at Dec. 31, 2023	20,011					$ 3,066	$ 539,240	$ (490,176)	$ (32,349)	$ 230
Increase (Decrease) in Temporary Equity [Roll Forward]
Net (loss) income	30,543
Tax distributions, net	(14,199)
Redeemable non-controlling interest, ending balance at Dec. 31, 2023	$ 41,293

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net (loss) income	$ (48,722)	$ (254,789)	$ 20,170
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	229,400	240,175	233,406
Unrealized foreign currency (gain) loss	(768)	15,190	175
Amortization of debt issuance costs and discount	8,182	8,595	9,203
Loss on refinancing	40,805	291	0
Intangible asset impairment charges	66,932	24,081	23,402
Change in fair value of contingent consideration	(14,497)	731	200
Stock-based compensation	26,822	31,847	28,412
Inventory provision	74,686	51,096	54,660
Insurance recoveries for property and equipment losses	0	(1,000)	(5,000)
Non-cash property losses	0	0	5,152
Other operating charges and credits, net	9,923	8,828	5,633
Changes in assets and liabilities:
Trade accounts receivable, net	126,289	(79,717)	(23,621)
Inventories	(126,182)	(102,396)	(49,015)
Prepaid expenses, other current assets and other assets	37,814	9,882	(21,981)
Related party receivables	(490)	646	7,311
Accounts payable, accrued expenses and other liabilities	(94,446)	109,568	(43,932)
Related party payables	9,829	2,072	(2,355)
Net cash provided by operating activities	345,577	65,100	241,820
Cash flows from investing activities:
Purchases of property, plant and equipment	(43,216)	(46,407)	(47,728)
Acquisition of intangible assets	(22,388)	(41,800)	(1,700)
Deposits for future acquisition of property, plant, and equipment	(3,585)	(2,388)	(3,211)
Acquisitions of businesses, net of cash acquired	0	(84,714)	(146,543)
Proceeds from insurance recoveries for property and equipment losses	0	1,000	5,000
Net cash used in investing activities	(69,189)	(174,309)	(194,182)
Cash flows from financing activities:
Payments of deferred financing and refinancing costs	(162,415)	(1,663)	0
Payments of principal on debt, revolving credit facility, financing leases and other	(414,080)	(123,272)	(78,086)
Proceeds from issuance of debt	217,732	0	0
Borrowings on revolving credit facility	219,000	85,000	0
Proceeds from exercise of stock options	451	662	853
Employee payroll tax withholding on restricted stock unit vesting	(2,378)	(3,571)	(2,664)
Payments of deferred consideration for acquisitions - related party	0	(44,498)	0
Acquisition of redeemable non-controlling interests	0	(1,722)	0
Tax distributions to non-controlling interest	(70,883)	(17,556)	(57,132)
Payments of principal on financing lease - related party	0	0	(93)
Repayment of related party note	0	0	(1,000)
Net cash used in financing activities	(212,573)	(106,620)	(138,122)
Effect of foreign exchange rate on cash	65	(5,683)	102
Net increase (decrease) in cash, cash equivalents, and restricted cash	63,880	(221,512)	(90,382)
Cash, cash equivalents, and restricted cash - beginning of period	35,227	256,739	347,121
Cash, cash equivalents, and restricted cash - end of period	99,107	35,227	256,739
Cash and cash equivalents - end of period	91,542	25,976	247,790
Restricted cash - end of period	7,565	9,251	8,949
Supplemental disclosure of cash flow information:
Cash paid for interest	192,806	142,722	121,747
Cash paid, net for income taxes	(2,496)	(12,649)	(15,558)
Supplemental disclosure of non-cash investing and financing activity:
Notes payable for acquisitions - related party	0	0	14,162
Deferred consideration for acquisition - related party	0	0	30,099
Contingent consideration for acquisition	0	8,796	0
Contingent consideration for acquisition - related party	0	0	5,700
Payable for acquisition of product rights and licenses	$ 2,100	$ 0	$ 300

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations Amneal Pharmaceuticals, Inc. (the “Company”) is a global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, biosimilars and specialty branded pharmaceuticals. The Company operates principally in the United States (“U.S.”), India, and Ireland, and sells to wholesalers, distributors, hospitals, governmental agencies, chain pharmacies and individual pharmacies, either directly or indirectly. The Company is a holding company, whose principal assets are common units (“Amneal Common Units”) of Amneal Pharmaceuticals, LLC (“Amneal”). Immediately prior to the Reorganization (as defined herein), the Company held 50.4% of the Amneal Common Units and the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the “Members” or the “Amneal Group”) held the remaining 49.6%. On November 7, 2023, the Company implemented a plan pursuant to which the Company and Amneal reorganized and simplified the Company’s corporate structure by eliminating its umbrella partnership-C-corporation structure and converting to a more traditional C-corporation structure whereby all stockholders hold their voting and economic interests directly through the public company (the “Reorganization”). Effective with the Reorganization, the Company holds 100% of the Amneal Common Units. Following the implementation of the Reorganization, Amneal Pharmaceuticals, Inc. (“Old PubCo”) became a wholly owned subsidiary of a new holding company, Amneal NewCo Inc. (“New PubCo”), which replaced Old PubCo as the public company trading on the New York Stock Exchange under Old PubCo’s ticker symbol “AMRX.” In addition, New PubCo changed its name to “Amneal Pharmaceuticals, Inc.” and Old PubCo changed its name to “Amneal Intermediate, Inc.” In connection with the Reorganization, holders of shares of Class A common stock, par value $0.01 per share, of Old PubCo (“Old PubCo Class A Common Stock”) ceased to hold such shares and received an equivalent number of shares of Class A common stock, par value $0.01 per share, of New PubCo that have the same voting and economic rights as Old PubCo Class A Common Stock. Additionally, holders of shares of Class B common stock, par value $0.01 per share, of Old PubCo (“Old PubCo Class B Common Stock”), ceased to hold such shares and received an equivalent number of shares of Class A common stock, par value $0.01 per share, of New PubCo that have the same voting and economic rights as Old PubCo Class A Common Stock. All outstanding shares of Old PubCo Class B Common Stock were surrendered and canceled. Accordingly, upon consummation of the Reorganization, Old PubCo stockholders automatically became stockholders of New PubCo, on a one-for-one basis, with the same number and ownership percentage of shares they held in Old PubCo immediately prior to the effective time of the Reorganization. On December 27, 2023, the Company voluntarily withdrew the listing of its Class A common stock from the New York Stock Exchange and transferred the listing to the Nasdaq Stock Market LLC under the same name and ticker symbol.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Accounting Principles The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated. Principles of Consolidation The consolidated financial statements include the accounts of all entities controlled by the Company, including Amneal and its subsidiaries, through the Company’s direct or indirect ownership of a majority voting interest. The Company records non-controlling interests for the portion of its subsidiaries’ economic interests that it does not hold. Although the Company had a minority economic interest in Amneal prior to March 31, 2023, it was Amneal’s sole managing member (and it continues to be the sole managing member), having the sole voting power to make all of Amneal’s business decisions and control its management. Therefore, the Company also consolidated the financial statements of Amneal and its subsidiaries for all periods prior to the Reorganization. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates. Revenue Recognition When assessing its revenue recognition, the Company performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the performance obligation. The Company recognizes revenue when it transfers control of its products to customers, in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those products. From time to time, the Company may enter into arrangements where it licenses certain products to a third-party distributor. Licensing arrangement performance obligations generally include intellectual property (“IP”) rights and research and development (“R&D”) and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company’s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company’s IP. Revenue from sales-based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. For further details on the Company’s revenue recognition policies, refer to Note 4. Revenue Recognition. Stock-Based Compensation The Company’s stock-based compensation consists of stock options, restricted stock units (“RSUs”) and market performance-based restricted stock units (“MPRSUs”) awarded to employees and non-employee directors. Stock options are measured at their fair value on the grant date or date of modification, as applicable. RSUs, including MPRSUs, are measured at the stock price on the grant date or date of modification, as applicable. The Company recognizes compensation expense on a straight-line basis over the requisite service and/or performance period, as applicable. Forfeitures of awards are accounted for as a reduction in stock-based compensation expense in the period such awards are forfeited. The Company's policy is to issue new shares upon option exercises and the vesting of RSUs and MPRSUs. Contingent consideration Business acquisitions may include future payments that are contingent upon the occurrence of certain pharmaceutical regulatory milestones or net sales of pharmaceutical products. For acquisitions that are accounted for as a business combination, the obligations for such contingent consideration payments are recorded at fair value on the acquisition date. For contingent milestone payments, the Company uses a probability-weighted income approach utilizing an appropriate discount rate. For contingent tiered royalties on net sales, the Company uses a Monte Carlo simulation model. Contingent consideration liabilities are revalued to fair value at the end of each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in fair value of contingent consideration in the consolidated statements of operations. Refer to Note 3. Acquisitions and Note 19. Fair Value Measurements for additional information. Foreign Currencies The Company has operations in the U.S., India, Ireland, and other foreign jurisdictions. Generally, the Company’s foreign operating subsidiaries’ functional currency is the local currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of exchange prevailing on the balance sheet date. Translation adjustments are included in accumulated other comprehensive (loss) income and non-controlling interests in the consolidated balance sheets and are included in comprehensive (loss) income. Transaction gains and losses are included in net (loss) income in the Company’s consolidated statements of operations as a component of foreign exchange gain (loss), net. Such foreign currency transaction gains and losses include fluctuations related to long term intercompany loans that are payable in the foreseeable future. Translation gains and losses on intercompany balances of a long-term investment nature are included in foreign currency translation adjustments in accumulated other comprehensive (loss) income and non-controlling interests, and comprehensive (loss) income. Business Combinations Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, the acquiring entity in a business combination records the assets acquired and liabilities assumed at the date of acquisition at their fair values. Any excess of the purchase price over the fair value of net assets and other identifiable intangible assets acquired is recorded as goodwill. Acquisition-related costs, primarily professional fees, are expensed as incurred. Cash and Cash Equivalents Cash and cash equivalents consist of cash on deposit and highly liquid investments with original maturities of three months or less. A portion of the Company’s cash flows are derived outside the U.S. As a result, the Company is subject to market risk associated with changes in foreign exchange rates. The Company maintains cash balances at both U.S.-based and international-based commercial banks. At various times during the year, cash balances in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation. Restricted Cash At December 31, 2023 and 2022, respectively, the Company had restricted cash balances of $7.6 million and $9.3 million, respectively, in its bank accounts primarily related to the purchase of certain land and equipment in India. Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary. The Company does not require collateral to secure amounts owed to it by its customers. Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects the best estimate of expected credit losses of the accounts receivable portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. The Company determines its allowance methodology by pooling receivable balances at the customer level. The Company consider various factors, including its previous loss history, individual credit risk associated to each customer, and the current and future condition of the general economy. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent that any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of such customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, account balances are charged off against the allowance when management believes it is probable the receivable will not be recovered. The Company does not have any off-balance-sheet credit exposure related to customers. Chargebacks Received from Manufacturers When a sale occurs on a contracted item, the difference between the cost the Company pays to the manufacturer of that item and the contract price that the end customer has with the manufacturer is rebated to the Company by the manufacturer as a chargeback. Chargebacks are recorded as a reduction to cost of sales and either a reduction in the amount due to the manufacturer (if there is a right of offset) or as a receivable from the manufacturer. Inventories Inventories consist of finished goods held for sale, raw materials, and work in process. Inventories are stated at net realizable value, with cost determined using the first-in, first-out method. Adjustments for excess and obsolete inventories are established based upon historical experience and management’s assessment of current product demand. These assessments include inventory obsolescence based on its expiration date, damaged or rejected product, and slow-moving products. Property, Plant, and Equipment Property, plant, and equipment are stated at historical cost less accumulated depreciation. Depreciation expense is computed primarily using the straight-line method over the estimated useful lives of the assets, which are as follows: Asset Classification Estimated Useful Life Buildings 30 years Computer equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of asset's useful life or remaining life of lease Machinery and equipment 5 - 10 years Vehicles 5 years Upon retirement or disposal, the cost of the asset disposed and the accumulated depreciation are removed from the accounts, and any gain or loss is reflected as part of operating income (loss) in the period of disposal. Expenditures that significantly increase value or extend useful lives of property, plant, and equipment are capitalized, whereas those for normal maintenance and repairs are expensed. The Company capitalizes interest on borrowings during the construction period of major capital projects as part of the related asset and amortizes the capitalized interest into earnings over the related asset’s remaining useful life. Leases All significant lease arrangements are recognized as right-of-use (“ROU”) assets and lease liabilities at lease commencement. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of the future lease payments using the Company's incremental borrowing rate. Operating lease expense is recognized on a straight-line basis over the lease term. At each balance sheet date, operating and financing lease liabilities continue to represent the present value of the future payments. Financing lease ROU assets are expensed using the straight-line method, unless another basis is more representative of the pattern of economic benefit, to lease expense. Interest on financing lease liabilities is recognized in interest expense. Leases with an initial term of 12 months or less (short-term leases) are not recognized in the balance sheet and the related lease payments are recognized as incurred over the lease term. The Company separates lease and non-lease components. A portion of the Company's real estate leases are subject to periodic changes in the Consumer Price Index (“CPI”). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. For further details regarding the Company's leases, refer to Note 18. Leases . In-Process Research and Development The fair value of in-process research and development (“IPR&D”) acquired in a business combination is determined based on the present value of each research project’s projected cash flows using an income approach. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and the life of each research project’s underlying marketability. In determining the fair value of each research project, expected cash flows are adjusted for certain risks of completion, including technical and regulatory risk. The value attributable to IPR&D projects at the time of acquisition is capitalized as an indefinite-lived intangible asset and tested for impairment until the project is completed or abandoned. Upon completion of the project, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized over the estimated useful life of the asset based on the pattern in which the economic benefits are expected to be consumed or otherwise used up or, if that pattern is not readily determinable, on a straight-line basis. If the project is abandoned, the indefinite-lived intangible asset is charged to expense. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance. Goodwill Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. The Company reviews goodwill for possible impairment annually during the fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable. In order to test goodwill for impairment, an entity is permitted to first assess qualitative factors to determine whether a quantitative assessment of goodwill is necessary. The qualitative factors considered by the Company may include, but are not limited to, general economic conditions, the Company’s outlook, market performance of the Company’s industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. If a quantitative assessment is required, the Company determines the fair value of its reporting unit using a combination of the income and market approaches. If the net book value of the reporting unit exceeds its fair value, the Company recognizes a goodwill impairment charge for the reporting unit equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value. See Note 13. Goodwill and Other Intangible Assets , for further discussion of the Company's qualitative and quantitative assessments of goodwill. Assumptions and estimates used in the evaluation of impairment may affect the carrying value of long-lived assets, which could result in impairment charges in future periods. Such assumptions include projections of future cash flows and the current fair value of the asset. Amortization of Intangible Assets with Finite Lives Intangible assets, other than indefinite-lived intangible assets, are amortized over the estimated useful life of the asset based on the pattern in which the economic benefits are expected to be consumed or otherwise used up or, if that pattern is not readily determinable, on a straight-line basis. The useful life is the period over which the assets are expected to contribute directly or indirectly to future cash flows. Intangible assets are not written-off in the period of acquisition unless they become impaired during that period. The Company regularly evaluates the remaining useful life of each intangible asset that is being amortized to determine whether events and circumstances warrant a revision to the remaining period of amortization. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over that revised remaining useful life. See Note 13. Goodwill and Other Intangible Assets for further discussion of the Company's intangible assets. Impairment of Long-Lived Assets (Including Intangible Assets with Finite Lives) The Company reviews its long-lived assets, including intangible assets with finite lives, for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company evaluates assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value, which is generally an expected present value cash flow technique. Management’s policy in determining whether an impairment indicator exists comprises measurable operating performance criteria as well as other qualitative measures. See Note 13. Goodwill and Other Intangible Assets for further discussion of the Company’s assessment of intangible asset impairments. Financial Instruments The Company minimizes its risks from interest fluctuations through its normal operating and financing activities and, when deemed appropriate through the use of derivative financial instruments. Derivative financial instruments are used to manage risk and are not used for trading or other speculative purposes. The Company does not use leveraged derivative financial instruments. Derivative financial instruments that qualify for hedge accounting must be designated and effective as a hedge of the identified risk exposure at the inception of the contract. Accordingly, changes in fair value of the derivative contract must be highly correlated with changes in fair value of the underlying hedged item at inception of the hedge and over the life of the hedge contract. All derivatives are recorded on the balance sheet as assets or liabilities and measured at fair value. For derivatives designated as cash flow hedges, the effective portion of the changes in fair value of the derivatives are recorded in accumulated other comprehensive (loss) income net of income taxes and subsequently amortized as an adjustment to interest expense over the period during which the hedged forecasted transaction affects earnings, which is when the Company recognizes interest expense on the hedged cash flows. Cash flows of such derivative financial instruments are classified consistent with the underlying hedged item. Highly effective hedging relationships that use interest rate swaps as the hedging instrument and that meet criteria under ASC 815, Derivatives and Hedging (“ASC 815”), may qualify for the “short-cut method” of assessing effectiveness. The short-cut method allows the Company to make the assumption of no ineffectiveness, which means that the change in fair value of the hedged item can be assumed to be equal to the change in fair value of the derivative. Unless critical terms change, no further evaluation of effectiveness is performed for these hedging relationships unless a critical term is changed. For a hedging relationship that does not qualify for the short-cut method, the Company measures its effectiveness using the “hypothetical derivative method”, in which the change in fair value of the hedged item must be measured separately from the change in fair value of the derivative. At inception and quarterly thereafter, the Company formally assesses whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. The Company compares the change in the fair value of the actual interest rate derivative to the change in the fair value of a hypothetical interest rate derivative with critical terms that match the hedged interest rate payments. After the initial quantitative assessment, this analysis is performed on a qualitative basis and, if it is determined that the hedging relationship was and continues to be highly effective, no further analysis is required. All components of each derivative financial instrument's gain or loss are included in the assessment of hedge effectiveness. If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive (loss) income net of income taxes, unless it is probable that the forecasted transaction will not occur. If it is probable that the forecasted transaction will not occur by the originally specified time period, the Company discontinues hedge accounting, and any deferred gains or losses reported in accumulated other comprehensive (loss) income are reclassified into earnings immediately. The Company is subject to credit risk as a result of nonperformance by counterparties to the derivative agreements. Upon inception and quarterly thereafter, the Company makes judgments on each counterparty’s creditworthiness for nonperformance by counterparties. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes (“ASC 740”), which requires the recognition of tax benefits or expenses on temporary differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company’s consolidated balance sheets as deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. ASC 740-10 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected to be taken in a tax return that affect amounts reported in the financial statements. The Company has reviewed and will continue to review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company’s assessment of the conclusions reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain tax positions, if applicable, as a component of income tax expense. Comprehensive (Loss) Income Comprehensive (loss) income includes net (loss) income and all changes in stockholders’ equity (except those arising from transactions with stockholders) including foreign currency translation adjustments resulting from the consolidation of foreign subsidiaries’ financial statements and unrealized gains (losses) on cash flows hedges, net of income taxes. Research and Development R&D activities are expensed as incurred. R&D expenses primarily consist of direct and allocated expenses incurred with the process of formulation, clinical research, and validation associated with new product development. Upfront and milestone payments made to third parties in connection with R&D collaborations are expensed as incurred up to the point of regulatory approval or when there is no alternative future use. Intellectual Property Legal Development Expenses The Company expenses external IP legal development expenses as incurred. These costs relate to legal challenges of innovator’s patents for invalidity or non-infringement, which are customary in the generic pharmaceutical industry, and are incurred predominately during development of a product and prior to regulatory approval. Associated costs include, but are not limited to, formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend the IP supporting the Company's regulatory filings. Shipping Costs The Company records the costs of shipping product to its customers as a component of selling, general, and administrative expenses as incurred. Shipping costs were $21.7 million, $18.7 million and $18.1 million for the years ended December 31, 2023, 2022 and 2021, respectively. Advertising Costs Advertising costs are expensed as incurred. Advertising costs are included in selling, general and administrative expenses and were $12.4 million, $16.8 million and $15.1 million for the years ended December 31, 2023, 2022 and 2021, respectively. Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”) , which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers (“ASC 606”). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. ASU 2021-08 was effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective January 1, 2023 and will apply the guidance to subsequent acquisitions. The adoption of ASU 2021-08 did not have an impact on the Company’s consolidated financial statements because the Company did not acquire a business the during the year ended December 31, 2023. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference the London interbank offered rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848) , to expand and clarify the scope of Topic 848 to include derivative instruments on discounting transactions. In December 2022, the FASB issued ASU 2022-06, Reference Rate reform (Topic 848): Deferral of the Sunset Date of Topic 848 , which deferred the sunset date of Topic 848, Reference Rate Reform to December 31, 2024. The Company adopted ASU 2020-04 during the three months ended June 30, 2023 (refer to Note 16. Debt for additional information). The adoption of ASU 2020-04 did not have a material impact on the Company’s consolidated financial statements. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 requires disclosures to include the title and position of the chief operating decision maker (“CODM”), significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment’s profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 requires that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The update is effective for fiscal years beginning after December 15, 2024, with early adoption permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. Reclassification The prior period balances related to cost of goods sold impairment charges of $11.1 million and $22.7 million, formerly included in a separate caption in the consolidated statements of operations for the years ended December 31, 2022 and 2021, respectively, have been rec

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions Saol Baclofen Franchise Acquisition On December 30, 2021, the Company entered into an asset purchase agreement with certain entities affiliated with Saol International Limited (collectively, “Saol”), a private specialty pharmaceutical company, pursuant to which it agreed to acquire Saol’s baclofen franchise, including Lioresal®, LYVISPAH™, and a pipeline product under development (the “Saol Acquisition”). The Saol Acquisition expanded the Company’s commercial institutional and specialty portfolio in neurology while adding commercial infrastructure in advance of its entry into the biosimilar institutional market. The transaction closed on February 9, 2022. Consideration for the Saol Acquisition included $84.7 million, paid at closing with cash on hand, and contingent royalty payments based on annual net sales for certain acquired assets, beginning in June 2023. Cash paid at closing included $1.1 million for inventory acquired in excess of the normalized level, as defined in the asset purchase agreement (working capital adjustment). For the year ended December 31, 2022, the Company incurred $0.1 million in transaction costs associated with the Saol Acquisition, which was recorded in acquisition, transaction-related and integration expenses. The Saol Acquisition was accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer. The purchase price was calculated as follows (in thousands): Cash $ 84,714 Contingent consideration (royalties) (1) 8,796 Fair value of consideration transferred $ 93,510 (1) The estimated fair value of contingent consideration on the acquisition date wa s $8.8 million and was based on significant Level 3 inputs that were not observable in the market. Key assumptions included the discount rate, projected year of payments and expected net product sales. Refer to Note 19. Fair Value Measurements for additional information on the methodology and determination of this liability. The following is a summary of the purchase price allocation for the Saol Acquisition (in thousands): Final F air Values as of February 9, 2022 Inventory $ 2,162 Prepaid expenses and other current assets 98 Goodwill 7,553 Intangible assets 83,815 Total assets acquired 93,628 Accounts payable and accrued expenses 118 Fair value of consideration transferred $ 93,510 The acquired intangible assets are being amortized over their estimated useful lives as follows (in thousands): Final Fair Value Weighted-Average Marketed product rights $ 83,815 11.5 The estimated fair value of the identifiable intangible assets was determined using the “income approach,” which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. The assumptions, including the expected projected cash flows, utilized in the purchase price allocation and in determining the purchase price were based on management's best estimates as of the closing date of the Saol Acquisition on February 9, 2022. Some of the more significant assumptions inherent in the development of those asset valuations included the estimated net cash flows for each year for each asset (including net revenues, cost of sales, selling and marketing costs and working capital/ contributory asset charges), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream, as well as other factors. The underlying assumptions used to prepare the discounted cash flow analysis may change; accordingly, for these and other reasons, actual results may vary significantly from estimated results. Goodwill is calculated as the excess of the consideration transferred over the net assets recognized. Of the total goodwill acquired in connection with the Saol Acquisition, $5.2 million was allocated to the Company’s Generics segment and $2.4 million was allocated to the Company’s Specialty segment, of which $4.9 million was deductible for tax purposes. Refer to Note 13. Goodwill and Other Intangible Assets for information on the impairment of the Company’s LYVISPAH™ intangible asset during the year ended December 31, 2023. From the acquisition date of February 9, 2022 to December 31, 2022, the Saol Acquisition contributed net revenue and an operating loss of $19.8 million and $7.1 million, respectively. Puniska Healthcare Pvt. Ltd. On November 2, 2021, the Company entered into a definitive agreement to acquire Puniska Healthcare Pvt. Ltd. (“Puniska”), a privately held manufacturer of parenteral and injectable drugs in India, and land in a transaction valued at approximately $93.0 million (the “Puniska Acquisition”). Upon execution of the agreement, the Company paid $72.9 million with cash on hand to acquire approximately 74% of the equity interests of Puniska on November 2, 2021. Upon approval of the transaction by the government of India in March 2022, the Company paid, with cash on hand, an additional $1.7 million for the remaining 26% of the equity interests of Puniska and $14.2 million for the satisfaction of a preexisting payable to the sellers. In December 2021, the Company paid $4.3 million with cash on hand for land associated with the Puniska Acquisition. For the year ended December 31, 2021, the Company incurred $1.0 million in transaction costs associated with the Puniska Acquisition, which were recorded in acquisition, transaction-related and integration expenses. The Puniska Acquisition, excluding the land acquired in December 2021, was accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer. From the acquisition date of November 2, 2021 to December 31, 2021, the Puniska Acquisition contributed an operating loss of $1.8 million. Kashiv Specialty Pharmaceuticals, LLC Acquisition On January 11, 2021, the Company and Kashiv Biosciences, LLC (a related party, see Note 24. Related Party Transactions ) (“Kashiv”) entered into a definitive agreement for Amneal to acquire a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (“KSP”), a subsidiary of Kashiv focused on the development of innovative drug delivery platforms, novel 505(b)(2) drugs and complex generics (the “KSP Acquisition”). On April 2, 2021, the Company completed the KSP Acquisition. Under the terms of the transaction, the cash portion of the consideration was $104.5 million, comprised of a purchase price of $100.1 million (including deferred consideration of $30.5 million) and a working capital adjustment of $4.4 million. The cash purchase price was funded by cash on hand. Kashiv is eligible to receive up to an additional $8.0 million in contingent payments upon the achievement of certain regulatory milestones and potential royalty payments from high single-digits to mid double-digits, depending on the amount of aggregate annual net sales for certain future pharmaceutical products. The KSP Acquisition was accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer. Transaction costs associated with the KSP Acquisition were $3.1 million f or the year ended December 31, 2021 and were included in acquisition, transaction-related and integration expenses. From the acquisition date of April 2, 2021, to December 31, 2021, the KSP Acquisition contributed an operating loss to the Company’s consolidated statements of operations of $21.3 million, which included approximately $5.8 million of amortization expense from intangible assets acquired in the KSP Acquisition. Offsetting the operating loss was a reduction of third-party consulting services and the elimination of royalties due to KSP. Acquisition, Transaction-Related and Integration Expenses For the year ended December 31, 2022, acquisition, transaction-related and integration expenses of $0.7 million primarily consisted of professional services fees associated with the Saol Acquisition.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Pharmaceutical Product Sales Performance Obligations The Company’s performance obligation is the supply of finished pharmaceutical products to its customers. The Company’s customers consist primarily of major wholesalers, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions and pharmaceutical companies. The Company’s customer contracts generally consist of both a master agreement, which is signed by the Company and its customer, and a customer submitted purchase order, which is governed by the terms and conditions of the master agreement. Customers purchase product by direct channel sales from the Company or by indirect channel sales through various distribution channels. Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time. The Company offers standard payment terms to its customers and has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing, since the period between when the Company transfers the product to the customer and when the customer pays for that product is one year or less. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues. The consideration amounts due from customers as a result of product sales are subject to variable consideration, as described further below. The Company offers standard product warranties which provide assurance that the product will function as expected and in accordance with specifications. Customers cannot purchase warranties separately and these warranties do not give rise to a separate performance obligation. The Company permits the return of product under certain circumstances, mainly upon product expiration, instances of shipping errors or where product is damaged in transit. The Company accrues for the customer’s right to return as part of its variable consideration. See below for further details. Variable Consideration The Company includes an estimate of variable consideration in its transaction price at the time of sale, when control of the product transfers to the customer. Variable consideration includes but is not limited to: chargebacks, distribution fees, rebates, group purchasing organization (”GPO”) fees, prompt payment (cash) discounts, consideration payable to the customer, billbacks, Medicaid and other government pricing programs, price protection and shelf stock adjustments, sales returns, and profit shares. The Company assesses whether or not an estimate of its variable consideration is constrained and has determined that the constraint does not apply, since it is probable that a significant reversal in the amount of cumulative revenue will not occur in the future when the uncertainty associated with the variable consideration is subsequently resolved. The Company’s estimates for variable consideration are adjusted as required at each reporting period for specific known developments that may result in a change in the amount of total consideration it expects to receive. Chargebacks In the case an indirect customer purchases product from their preferred wholesaler instead of directly from the Company, and the contract price charged to the indirect customer is lower than the wholesaler pricing, the Company pays the direct customer (wholesaler) a chargeback for the price differential. The Company estimates its chargeback accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to chargebacks, current contract terms and historical experience. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Rebates The Company pays fixed or volume-based rebates to its customers based on a fixed amount, fixed percentage of product sales or based on the achievement of a specified level of purchases. The Company’s rebate accruals are based on actual net sales, contractual rebate rates negotiated with customers, and expected purchase volumes / corresponding tiers based on actual sales to date and forecasted amounts. Group Purchasing Organization Fees The Company pays fees to GPOs for administrative services that the GPOs perform in connection with the purchases of product by the GPO participants who are the Company’s customers. The Company’s GPO fee accruals are based on actual net sales, contractual fee rates negotiated with GPOs and the mix of the products in the distribution channel that remain subject to GPO fees. Prompt Payment (Cash) Discounts The Company provides customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The Company’s prompt payment discount accruals are based on actual net sales and contractual discount rates. Consideration Payable to the Customer The Company pays administrative and service fees to its customers based on a fixed percentage of the product price. These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price. The Company accrues for these fees based on actual net sales, contractual fee rates negotiated with the customer and the mix of the products in the distribution channel that remain subject to fees. Billbacks In the case an indirect customer purchases product from their preferred wholesaler instead of directly from the Company, and the contract price charged to the indirect customer is higher than contractual pricing, the Company pays the indirect customer a billback for the price differential. The Company estimates its billback accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to billbacks, current contract terms and historical experience. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Medicaid and Other Government Pricing Programs The Company complies with required rebates mandated by law under Medicaid and other government pricing programs. The Company estimates its government pricing accruals based on monthly sales, historical experience of claims submitted by the various states and jurisdictions, historical rates and estimated lag time of the rebate invoices. Price Protection and Shelf Stock Adjustments The Company provides customers with price protection and shelf stock adjustments which may result in an adjustment to the price charged for the product transferred, based on differences between old and new prices which may be applied to the customer’s on-hand inventory at the time of the price change. The Company accrues for these adjustments when its expected value of an adjustment is greater than zero, based on contractual pricing, actual net sales, accrual rates based on historical average rates, and estimates of the level of inventory of its products in the distribution channel that remain subject to these adjustments. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Sales Returns The Company permits the return of product under certain circumstances, mainly due to product expiration, instances of shipping errors or where product is damaged in transit, and occurrences of product recalls. The Company’s product returns accrual is primarily based on estimates of future product returns based generally on actual net sales, estimates of the level of inventory of its products in the distribution channel that remain subject to returns, estimated lag time of returns and historical return rates. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Profit Shares For certain product sale arrangements, the Company earns a profit share upon the customer’s sell-through of the product purchased from the Company. The Company estimates its profit shares based on actual net sales, estimates of the level of inventory of its products in the distribution channel that remain subject to profit shares, and historical rates of profit shares earned. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. License Agreements Refer to Note 5. Alliance and Collaboration for further information related to revenue recognition associated with a license agreement with multiple performance obligations. Concentration of Revenue The following table summarizes the percentages of net revenues from each of the Company's customers that individually accounted for 10% or more of its net revenues: For the year ended December 31, 2023 2022 2021 Customer A 24 % 21 % 21 % Customer B 16 % 18 % 20 % Customer C 21 % 22 % 24 % Customer D 9 % 10 % 10 % Disaggregated Revenue The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for each of the years ended December 31, 2023, 2022 and 2021, are set forth below (in thousands): Year ended December 31, 2023 2022 2021 Generics Anti-infective $ 25,885 $ 23,193 $ 30,501 Hormonal / allergy 451,736 444,909 427,077 Antiviral (1) 39,910 40,601 4,832 Central nervous system 369,201 393,281 381,110 Cardiovascular system 139,942 118,183 141,866 Gastroenterology 67,519 70,796 76,497 Oncology 110,455 64,285 103,327 Metabolic disease / endocrine 45,900 41,128 38,462 Respiratory 42,710 41,085 35,965 Dermatology 70,872 66,553 55,474 Other therapeutic classes 105,106 118,573 69,928 License agreement (2) — 8,018 — International and other 2,165 1,468 1,299 Total Generics net revenue 1,471,401 1,432,073 1,366,338 Specialty Hormonal / allergy 110,486 91,465 68,397 Central nervous system 249,981 255,656 277,196 Other therapeutic classes 29,990 27,000 32,726 Total Specialty net revenue 390,457 374,121 378,319 AvKARE Distribution 347,406 260,560 192,921 Government label 121,829 98,234 118,379 Institutional 38,016 27,742 25,176 Other 24,498 19,574 12,536 Total AvKARE net revenue 531,749 406,110 349,012 Total net revenue $ 2,393,607 $ 2,212,304 $ 2,093,669 (1) Antiviral net revenue for the year ended December 31, 2021 was lower in comparison to the years ended December 31, 2023 and 2022 primarily due to a decline in Oseltamivir (generic Tamiflu®) sales from lower demand and increased returns activity above historical levels as a result of decreased influenza activity during the onset of the COVID-19 pandemic. (2) Refer to Note 5. Alliance and Collaboration for information on revenue recognized under a license agreement. A rollforward of the major categories of sales-related deductions for the years ended December 31, 2023, 2022 and 2021 is as follows (in thousands): Contract Charge- Cash Accrued Accrued Balance at December 31, 2020 $ 628,804 $ 22,690 $ 174,984 $ 131,088 Provision related to sales recorded in the period 3,164,331 107,810 105,127 137,452 Credits/payments issued during the period (3,289,233) (106,858) (118,133) (182,803) Balance at December 31, 2021 503,902 23,642 161,978 85,737 Provision related to sales recorded in the period 3,416,149 112,609 84,306 129,203 Credits/payments issued during the period (3,346,459) (108,797) (101,224) (128,910) Balance at December 31, 2022 573,592 27,454 145,060 86,030 Provision related to sales recorded in the period 3,384,360 113,396 73,172 246,608 Credits/payments issued during the period (3,398,618) (116,958) (81,746) (241,948) Balance at December 31, 2023 $ 559,334 $ 23,892 $ 136,486 $ 90,690

Alliance and Collaboration

Alliance and Collaboration	12 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Alliance and Collaboration	Alliance and Collaboration The Company has entered into several alliance, collaboration, license, distribution and similar agreements with respect to certain of its products and services with third-party pharmaceutical companies. The consolidated statements of operations include revenue recognized under agreements the Company has entered into to develop marketing and/or distribution relationships with its partners to fully leverage the technology platform and revenue recognized under development agreements which generally obligate the Company to provide R&D services over multiple periods. The Company's significant arrangements are discussed below. Orion Corporation License Agreement On December 28, 2022, Amneal signed a long-term license agreement with Orion Corporation (“Orion”), a globally operating Finnish pharmaceutical company, to commercialize a number of our complex generic products in most parts of Europe, Australia and New Zealand (the “Orion Agreement”). The initial term of the Orion Agreement commences upon commercial launch of the products and will continue for eight years. The Orion Agreement will automatically renew for successive two-year terms unless either party declines such renewal in writing at least one year in advance. Under the terms of the Orion Agreement, Amneal granted Orion licenses to certain generic products commercially available in the U.S. today and select high-value pipeline products currently under development. In addition, Amneal will be responsible for the performance of all R&D activities to be conducted to obtain regulatory approval for each product. Amneal is entitled to be reimbursed for a percentage of mutually agreed upon R&D expenses from Orion. Orion will be responsible for preparing and filing regulatory documentation, along with paying any application fees seeking regulatory approval for the products. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Orion. Orion will be responsible for all commercialization and marketing activities for the territories described above. Amneal will earn revenue for supplying products to Orion at the greater of: (i) cost plus a stated margin, or (ii) a fixed percentage of the net selling price, as defined in the Orion Agreement. Upon signing of the Orion Agreement, Amneal was entitled to an upfront, non-refundable payment of €20.0 million, or $21.4 million (based on the exchange rate at that date). Amneal is eligible to receive certain one-time sales-based milestones in the aggregate of €45.0 million, or $49.7 million (based on the exchange rate as of December 31, 2023) contingent upon whether Orion achieves certain annual sales targets. The Orion Agreement is within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”). The Company identified performance obligations related to: (1) the grant of a license of functional IP, (2) the performance of R&D activities, and (3) the supply of products. The Company evaluated that the grant of licenses is in the scope of ASC 606, whereas the performance of R&D activities is in the scope of ASC 730-20, Research and Development Arrangements , because the Company determined that performing R&D activities on behalf of other parties is not part of the ordinary activities of its business. The Company will record reimbursement received from Orion for R&D activities as a reduction of R&D expense. The Company concluded each future purchase order from Orion represents a separate contract. Amneal will record revenue related to each purchase order when it transfers control of the products to Orion. For the year ended December 31, 2023, Amneal recognized $0.5 million as a reduction of R&D expense for reimbursable R&D activities under the Orion Agreement. The Company determined that the transaction price under the arrangement was the upfront payment of $21.4 million, which was allocated to the performance obligations based on their relative standalone selling prices. The remaining sales-based milestones payments of $49.7 million are variable consideration and were not included in the transaction price because they were fully constrained under ASC 606. For the year ended December 31, 2022, the Company recorded a $21.4 million receivable in prepaid expenses and other current assets for the upfront payment due from Orion, which was received in January 2023. For the year ended December 31, 2022, the Company recognized $8.0 million in license revenue related to the delivery of functional IP, which was recorded in net revenues. The remaining $13.4 million of the transaction price was allocated to the R&D activities performance obligation and was recorded as deferred income, of which $6.7 million was recorded in accounts payable and accrued expenses and $6.7 million was recorded in other long-term liabilities as of December 31, 2022. During the year ended December 31, 2023, the Company recognized $0.9 million as a reduction to R&D expense related to services performed under the Orion Agreement. As of December 31, 2023, deferred income of $7.8 million and $4.7 million was recorded in accounts payable and accrued expenses and other long-term liabilities, respectively. As of December 31, 2023, no products have been supplied by Amneal under the Orion Agreement. ONGENTYS® License Agreement On December 5, 2023, the Company entered into a license agreement with BIAL-Portela & Ca., S.A. (“BIAL”) for the exclusive royalty-free right to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023 and ending at such time when generic opicapone sales reach certain predetermined thresholds (the “BIAL License Agreement”). ONGENTYS® is BIAL’s proprietary, once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase inhibitor approved by the FDA in 2020 as an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing “Off” episodes. Under the BIAL Agreement, the Company is responsible for commercialization and marketing of ONGENTYS® in the U.S. and BIAL is responsible for manufacturing and supply. The BIAL Agreement also requires the Company to spend a minimum of $6.0 million in medical and marketing activities directly related to ONGENTYS®. The Company commenced distribution of ONGENTYS® in early 2024. During December 2023, the Company paid a nonrefundable license fee of $12.5 million to BIAL, which was capitalized as an intangible asset and will be amortized to cost of sales over a period of eight years. The BIAL License Agreement provides for potential future milestone payments totaling $22.5 million, depending on cumulative net sales of ONGENTYS®. Levothyroxine License and Supply Agreement; Transition Agreement On August 16, 2018, the Company entered into a license and supply agreement with Jerome Stevens Pharmaceuticals, Inc. (“JSP”) for levothyroxine sodium tablets (“Levothyroxine”). This agreement designated the Company as JSP’s exclusive commercial partner for Levothyroxine in the U.S. market for a 10-year term commencing on March 22, 2019. Under this license and supply agreement with JSP, the Company paid an up-front license payment of $50.0 million in April 2019. The agreement also provides for the Company to pay a profit share to JSP based on net profits of the Company's sales of Levothyroxine, after considering product costs. As a result of significant price erosion associated with the Levothyroxine products licensed from JSP, the Company recorded a $17.7 million impairment charge in cost of goods sold for the year ended December 31, 2021 to recognize an impairment on the entire unamortized balance of the up-front license payment (refer to Note 13. Goodwill and Other Intangible Assets for additional information on the Company’s intangible asset impairments). Biosimilar Licensing and Supply Agreements Bevacizumab On May 7, 2018, the Company entered into a licensing and supply agreement with mAbxience S.L. (“mAbxience”), for its biosimilar candidate for Avastin® (bevacizumab). The supply agreement was subsequently amended on March 2, 2021 and the licensing agreement was amended on March 4, 2021. The Company will be the exclusive partner in the U.S. market. The Company will pay up-front, development and regulatory milestone payments as well as commercial milestone payments on reaching pre-agreed sales targets in the market to mAbxience, up to $78.3 million. For the year ended December 31, 2021, the Company recognized $11.7 million of milestones in R&D expense related to the agreement (none for the years ended December 31, 2023 and 2022). On April 13, 2022, the Food and Drug Administration (“FDA”) approved the Company’s biologics license application for bevacizumab-maly, a biosimilar referencing Avastin®. In connection with this regulatory approval and associated activity, the Company paid milestones of $26.5 million during the year ended December 31, 2022, which were capitalized as product rights intangible assets and are being amortized to cost of sales over their estimated useful lives of seven years. Denosumab On October 12, 2023, the Company entered into a licensing and supply agreement with mAbxience to be the exclusive U.S. partner for two denosumab biosimilars referencing both Prolia® and XGEVA®. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for two major categories of therapy: bone metastasis from various forms of cancer and prevention of bone pain and fractures, including osteoporosis-related injuries. mAbxience is responsible for the clinical and regulatory approval for the two products and regulatory fees will be shared by the parties. Upon approval of each product, mAbxience will be responsible for supply and the Company will be responsible for commercialization. During the year ended December 31, 2023, the Company recorded R&D expense for a $2.5 million payment made upon execution of the agreement and an additional $2.5 million for a developmental milestone. The agreement provides for potential future milestone payments to mAbxience of up to $69.0 million as follows: (i) up to $6.5 million relating to clinical and developmental milestones; (ii) up to $15.0 million for regulatory approval and initial commercial launch milestones; and (iii) up to $47.5 million for the achievement of annual commercial milestones. Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited In January 2012, Impax Laboratories, Inc. (“Impax”), which was acquired by the Company in 2018, entered into an agreement with AstraZeneca UK Limited (“AstraZeneca”) to distribute branded products under the terms of a distribution, license, development and supply agreement (the “AZ Agreement”). The parties subsequently entered into a First Amendment to the AZ Agreement dated May 31, 2016 (as amended, the “AZ Amendment”). Under the terms of the AZ Agreement, AstraZeneca granted to Impax an exclusive license to commercialize the tablet, orally disintegrating tablet and nasal spray formulations of Zomig® (zolmitriptan) products for the treatment of migraine headaches in the U.S. and in certain U.S. territories, except during an initial transition period when AstraZeneca fulfilled all orders of Zomig® products on Impax’s behalf and AstraZeneca paid to Impax the gross profit on such Zomig® products. Pursuant to the AZ Amendment, under certain conditions, and depending on the nature and terms of the study agreed to with the FDA, Impax agreed to conduct, at its own expense, the juvenile toxicity study and pediatric study required by the FDA under the Pediatric Research Equity Act (“PREA”) for approval of the nasal formulation of Zomig® for the acute treatment of migraine in pediatric patients ages six through eleven years old, as further described in the study protocol mutually agreed to by the parties (the “PREA Study”). In consideration for Impax conducting the PREA Study at its own expense, the AZ Amendment provided for the total royalty payments payable by Impax to AstraZeneca on net sales of Zomig® products under the AZ Agreement to be reduced by an aggregate amount of $30.0 million to be received in quarterly amounts specified in the Amendment beginning from the quarter ended June 30, 2016 through the quarter ended December 31, 2020. In the event the royalty reduction amounts exceeded the royalty payments payable by Impax to AstraZeneca pursuant to the AZ Agreement in any given quarter, AstraZeneca was required to pay Impax an amount equal to the difference between the royalty reduction amount and the royalty payment payable by Impax to AstraZeneca. Impax’s commitment to perform the PREA Study could have been terminated, without penalty, under certain circumstances as set forth in the AZ Amendment. The Company recognized the amounts received from AstraZeneca for the PREA Study as a reduction of R&D expense. The PREA study was completed during March 2021. In May 2013, Impax’s exclusivity period for branded Zomig® tablets and orally disintegrating tablets expired and Impax launched authorized generic versions of those products in the U.S. The pediatric exclusivity of the AstraZeneca patent licensed to Impax for Zomig® Spray expired in May 2021 and the Company lost market exclusivity in the fourth quarter of 2021. As discussed above, pursuant to the AZ Amendment, the total royalty payments payable by Impax to AstraZeneca on net sales of Zomig® products under the AZ Agreement was reduced by certain specified amounts beginning from the quarter ended June 30, 2016 through the quarter ended December 31, 2020, with such reduced royalty amounts totaling an aggregate amount of $30.0 million. On February 14, 2023, the rights and obligations of the AZ Amendment was transferred to Grünenthal GMBH (“Grünenthal”), with an effective date of December 31, 2022. Following the transfer, the Company and Grünenthal mutually terminated the AZ Amendment and entered into a new supply agreement, effective December 31, 2022. The Company recorded cost of goods sold for royalties under this agreement of $0.9 million, $1.4 million, and $12.5 million for the years ended December 31, 2023, 2022 and 2021, respectively. Agreements with Kashiv Biosciences, LLC For detail on the Company’s related party agreements with Kashiv Biosciences, LLC, refer to Note 24. Related Party Transactions .

Government Grants

Government Grants	12 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
Government Grants	Government Grants In November 2021, Amneal Pharmaceuticals Private Limited, a subsidiary of the Company in India, was selected as one of 55 companies to participate in the PLI Scheme. The Government of India established the PLI Scheme to make India’s domestic manufacturing more globally competitive and to create global champions within the pharmaceutical sector by encouraging investment and product diversification with a focus on manufacturing complex and high value goods. Under the PLI Scheme, the Company is eligible to receive up to 10.0 billion Indian rupees, or approximately $120.2 million (based on conversion rates as of December 31, 2023), over a maximum six-year period, starting in 2022. To be eligible to receive the cash incentives, Amneal must achieve (i) minimum cumulative expenditures towards developmental and/or capital investments; and (ii) a minimum percentage growth in sales of eligible products. The Company has concluded the PLI Scheme is government assistance in the form of a grant and, in the absence of specific accounting guidance under U.S. GAAP, the Company has analogized to International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance . The Company evaluated the PLI Scheme to be a grant related to income and will recognize the cash incentives on a systematic basis in other operating income. For the year ended December 31, 2023 and 2022, the Company recognized $1.2 million and $4.0 million, respectively, of other operating income from the PLI Scheme. As of December 31, 2023 and 2022, the Company had receivables from the government of India of $1.3 million and $4.0 million, respectively, within prepaid and other current assets.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Amneal is a limited liability company that is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, Amneal is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by Amneal is passed through to and included in the taxable income or loss of its members, including the Company, on a pro rata basis subject to applicable tax regulations. The Company is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to its allocable share of any taxable income or loss of Amneal, as well as any stand-alone income or loss generated by the Company. Amneal provides for income taxes in the various foreign jurisdictions in which it operates. Effective with the Reorganization on November 7, 2023, the Company and a wholly-owned subsidiary are the only members of Amneal. The Company recorded deferred tax assets for (i) its outside basis difference in its investment in Amneal on May 4, 2018, (ii) the net operating loss of Impax from January 1, 2018 through May 4, 2018, (iii) certain federal and state credits, and (iv) interest carryforwards of Impax that were attributable to the Company. The Company records its valuation allowances against its deferred tax assets (“DTAs”) when it is more likely than not that all or a portion of a DTA will not be realized. The Company routinely evaluates the realizability of its DTAs by assessing the likelihood that its DTAs will be recovered based on all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, estimates of future taxable income, tax planning strategies and results of operations. Estimating future taxable income is inherently uncertain and requires judgment. In projecting future taxable income, the Company considers its historical results and incorporates certain assumptions, including projected new product launches, revenue growth, and operating margins, among others. The Company established a valuation allowance based upon all available objective and verifiable evidence both positive and negative, including historical levels of pre-tax income (loss) both on a consolidated basis and tax reporting entity basis, legislative developments, expectations and risks associated with estimates of future pre-tax income, and prudent and feasible tax planning strategies. Since first establishing a valuation allowance, the Company has generated cumulative consolidated three year pre-tax losses through December 31, 2023. As a result of the losses through December 31, 2023, the Company determined that it is more likely than not that it will not realize the benefits of its gross DTAs and therefore maintained its valuation allowance. As of December 31, 2023, this valuation allowance was $566.5 million , and it reduced the carrying value of these gross DTAs, net of the impact of the reversal of taxable temporary differences, to zero. In connection with the acquisition of Impax, the Company entered into a tax receivable agreement (“TRA”) for which it was generally required to pay the other holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it was deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal Common Units for shares of Class A common stock and (ii) tax benefits attributable to payments made under the TRA. In connection with the valuation allowance recorded on the DTAs, the Company reversed the accrued TRA liability of $192.8 million during 2019. As a part of the Reorganization, the TRA was amended to reduce the Company’s future obligation to pay 85% of the realized tax benefits subject to the TRA to 75% of such realized benefits. As of December 31, 2023, the contingent TRA liability, including the impact of the amendment, was $185.2 million. The timing and amount of any payments under the TRA may vary, depending upon a number of factors including the timing and amount of the Company’s taxable income, and the corporate tax rate in effect at the time of realization of the Company’s taxable income (the TRA liability is determined based on a percentage of the corporate tax savings from the use of the TRA’s attributes). Because the Amneal Group has exchanged all of its Amneal Common Units pursuant to the Reorganization, the primary remaining factor that could increase the contingent TRA liability is an increase in the effective tax rate. The timing and amount of payments may also be accelerated under certain conditions, such as a change of control or other early termination event, which could give rise to the Company being obligated to make TRA payments in advance of tax benefits being realized. As noted above, the Company has determined it is more-likely-than-not it will be unable to utilize its DTAs subject to TRA; therefore, as of December 31, 2023, the Company has not recognized the contingent liability under the TRA related to the tax savings it may realize from common units sold or exchanged. If utilization of these DTAs becomes more-likely- than-not in the future, at such time, these TRA liabilities (which amounted to approximately $185.2 million at December 31, 2023) will be recorded through charges in the Company’s consolidated statements of operations. Each year, we evaluate the realizability of the deferred tax assets that resulted from sales or exchanges of Amneal Common Units for Class A common stock prior to the Reorganization. Although the deferred tax assets were not determined to be realizable as of December 31, 2023 and 2022, the Company assessed that a TRA liability of $3.7 million and $0.6 million at those dates, respectively, had become probable. Accordingly, the Company recorded expenses associated with the TRA in other income, net of $3.1 million and $0.6 million for the years ended December 31, 2023 and 2022, respectively. In future periods, the Company will continue to evaluate whether any future TRA payments become probable and can be estimated and, if so, an estimate of payment will be accrued. For the years ended December 31, 2023, 2022 and 2021 the Company's provision for (benefit from) income taxes and effective tax rates were $8.5 million and (21.0)%, $6.7 million and (2.7)%, and $11.2 million and 35.7%, respectively. The Company and its subsidiaries file income tax returns in the U.S. federal, and various state, local and foreign jurisdictions. In the year ended December 31, 2021, the Internal Revenue Services (“IRS”) completed an income tax audit for the 2018 tax return, the year of the Company’s Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) carryback. The Company sustained the entire $345 million carryback, and the statute is closed for 2018 and prior years. The Company’s 2020 through 2022 tax years remain open to IRS exam. In the U.S., income tax returns are generally subject to examination for a period of three years. Neither the Company nor any of its other affiliates is currently under audit by the IRS. The Amneal partnership is currently under examination in certain states and the Company does not expect any material adjustments as of December 31, 2023. The components of the Company's (loss) income before income taxes were as follows (in thousands): Years Ended December 31, 2023 2022 2021 United States $ (59,781) $ (260,616) $ (10,540) International 19,511 12,489 41,906 Total (loss) income before income taxes $ (40,270) $ (248,127) $ 31,366 The provision for (benefit from) income taxes was comprised of the following (in thousands): Years Ended December 31, 2023 2022 2021 Current: Domestic $ 2,470 $ (1,073) $ 1,311 Foreign 5,982 7,735 9,885 Total current income tax $ 8,452 $ 6,662 $ 11,196 For the years ended December 31, 2023, 2022, and 2021, the Company did not record a provision for deferred income taxes as a result of recording a full valuation allowance on its DTAs. The Company’s effective tax rates were as follows: Years Ended December 31, 2023 2022 2021 Federal income tax at the statutory rate 21.0 % 21.0 % 21.0 % State income tax, net of federal benefit (5.5) (0.8) 4.2 Income not subject to tax 14.5 (10.7) 6.4 Foreign rate differential (19.5) (3.4) 17.3 Permanent book/tax differences (2.1) (0.3) 4.8 Change in prior year estimates 7.7 0.7 (0.3) Deferred tax adjustment (5.7) — 0.1 Valuation allowance (32.3) (10.3) (13.5) Other 0.9 1.1 (4.3) Effective income tax rate (21.0) % (2.7) % 35.7 % The change in effective income tax rate for the year ended December 31, 2023 compared to the year ended December 31, 2022 was primarily due to the timing and mix of income and to the release of reserves for uncertain tax positions in 2022. The change in effective income tax rate for the year ended December 31, 2022 compared to the year ended December 31, 2021 was primarily due to the timing and mix of income and to the release of reserves for uncertain tax positions. The following table summarizes the changes in the Company’s valuation allowance on deferred tax assets (in thousands): Years Ended December 31, 2023 2022 2021 Balance at the beginning of the period $ 434,895 $ 416,588 $ 422,812 Increase (decrease) due to net operating losses and temporary differences 23,078 25,589 (10,828) Increase due to stock-based compensation 1,652 224 5,513 Decrease recorded against goodwill — (1,590) — Increase recorded against additional paid-in capital 96,316 2,720 2,842 Increase (decrease) recorded against other comprehensive income 10,603 (8,636) (3,751) Balance at the end of the period $ 566,544 $ 434,895 $ 416,588 At December 31, 2023, the Company had approximately $145.6 million of foreign net operating loss carry forwards. These net operating loss carry forwards will partially expire, if unused, by 2032. At December 31, 2023, the Company had approximately $216.6 million of federal and $174.9 million of state net operating loss carry forwards. The federal net operating losses are generally allowed to be carried forward indefinitely, and the majority of the state net operating loss es will expire, if unused, between 2032 and 2042. At December 31, 2023, the Company had approximately $13.4 million of federal R&D credit carry forwards and $12.3 million of state R&D credit carry forwards. The majority of the federal R&D credit carry forwards will expire if unused, between 2034 and 2043 and the majority of state credits can be carried forward indefinitely. At December 31, 2023, the Company had approximately $5.0 million of federal capital loss carry forwards, which will expire if unused at the end of 2028. The tax effects of temporary differences that give rise to deferred taxes were as follows (in thousands): December 31, December 31, Deferred tax assets: Partnership interest in Amneal $ 318,140 $ 203,336 Projected imputed interest on TRA 22,730 25,255 Net operating loss carryforward 74,340 82,338 IRC Section 163(j) interest carryforward 72,513 54,996 Capitalized costs 2,537 2,505 Accrued expenses 648 431 Stock-based compensation 14,672 5,737 Intangible assets 21,901 23,967 Tax credits and other 39,063 36,330 Total deferred tax assets 566,544 434,895 Valuation allowance (566,544) (434,895) Net deferred tax assets $ — $ — The Company's Indian subsidiaries are primarily export-oriented, and the tax holiday benefits provided by the Indian government for export activities within Special Economic Zones (“SEZ”) expired in March 2023. Without availing the SEZ benefit in India, the Company is eligible to claim a reduced tax rate of approximately 25.17%. The Company accounts for income tax contingencies using the benefit recognition model. The Company will recognize a benefit if a tax position is more likely than not to be sustained upon audit, based solely on the technical merits. The benefit is measured by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information. The amount of unrecognized tax benefits at December 31, 2023, 2022, and 2021, was $3.7 million, $3.6 million and $5.5 million, respectively, of which $3.6 million, $3.5 million and $5.4 million, respectively, would impact the Company’s effective tax rate if recognized. The Company currently does not believe that the total amount of unrecognized tax benefits will increase or decrease significantly over the next 12 months. Interest expense related to income taxes is included in provision for (benefit from) income taxes. Net interest benefit related to unrecognized tax benefits for the year ended December 31, 2023 was minimal. Net interest expense (benefit) related to unrecognized tax benefits for the years ended December 31, 2022 and 2021 was $(0.7) million and $0.1 million, respectively. Accrued interest expense as of December 31, 2023, 2022, and 2021 was $0.1 million, $0.1 million, and $0.8 million, respectively. Income tax penalties are included in provision for (benefit from) income taxes. Accrued tax penalties as of December 31, 2023, 2022 and 2021 were immaterial. A rollforward of unrecognized tax benefits for the years ended December 31, 2023, 2022 and 2021 is as follows (in thousands): Years Ended December 31, 2023 2022 2021 Unrecognized tax benefits at the beginning of the period $ 3,616 $ 5,489 $ 5,368 Gross change for current period positions 170 110 131 Gross change for prior period positions (51) (1,983) (10) Unrecognized tax benefits at the end of the period $ 3,735 $ 3,616 $ 5,489 In India, the income tax returns for the fiscal years ending March 31, 2021 and 2022 are currently being reviewed by tax authorities as part of the normal procedures, and the Company is not expecting any material adjustments. There are no other income tax returns in the process of examination, administrative appeal, or litigation. Income tax returns are generally subject to examination for a period of 3 years, 5 years, and 4 years after the tax year in India, Switzerland, a nd Ireland, respectively. Applicable foreign taxes (including withholding taxes) have not been provided on the approximately $130.8 million of undistributed earnings of foreign subsidiaries as of December 31, 2023. These earnings have been and currently are considered to be indefinitely reinvested. Quantification of additional taxes that may be payable on distribution is not practicable. The Company continuously monitors government proposals to make changes to tax laws, including comprehensive tax reform in the U.S. and proposed legislation in certain foreign jurisdictions resulting from the adoption of the Organization for Economic Cooperation and Development (“OECD”) policies. If legislative changes are enacted in other countries, any of these proposals may include increasing or decreasing existing statutory tax rates. A change in statutory tax rates in any country would result in the revaluation of Amneal’s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. As a U.S. company with subsidiaries in, among other countries, India, Switzerland, Ireland and the U.K, we carefully evaluate how many of these many countries are implementing legislation and other guidance to align their international tax rules with the OECD Base Erosion and Profit Shifting recommendations and action plan that aim to standardize and modernize global corporate tax policy, including changes to cross-border tax, transfer pricing documentation rules, and nexus-based tax incentive practices. The OECD has issued a two-pillar approach to global taxation, focusing on global profit allocation and a global minimum tax rate. The “Pillar One” global profit allocation proposal would not apply to the Company, since it generally applies to companies with global revenues exceeding €20 billion (approximately $22 billion using the exchange rate as of December 31, 2023). The Company has begun to evaluate the “Pillar Two” proposal which focuses on a global minimum tax of at least 15%. Legislation for the “Pillar Two” proposal has been enacted in certain jurisdictions in which the Company operates. The legislation will be effective with the financial year beginning on January 1, 2024. While the tax rates in most of the jurisdictions in which the Company operates exceed 15%, the Company is assessing whether there will be any potential exposure to Pillar Two income taxes. The potential exposure, if any, is currently not known or reasonably estimable.

(Loss) Earnings per Share

(Loss) Earnings per Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
(Loss) Earnings per Share	(Loss) Earnings per Share Following the implementation of the Reorganization on November 7, 2023 (refer to Note 1. Nature of Operations for additional information), all outstanding shares of Old PubCo Class A Common Stock and Old PubCo Class B Common Stock were exchanged for an equivalent number of shares of Class A common stock of the Company. Basic (loss) earnings per share of Class A common stock was computed by dividing net (loss) income attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period. Diluted (loss) earnings per share of Class A common stock was computed by dividing net (loss) income attributable to Amneal Pharmaceuticals, Inc. by the weighted-average number of shares of Class A common stock outstanding during the period, adjusted to give effect to potentially dilutive securities. The weighted-average number of shares of Class A common stock for all periods prior to the Reorganization includes shares of Old PubCo Class A Common Stock. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted (loss) earnings per share of Class A common stock (in thousands, except per share amounts): Year Ended December 31, 2023 2022 2021 Numerator: Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (83,993) $ (129,986) $ 10,624 Denominator: Weighted-average shares outstanding - basic 176,136 150,944 148,922 Effect of dilutive securities: Stock options — — 767 Restricted stock units — — 2,132 Weighted-average shares outstanding - diluted 176,136 150,944 151,821 Net loss (income) per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: Basic $ (0.48) $ (0.86) $ 0.07 Diluted $ (0.48) $ (0.86) $ 0.07 Prior to the Reorganization, shares of Old PubCo Class B Common Stock did not share in the earnings or losses of the Company and, therefore, were not participating securities. As such, separate presentation of basic and diluted (loss) earnings per share of Old PubCo Class B Common Stock under the two-class method was not presented. Effective with the Reorganization, all outstanding shares of Old PubCo Class B Common Stock were surrendered and canceled. The following table presents potentially dilutive securities excluded from the computations of diluted (loss) earnings per share of Class A common stock (in thousands): Years Ended December 31, 2023 2022 2021 Stock options 2,416 (1) 2,648 (1) 347 (3) Restricted stock units 10,511 (1) 10,755 (1) — Performance stock units 6,944 (1) 7,174 (1) 5,055 (4) Shares of Old PubCo Class B Common Stock — 152,117 (2) 152,117 (2) (1) Excluded from the computation of diluted loss per share of Class A common stock for the years ended December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company for the years ended December 31, 2023 and 2022. (2) Shares of Old PubCo Class B Common Stock were considered potentially dilutive shares of Class A common stock. Shares of Old PubCo Class B Common Stock were excluded from the computations of diluted (loss) earnings per share of Class A common stock for each of the years ended December 31, 2022 and 2021 because the effect of their inclusion would have been anti-dilutive under the if-converted method. (3) Excluded from the computation of diluted earnings per share of Class A common stock for the year ended December 31, 2021 because the exercise price of the stock options exceeded the average market price of the Class A common stock during the period (out-of-the-money). (4) Excluded from the computation of diluted earnings per share of Class A common stock for the year ended December 31, 2021 because the performance vesting conditions were not met.

Trade Accounts Receivable, Net

Trade Accounts Receivable, Net	12 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
Trade Accounts Receivable, Net	Trade Accounts Receivable, Net Trade accounts receivable, net is comprised of the following (in thousands): December 31, December 31, Gross accounts receivable $ 1,199,980 $ 1,344,959 Allowance for credit losses (3,022) (2,122) Contract charge-backs and sales volume allowances (1) (559,334) (573,592) Cash discount allowances (23,892) (27,454) Subtotal (586,248) (603,168) Trade accounts receivable, net $ 613,732 $ 741,791 (1) Refer to Note 4. Revenue Recognition for additional information. Concentration of Receivables Trade accounts receivables from customers representing 10% or more of the Company’s total trade accounts receivable were as follows: December 31, 2023 December 31, 2022 Customer A 40 % 41 % Customer B 24 % 25 % Customer C 22 % 21 %

Inventories

Inventories	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are comprised of the following (in thousands): December 31, December 31, Raw materials $ 217,744 $ 224,607 Work in process 59,563 58,522 Finished goods 304,077 247,606 Total inventories $ 581,384 $ 530,735

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are comprised of the following (in thousands): December 31, December 31, Deposits and advances $ 2,200 $ 1,821 Prepaid insurance 8,334 8,090 Prepaid regulatory fees 6,331 5,298 Income and other tax receivables 13,168 12,881 Prepaid taxes 11,899 16,593 Other current receivables (1) 9,929 33,133 Chargebacks receivable (2) 7,876 8,605 Other prepaid assets 22,948 17,144 Total prepaid expenses and other current assets $ 82,685 $ 103,565 (1) Other current receivables as of December 31, 2022 included a $21.4 million receivable for an upfront payment associated with the Orion Agreement which was collected in January 2023. Refer to Note 5. Alliance and Collaboration for additional information. (2) When a sale occurs on a contract item, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback (rebate) receivable and a reduction to cost of goods sold in the same period as the related sale.

Property, Plant, and Equipment,

Property, Plant, and Equipment, Net	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant, and Equipment, Net	Property, Plant, and Equipment, Net Property, plant, and equipment, net was comprised of the following (in thousands): December 31, December 31, Land $ 9,024 $ 10,706 Buildings 227,837 225,630 Leasehold improvements 126,461 124,668 Machinery and equipment 443,532 411,572 Furniture and fixtures 14,757 13,823 Vehicles 2,098 1,699 Computer equipment 64,227 58,344 Construction-in-progress 67,665 69,344 Total property, plant, and equipment 955,601 915,786 Less: Accumulated depreciation (508,027) (445,971) Property, plant, and equipment, net $ 447,574 $ 469,815

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The changes in goodwill were as follows (in thousands): Years Ended December 31, 2023 2022 Balance, beginning of period $ 598,853 $ 593,017 Goodwill acquired during the period — 7,553 Adjustment during the period for the Puniska Acquisition — 3,075 Currency translation (224) (4,792) Balance, end of period $ 598,629 $ 598,853 As of December 31, 2023, $366.3 million, $162.8 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. As of December 31, 2022, $366.3 million, $163.1 million, and $69.5 million of goodwill was allocated to the Specialty, Generics, and AvKARE segments, respectively. For the year ended December 31, 2022, goodwill acquired during the period was associated with the Saol Acquisition. Refer to Note 3. Acquisitions for additional information about the Saol Acquisition and Puniska Acquisition. Interim Goodwill and In-Process Research and Development Intangible Asset Impairment Tests On June 30, 2023, the Company received a complete response letter (“CRL”) from the FDA regarding its new drug application (“NDA”) for IPX203 for the treatment of Parkinson’s disease. The CRL indicated that although an adequate scientific bridge was established for the safety of one ingredient, levodopa, based on pharmacokinetic studies, it was not adequately established for the other ingredient, carbidopa, and the FDA requested additional information. The CRL did not identify any issues with respect to the efficacy or manufacturing of IPX203. As of June 30, 2023, the Company identified the receipt of this CRL as an indicator of impairment, performed the necessary fair value test, and concluded that the IPX203 IPR&D intangible asset was not impaired. During October 2023, the Company met with the FDA to align on the path to approval for IPX203. During the meeting, the FDA asked the Company to perform a QT study, a routine cardiac safety study that is required for new drugs. The Company considered the FDA’s requirement for a QT study in its June 30, 2023 fair value test. On February 7, 2024, the Company provided a complete response resubmission to the FDA for IPX203. Additionally, in light of the significance of IPX203 to the Specialty reporting unit, the Company performed an interim goodwill impairment test for its Specialty reporting unit, which is the same as the Company’s Specialty reportable segment, as of June 30, 2023. Based on the results of this test, the Company determined that the estimated fair value of the Specialty reporting unit exceeded its carrying value and there was no impairment of goodwill as of June 30, 2023. Refer to the section Annual Goodwill Impairment Test below for additional information. Annual Goodwill Impairment Test The Company performed a quantitative annual goodwill impairment test for the Generics and Specialty reporting units and a qualitative annual goodwill impairment test for the AvKARE reporting unit on October 1, 2023, the measurement date. The quantitative analysis performed included estimating the fair value of each reporting unit using both the income and market approaches. Based on the results of the annual impairment tests, the Company determined that the estimated fair values of the Generics and Specialty reporting units exceeded their respective carrying amounts as of the measurement date. Additionally, the Company concluded, as of the measurement date, that it was more likely than not that the fair value of the AvKARE reporting unit exceeded its carrying value and its goodwill was not impaired. Therefore, the Company did not record an impairment charge for the year ended December 31, 2023. Except for the receipt of the IPX203 CRL, there were no indicators of goodwill impairment during the year ended December 31, 2023, including the period subsequent to the measurement date. In performing the quantitative annual goodwill impairment test, the Company utilized long-term growth rates for its Generics and Specialty reporting units ranging from no growth to 1.0% and a discount rate of 13.0% in its estimation of fair value. As of October 1, 2023, the estimated fair value of the Generics reporting unit was in excess of its carrying value by approximately 46%, and the estimated fair value of the Specialty reporting unit was in excess of its carrying value by approximately 88%. A 500-basis point increase in the assumed discount rates utilized in each test would not have resulted in a goodwill impairment charge in the Company's Generics or Specialty reporting units. While management believes the assumptions used were reasonable and commensurate with the views of a market participant, changes in key assumptions for these reporting units, including increasing the discount rate, lowering forecasts for revenue and operating margin or lowering the long-term growth rate, could result in a future goodwill impairment. Intangible assets were comprised of the following (in thousands): December 31, 2023 December 31, 2022 Weighted- Cost Accumulated Net Cost Accumulated Amortization Net Amortizing intangible assets: Product rights 6.3 $ 1,198,971 $ (703,297) $ 495,674 $ 1,222,762 $ (573,281) $ 649,481 Other intangible assets 3.3 111,800 (72,896) 38,904 133,800 (77,943) 55,857 Total 1,310,771 (776,193) 534,578 1,356,562 (651,224) 705,338 In-process research and development 355,845 — 355,845 390,755 — 390,755 Total intangible assets $ 1,666,616 $ (776,193) $ 890,423 $ 1,747,317 $ (651,224) $ 1,096,093 For the year ended December 31, 2023, the Company recognized a total of $66.9 million of intangible asset impairment charges, of which $36.1 million was recognized in cost of goods sold and $30.8 million was recognized in in-process research and development impairment charges. Cost of sales impairment charges for the year ended December 31, 2023 of $36.1 million primarily related to a reduction in promotional focus on LYVISPAH™, resulting in significantly lower than forecasted future cash flows. IPR&D impairment charges for the year ended December 31, 2023 of $30.8 million were related to one Generics asset and one Specialty asset, both of which experienced adverse clinical trials results in the fourth quarter of 2023 and resulted in significantly lower than expected future cash flows. For the year ended December 31, 2022, the Company recognized a total of $24.1 million of intangible asset impairment charges, of which $11.1 million was recognized in cost of goods sold and $13.0 million was recognized in in-process research and development impairment charges. Cost of sales impairment charges for the year ended December 31, 2022 of $11.1 million related to currently marketed products of which (i) one product experienced significant price erosion during 2022, resulting in significantly lower than expected future cash flows and negative margins, (ii) the supply agreement of one product was terminated during 2022 and therefore the asset was not recoverable and (iii) one product was no longer expected to be sold to a key customer, and therefore the asset was not recoverable. IPR&D impairment charges for the year ended December 31, 2022 of $13.0 million related to (i) one asset that experienced a delay in its expected launch date and (ii) one asset that experienced significant expected price erosion, both of which resulted in significantly lower than expected future cash flows. For the year ended December 31, 2021, the Company recognized a total of $23.4 million of intangible asset impairment charges, of which $22.7 million was recognized in cost of goods sold refer to Note 5. Alliance and Collaboration for additional information about the Company’s Levothyroxine license with JSP) . Additionally, the supply agreements for two currently marketed products were terminated early due to market conditions. The IPR&D impairment charge of $0.7 million was related to one product that experienced a delay in its expected launch date, resulting in significantly lower than expected future cash flows. Amortization expense related to intangible assets for the years ended December 31, 2023, 2022 and 2021 was $163.2 million, $172.1 million and $172.7 million, respectively. The following table presents future amortization expense for the next five years and thereafter, excluding $355.8 million of IPR&D intangible assets (in thousands): Future 2024 $ 159,059 2025 119,404 2026 70,708 2027 50,380 2028 31,656 Thereafter 103,371 Total $ 534,578

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2023
Other Assets [Abstract]
Other Assets	Other Assets Other assets were comprised of the following (in thousands): December 31, December 31, Interest rate swap (1) $ 37,089 $ 85,586 Security deposits 3,602 3,523 Long-term prepaid expenses 3,273 3,711 Deferred revolving credit facility costs 4,427 2,206 Other long-term assets 7,126 8,191 Total $ 55,517 $ 103,217 (1) Refer to Note 19. Fair Value Measurements and Note 20. Financial Instruments

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Accounts Payable and Accrued Expenses Accounts payable and accrued expenses were comprised of the following (in thousands): December 31, December 31, Accounts payable $ 143,572 $ 165,980 Accrued returns allowance (1) 136,486 145,060 Accrued compensation 71,122 54,038 Accrued Medicaid and commercial rebates (1) 90,690 86,030 Accrued royalties 23,342 19,309 Commercial chargebacks and rebates 10,226 10,226 Accrued professional fees 11,005 11,386 Accrued other 48,219 46,170 Total accounts payable and accrued expenses $ 534,662 $ 538,199 (1) Refer to Note 4. Revenue Recognition for additional information.

Debt

Debt	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Debt	Debt The following is a summary of the Company’s term loan indebtedness (in thousands): December 31, December 31, Term Loan Due 2025 $ 191,979 $ 2,563,876 Term Loan Due 2028 2,351,647 — Rondo Term Loan due 2025 — 72,000 Total debt 2,543,626 2,635,876 Less: debt issuance costs (123,497) (13,934) Total debt, net of debt issuance costs 2,420,129 2,621,942 Less: current portion of long-term debt (34,125) (29,961) Total long-term debt, net $ 2,386,004 $ 2,591,981 Overview of Amneal Credit Facilities On May 4, 2018 the Company entered into a Term Loan Credit Agreement (the “Term Loan Credit Agreement”) that provided a term loan (“Term Loan Due 2025”) with a principal amount of $2.7 billion and an asset backed revolving credit facility (“Revolving Credit Facility”) under which loans and letters of credit up to a principal amount of $500.0 million were available (principal amount of up to $25.0 million was available for letters of credit). On June 2, 2022, the Company entered into a revolving credit agreement (the “New Credit Agreement”) that terminated the lender commitments under the Revolving Credit Facility, and replaced them with a new $350.0 million senior secured revolving credit facility that matures on June 2, 2027 (the “New Revolving Credit Facility”). In addition, the New Credit Agreement (i) provided for up to $25.0 million for the purpose of issuing letters of credit, (ii) provided for up to $35.0 million for the purpose of issuing swingline loans, and (iii) allowed the Company to request an incremental increase in the revolving facility commitments by up to $150.0 million. On November 14, 2023, the Company and certain existing consenting lenders under the Term Loan Credit Agreement entered into an amendment to the Term Loan Due 2025 (the “New Term Loan Credit Agreement”). As a result of this transaction (the “Refinancing”), the Company exchanged and refinanced $2.35 billion of the $2.54 billion of principal then outstanding under the Term Loan Due 2025, at par, for new term loans that mature on May 4, 2028 (the “Term Loan Due 2028”). After the Refinancing, the principal remaining on the Term Loan Due 2025 was $192.0 million. From the date of the Refinancing to December 31, 2023, no principal payments were due or paid under the Term Loan Due 2025 or the Term Loan Due 2028. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company’s interest rate exposure associated with the variability in future cash flows with its Term Loan Due 2025. In connection with the refinancing, the Company amended this interest rate agreement. For further details on this, refer to Note 20. Financial Instruments. Additionally on November 14, 2023, the Company entered into an amendment to the New Revolving Credit Facility (the “Amended New Revolving Credit Facility”), pursuant to which certain lenders agreed to increase their commitments such that the aggregate revolving commitments increased to up to $600.0 million. The Term Loan Due 2028, Term Loan Due 2025, Amended New Revolving Credit Facility, New Revolving Credit Facility and Revolving Credit Facility are collectively referred to as the “Senior Secured Credit Facilities”. The proceeds of any loans made under the Senior Secured Credit Facilities can be used for capital expenditures, acquisitions, working capital needs and other general purposes, subject to covenants as described below. Amneal Term Loans Term Loan Due 2025 The Term Loan Due 2025 required principal repayments in equal quarterly installments at a rate of 1.00% of the original principal amount annually, with the balance payable at maturity on May 4, 2025. Subject to the refinancing on November 14, 2023, the Company is no longer required to repay quarterly principal installments, and as a result, the Company is required to repay the remaining principal balance of $192.0 million at maturity on May 4, 2025. Prior to May 31, 2023, the Term Loan Due 2025’s variable annual interest rate was a LIBOR-designated rate plus 3.5%. On May 31, 2023, the Company executed an amendment to the Term Loan Due 2025, which changed the variable reference rate from LIBOR to the one-month adjusted term secured overnight financing rate (“SOFR”), subject to a floor of (0.11448%) plus 3.5%. After adopting ASC 848, Reference Rate Reform and electing certain applicable practical expedients, this amendment did not have a material impact on the Company’s consolidated financial statements for the year ended December 31, 2023. As of December 31, 2023, the interest rate for borrowings under the Term Loan Due 2025 was approximately 9.0%. The Term Loan Due 2025 was recorded in the balance sheet net of issuance costs. In 2018, the Company incurred costs associated with the Term Loan Due 2025 of $38.1 million, which were capitalized and amortized over the life of the Term Loan Due 2025 to interest expense using the effective interest method. Subject to the amendment to the Term Loan Due 2025, unamortized debt issuance costs of $0.6 million and $7.3 million were allocated on a pro rata basis to the Term Loan Due 2025 and Term Loan Due 2028, respectively. The remaining unamortized debt issuance costs will be amortized over the life of the Term Loan Due 2025 to interest expense using the effective interest method. For each of the years ended December 31, 2023, 2022 and 2021, amortization of debt issuance costs related to the Term Loan Due 2025 were $4.7 million, $5.4 million and $5.5 million, respectively. Refinancing and Term Loan Due 2028 The Term Loan Due 2028 is repayable in equal quarterly installments in an amount equal to 2.50% per annum of the original principal amount thereof, with the remaining balance due at final maturity on May 4, 2028. Interest is payable on borrowings under the Term Loan Due 2028 at a rate equal to the term SOFR benchmark rate or the base rate, plus an applicable margin, in each case, subject to a term SOFR benchmark rate floor of 0.00% or a base rate floor of 1.00%, as applicable. The applicable margin for borrowings under the Term Loan Due 2028 is 5.50% per annum for term SOFR benchmark rate loans and 4.50% per annum for base rate loans. As of December 31, 2023, the interest rate for borrowings under the Term Loan Due 2028 was approximately 10.9%. The Refinancing involved multiple lenders that were considered members of a loan syndicate. In determining whether the refinancing of the Term Loan Due 2025 was to be accounted for as a debt extinguishment or a debt modification, the Company considered whether creditors remained the same or changed and whether the changes in debt terms were substantial, on a lender-by-lender basis, in accordance with the guidance in ASC 470, Debt . As a result of this analysis, the Company legally has separate loans from each lender in the syndicate of the Term Loan Due 2028 and each lender has a contractual right to payments from the Company. The Company concluded that, on a lender-by-lender basis, debt held by 99% of the lenders included in the Refinancing is considered modified, with the remaining debt held by lenders considered to be extinguished. In accordance with ASC 470, Debt , the Company capitalized costs of $118.6 million associated with the Term Loan Due 2028, primarily comprised of lender fees, which were combined with $7.3 million of unamortized debt issuance costs associated with the Term Loan Due 2025 (as discussed above), both to be amortized to interest expense over the life of the Term Loan Due 2028 using the effective interest method. In connection with the Refinancing, the Company recognized a loss of $40.8 million for the year ended December 31, 2023, which was primarily comprised of debt issuance costs associated with the portion of the Term Loan Due 2025 that was modified. For the year ended December 31, 2023, amortization of debt issuance costs related to the Term Loan Due 2028 was $2.9 million. The borrowings under the Term Loan Due 2028 are guaranteed by certain wholly-owned subsidiaries of the Company that also guarantee the Term Loan Due 2025 (together with the Company, the “Loan Parties”). The Loan Parties’ obligations under the New Term Loan Credit Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in (i) all tangible and intangible assets of the Loan Parties, except for certain excluded assets, and (ii) all of the equity interests of the subsidiaries of the Loan Parties (except for certain excluded subsidiaries and excluded assets and limited, in the case of the voting equity interests of certain foreign subsidiaries and certain domestic subsidiaries that hold no assets other than equity interests of foreign subsidiaries, to 65% of the voting equity interests of such subsidiaries). New Credit Agreement, New Revolving Credit Facility and Amended New Credit Facility The New Revolving Credit Facility bears an interest rate equal to the alternate base rate (“ABR”) or SOFR, plus an applicable margin, in each case, subject to an ABR floor of 1.00% or a SOFR floor of 0.00%, as applicable. The applicable margin for the New Revolving Credit Facility was initially 0.25% per annum for ABR loans and 1.25% per annum for SOFR loans. The applicable margin on borrowings under the New Revolving Credit Facility thereafter adjusts, ranging from 0.25% to 0.50% per annum for ABR loans and from 1.25% to 1.50% per annum for SOFR loans determined by the average historical excess availability. The Company paid a commitment fee based on the average daily unused amount of the New Revolving Credit Facility at a rate of 0.25% per annum. The Amended New Revolving Credit Facility bears interest rate consistent with the New Revolving Credit Facility. The maturity date of the Amended New Revolving Credit Facility is June 2, 2027, subject to a springing maturity in certain circumstances set forth in the Amended New Revolving Credit Facility. The Company incurred costs associated with the Revolving Credit Facility of $4.6 million, which were capitalized and are being amortized over the life of the agreement. Subject to the June 2, 2022 refinancing, there was a decrease in the borrowing capacity of certain lenders between the New Revolving Credit Facility and the Revolving Credit Facility. As a result, the Company recorded a $0.3 million charge for the year ended December 31, 2022 in loss on refinancing. Additionally, the Company incurred costs of $1.6 million associated with the New Credit Agreement, which were capitalized as deferred financing costs with the remaining unamortized costs associated with the Revolving Credit Facility, and were amortized over the life of the New Credit Agreement. Subject to the November 14, 2023 amendment, there was an increase in the borrowing capacity of all lenders between the Amended New Revolving Credit Facility and the New Revolving Credit Facility. The Company incurred costs of $2.4 million associated with the Amended New Revolving Credit Facility, which were capitalized as deferred financing costs with the remaining unamortized costs associated with the New Revolving Credit Facility, and will be amortized over the life of the Amended New Credit Agreement. Costs associated with the Amended New Revolving Credit Facility and the New Revolving Credit Facility have been recorded in other assets. For each of the years ended December 31, 2023, 2022 and 2021, amortization of deferred financing costs were $0.5 million, $0.7 million and $0.9 million, respectively. In January 2023, the Company borrowed $80.0 million under the New Revolving Credit Facility to fund an $83.9 million payment related to the Opana ER® antitrust litigation settlement agreements (refer to Note 21. Commitments and Contingencies ). Prior to the Refinancing, the Company repaid $70.0 million of its borrowings under the New Revolving Credit Facility from cash on hand. On November 14, 2023, the Company borrowed $109.0 million under the Amended New Revolving Credit Facility to fund transaction costs related to the refinancing of the Company’s Term Loan Due 2025 and New Revolving Credit Facility. As of December 31, 2023, the Company had $179.0 million in borrowings and $225.2 million of available capacity under the Amended New Revolving Credit Facility (principal amount of up to $20.9 million remains available for letters of credit) . At December 31, 2022, the Company had $60.0 million outstanding under the New Revolving Credit Facility. Covenants to the Senior Secured Credit Facilities The Senior Secured Credit Facilities contain a number of covenants that, among other things, create liens on Amneal’s and its subsidiaries’ assets. The Senior Secured Credit Facilities contain certain negative covenants that, among other things and subject to certain exceptions, restrict Amneal’s and its subsidiaries’ ability to incur additional debt or guarantees, grant liens, make loans, acquisitions or other investments, dispose of assets, merge, dissolve, liquidate or consolidate, pay dividends or other payments on capital stock, make optional payments or modify certain debt instruments, modify certain organizational documents, enter into arrangements that restrict the ability to pay dividends or grant liens, or enter into or consummate transactions with affiliates. The Senior Secured Credit Facilities contain customary events of default, subject to certain exceptions. Upon the occurrence of certain events of default, the obligations under the Senior Secured Credit Facilities may be accelerated and the commitments may be terminated. In addition, the Amended New Revolving Credit Facility also included a financial covenant whereby the Company was required to maintain a minimum fixed-charge coverage ratio if certain borrowing conditions were met. At December 31, 2023, Amneal was in compliance with all covenants associated with the Senior Secured Credit Facilities. Annually, the Company is also required to calculate the amount of excess cash flows, as defined in the Term Loan Credit Agreement and New Term Loan Credit Agreement. Based on the results of the excess cash flows calculation for the years ended December 31, 2023, 2022 and 2021, no additional principal payments were due. Rondo Credit Facilities and Note Payable - Related Party Rondo Acquisitions Financing - Revolving Credit and Term Loan Agreement On January 31, 2020, in connection with the Rondo Acquisitions, Rondo Intermediate Holdings, LLC (“Rondo Holdings”), a wholly-owned subsidiary of Rondo Holdings, LLC, entered into a revolving credit and term loan agreement (“Rondo Credit Facility”) that provided a term loan (“Rondo Term Loan”) with a principal amount of $180.0 million and a revolving credit facility (“Rondo Revolving Credit Facility”), which loans up to a principal amount of $30.0 million. The Rondo Term Loan was repayable in equal quarterly installments at a rate of 5.0% of the original principal amount annually, with the balance payable at maturity on January 31, 2025. For the year ended December 31, 2023, the Company paid the remaining outstanding principal under the Rondo Term Loan from cash on hand, of which the Company made prepayments totaling $63.0 million in excess of planned principal payments . The Rondo Credit Facility bore a variable annual interest rate, which originated as one-month LIBOR plus 3.0%. On April 30, 2023, the Company executed an amendment to the Rondo Revolving Credit Facility, which changed the variable reference rate in the Rondo Term Loan from LIBOR to the one-month adjusted term SOFR, subject to a floor of 0.1% plus 2.25%. This amendment to the Rondo Revolving Credit Facility did not have a material impact on the Company’s consolidated financial statements for the year ended December 31, 2023. On September 21, 2023, the Company executed an amendment to the Rondo Revolving Credit Facility (the “Amended Rondo Revolving Credit Facility”) that, among other things, (i) increased the aggregate revolving commitment from $30.0 million to $70.0 million, and (ii) increased the letter of credit commitment from $10.0 million to $60.0 million. The Amended Rondo Revolving Credit Facility bears a variable annual interest rate, which did not change as a result of this amendment, of one-month adjusted term SOFR, subject to a floor of 0.1% plus 2.25%. The Amended Rondo Revolving Credit Facility matures on January 31, 2025. At December 31, 2023, the variable annual interest rate is one-month SOFR plus 2.5%. Additionally, the annual interest rate for borrowings under the Amended Rondo Revolving Credit Facility may be reduced or increased by 0.25% based on step-downs and step-ups determined by the total net leverage ratio, as defined in that agreement. A commitment fee based on the average daily unused amount of the Amended Rondo Revolving Credit Facility is assessed at a rate based on total net leverage ratio, between 0.25% and 0.50% per annum. At December 31, 2023, the Amended Rondo Revolving Credit Facility commitment fee rate was 0.25% per annum. Costs associated with the Rondo Term Loan of $3.5 million and the Amended Rondo Revolving Credit Facility of $0.6 million have been capitalized and are being amortized over the life of the applicable debt instrument to interest expense using the effective interest method. The Rondo Term Loan was recorded in the balance sheet net of issuance costs. Costs associated with the Amended Rondo Revolving Credit Facility were recorded in other assets. For the year ended December 31, 2023, amortization of deferred financing costs associated with the Rondo Term Loan and Amended Rondo Revolving Credit Facility was $1.6 million. The Amended Rondo Revolving Credit Facility contains a number of covenants that, among other things, create liens on the equity securities and assets of Rondo Holdings, Rondo, AvKARE, LLC and R&S. The Amended Rondo Revolving Credit Facility contains certain negative, affirmative and financial covenants that, among other things, restrict the ability to incur additional debt, grant liens, transact in mergers and acquisitions, make certain investments and payments or engage in certain transactions with affiliates. The Amended Rondo Revolving Credit Facility also contains customary events of default. Upon the occurrence of certain events of default, the obligations under the Amended Rondo Revolving Credit Facility may be accelerated and/or the interest rate may be increased. At December 31, 2023, Rondo was in compliance with all covenants. The Company is not party to the Amended Rondo Revolving Credit Facility and is not a guarantor of any debt incurred thereunder. During the year ended December 31, 2023, the Company borrowed $30.0 million under the Amended Rondo Revolving Credit Facility for working capital purposes. The Company repaid $30.0 million of these borrowings during the year ended December 31, 2023 from cash on hand. On September 26, 2023, Rondo entered into a standby letter of credit guarantee arrangement under the Amended Rondo Revolving Credit Facility in the amount of $42.0 million for purposes of securing inventory from a certain supplier. As of December 31, 2023 , the Company had no outstanding borrowings and outstanding letters of credit of $42.0 million under the Amended Rondo Revolving Credit Facility and unused borrowing capacity of $28.0 million. Rondo Acquisitions Financing – Notes Payable-Related Party On January 31, 2020, the closing date of the Rondo Acquisitions, Rondo Partners, LLC or its subsidiary, Rondo Top Holdings, LLC, issued notes to the sellers (the “Sellers Notes”) with a stated aggregate principal amount of $44.2 million and a short-term note to a seller (the “Short-Term Seller Note”) with a stated principal amount of $1.0 million. The Sellers Notes are unsecured and accrue interest at a rate of 5% per annum, not compounded, until June 30, 2025. The Sellers Notes are subject to prepayment at the option of Rondo, as the obligor, without premium or penalty. Mandatory payment of the outstanding principal and interest is due on June 30, 2025 if certain financial targets are achieved, the borrowers’ cash flows are sufficient (as defined in the Sellers Notes) and repayment is not prohibited by senior debt. If repayment of all outstanding principal and accrued interest on the Sellers Notes is not made on June 30, 2025, the requirements for repayment are revisited on June 30 of each subsequent year until all principal and accrued interest are satisfied no later than January 31, 2030 or earlier, upon a change in control, as defined. The Short-Term Sellers Note was also unsecured, accrued interest at a rate of 1.6%, and was paid during February 2021. In accordance with ASC 805, Business Combinations, all consideration transferred was measured at its acquisition-date fair value. The Sellers Notes were stated at the fair value estimate of $35.0 million, which was estimated using the Monte-Carlo simulation approach under the option pricing framework. The Short-Term Sellers Note of $1.0 million was recorded at the stated principal amount of $1.0 million, which approximated fair value. The $9.2 million discount on the Sellers Notes will be amortized to interest expense using the effective interest method from January 31, 2020 to June 30, 2025 and the carrying value of the Sellers Notes will accrete to the stated principal amount of $44.2 million. During the year ended December 31, 2023, 2022 and 2021, amortization of the discount related to the Sellers Notes was $1.7 million, $1.7 million and $1.6 million, respectively.

Other Long-Term Liabilities

Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2023
Other Liabilities [Abstract]
Other Long-Term Liabilities	Other Long-Term Liabilities Other long-term liabilities were comprised of the following (in thousands): December 31, 2023 December 31, 2022 Uncertain tax positions $ 497 $ 563 Long-term portion of liabilities for legal matters (1) 316 49,442 Long-term compensation (2) 21,283 16,737 Contingent consideration (3) 433 11,997 Other long-term liabilities 7,466 8,729 Total other long-term liabilities $ 29,995 $ 87,468 (1) Refer to Note 21. Commitments and Contingencies for additional information. (2) Includes $11.1 million and $7.6 million of long-term liabilities under deferred compensation plans (refer to Note 19. Fair Value Measurements for certain deferred compensation plan liabilities measured at fair value) as of December 31, 2023 and 2022, respectively, and $10.2 million and $9.1 million of long-term employee benefits for the Company’s international employees as of December 31, 2023 and 2022, respectively. (3) Refer to Note 19. Fair Value Measurements for additional information.

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Leases	Leases The majority of the Company's operating and financing lease portfolio consists of corporate offices, manufacturing sites, warehouse space, R&D facilities, and land. The Company's leases have remaining lease terms of 1 year to 21 years (excluding international land easements with remaining terms of approximately 27-96 years). Rent expense for the years ended December 31, 2023, 2022 and 2021 was $21.7 million, $22.6 million, and $19.8 million, respectively. The components of total lease costs were as follows (in thousands): Years Ended December 31, 2023 2022 2021 Operating lease cost (1) $ 16,734 $ 17,800 $ 15,057 Finance lease cost: Amortization of right-of-use assets 4,972 4,808 4,713 Interest on lease liabilities 4,583 4,508 4,601 Total finance lease cost 9,555 9,316 9,314 Total lease cost $ 26,289 $ 27,116 $ 24,371 (1) Includes variable and short-term lease costs. Supplemental balance sheet information related to the Company's leases was as follows (in thousands): Operating leases December 31, 2023 December 31, 2022 Operating lease right-of-use assets $ 30,329 $ 38,211 Operating lease right-of-use assets - related party (1) 12,954 17,910 Total operating lease right-of-use assets $ 43,283 $ 56,121 Operating lease liabilities $ 24,095 $ 32,126 Operating lease liabilities - related party (1) 12,787 15,914 Current portion of operating lease liabilities 9,207 8,321 Current portion of operating lease liabilities - related party (1) 2,825 2,869 Total operating lease liabilities $ 48,914 $ 59,230 Financing leases Financing lease right of use assets $ 59,280 $ 63,424 Financing lease liabilities $ 58,566 $ 60,769 Current portion of financing lease liabilities 2,467 3,488 Total financing lease liabilities $ 61,033 $ 64,257 (1) Refer to Note 24. Related Party Transactions for information about related party leases. Supplemental cash flow information related to leases was as follows (in thousands): Years Ended December 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 4,583 $ 4,539 Operating cash flows from operating leases $ 16,036 $ 16,217 Financing cash flows from finance leases $ 3,588 $ 3,484 Non-cash activity: Right-of-use assets obtained in exchange for new operating lease liabilities $ 773 $ 7,504 Right-of-use assets obtained in exchange for new financing lease liabilities $ 856 $ 4,606 The table below reflects the weighted average remaining lease term and weighted average discount rate for the Company's operating and finance leases: December 31, 2023 December 31, 2022 Weighted average remaining lease term - operating leases 5 years 5 years Weighted average remaining lease term - finance leases 18 years 19 years Weighted average discount rate - operating leases 8.9% 8.5% Weighted average discount rate - finance leases 7.3% 7.2% Maturities of lease liabilities as of December 31, 2023 were as follow (in thousands): Operating Financing 2024 $ 15,978 $ 6,856 2025 14,544 6,874 2026 10,693 6,140 2027 7,742 5,647 2028 5,467 5,647 Thereafter 6,916 79,573 Total lease payments 61,340 110,737 Less: Imputed interest (12,426) (49,704) Total $ 48,914 $ 61,033 Maturities of lease liabilities as of December 31, 2022 were as follows (in thousands): Operating Financing 2023 $ 15,843 $ 7,976 2024 16,558 6,913 2025 14,264 6,466 2026 10,393 5,989 2027 7,420 5,645 Thereafter 11,550 85,220 Total lease payments 76,028 118,209 Less: Imputed interest (16,798) (53,952) Total $ 59,230 $ 64,257
Leases	Leases The majority of the Company's operating and financing lease portfolio consists of corporate offices, manufacturing sites, warehouse space, R&D facilities, and land. The Company's leases have remaining lease terms of 1 year to 21 years (excluding international land easements with remaining terms of approximately 27-96 years). Rent expense for the years ended December 31, 2023, 2022 and 2021 was $21.7 million, $22.6 million, and $19.8 million, respectively. The components of total lease costs were as follows (in thousands): Years Ended December 31, 2023 2022 2021 Operating lease cost (1) $ 16,734 $ 17,800 $ 15,057 Finance lease cost: Amortization of right-of-use assets 4,972 4,808 4,713 Interest on lease liabilities 4,583 4,508 4,601 Total finance lease cost 9,555 9,316 9,314 Total lease cost $ 26,289 $ 27,116 $ 24,371 (1) Includes variable and short-term lease costs. Supplemental balance sheet information related to the Company's leases was as follows (in thousands): Operating leases December 31, 2023 December 31, 2022 Operating lease right-of-use assets $ 30,329 $ 38,211 Operating lease right-of-use assets - related party (1) 12,954 17,910 Total operating lease right-of-use assets $ 43,283 $ 56,121 Operating lease liabilities $ 24,095 $ 32,126 Operating lease liabilities - related party (1) 12,787 15,914 Current portion of operating lease liabilities 9,207 8,321 Current portion of operating lease liabilities - related party (1) 2,825 2,869 Total operating lease liabilities $ 48,914 $ 59,230 Financing leases Financing lease right of use assets $ 59,280 $ 63,424 Financing lease liabilities $ 58,566 $ 60,769 Current portion of financing lease liabilities 2,467 3,488 Total financing lease liabilities $ 61,033 $ 64,257 (1) Refer to Note 24. Related Party Transactions for information about related party leases. Supplemental cash flow information related to leases was as follows (in thousands): Years Ended December 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 4,583 $ 4,539 Operating cash flows from operating leases $ 16,036 $ 16,217 Financing cash flows from finance leases $ 3,588 $ 3,484 Non-cash activity: Right-of-use assets obtained in exchange for new operating lease liabilities $ 773 $ 7,504 Right-of-use assets obtained in exchange for new financing lease liabilities $ 856 $ 4,606 The table below reflects the weighted average remaining lease term and weighted average discount rate for the Company's operating and finance leases: December 31, 2023 December 31, 2022 Weighted average remaining lease term - operating leases 5 years 5 years Weighted average remaining lease term - finance leases 18 years 19 years Weighted average discount rate - operating leases 8.9% 8.5% Weighted average discount rate - finance leases 7.3% 7.2% Maturities of lease liabilities as of December 31, 2023 were as follow (in thousands): Operating Financing 2024 $ 15,978 $ 6,856 2025 14,544 6,874 2026 10,693 6,140 2027 7,742 5,647 2028 5,467 5,647 Thereafter 6,916 79,573 Total lease payments 61,340 110,737 Less: Imputed interest (12,426) (49,704) Total $ 48,914 $ 61,033 Maturities of lease liabilities as of December 31, 2022 were as follows (in thousands): Operating Financing 2023 $ 15,843 $ 7,976 2024 16,558 6,913 2025 14,264 6,466 2026 10,393 5,989 2027 7,420 5,645 Thereafter 11,550 85,220 Total lease payments 76,028 118,209 Less: Imputed interest (16,798) (53,952) Total $ 59,230 $ 64,257

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification for each reporting period. The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis (in thousands): Fair Value Measurement Based on December 31, 2023 Total Quoted Significant Significant Assets Interest Rate Swap (1) $ 37,089 $ — $ 37,089 $ — Liabilities Deferred compensation plan liabilities (2) $ 9,100 $ — $ 9,100 $ — Contingent consideration liability (3) $ 921 $ — $ — $ 921 December 31, 2022 Assets Interest Rate Swap (1) $ 85,586 $ — $ 85,586 $ — Liabilities Deferred compensation plan liabilities (2) $ 9,674 $ — $ 9,674 $ — Contingent consideration liability (3) $ 15,427 $ — $ — $ 15,427 (1) The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 20. Financial Instruments for information about the Company’s interest rate swap. (2) These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants. (3) The fair value measurement of contingent consideration liability has been classified as a Level 3 recurring liability as its valuation requires judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair value could be higher or lower than what the Company determined. As of December 31, 2023 and 2022, the contingent consideration liability associated with the Saol Acquisition included $0.1 million and $0.1 million, respectively, recorded in accounts payable and accrued expenses and $0.4 million and $12.0 million, respectively, recorded in other-longer term liabilities. As of December 31, 2023 and 2022, the contingent consideration liability associated with the KSP Acquisition included $0.4 million and $3.3 million, respectively, and was recorded within related party payables - long term. Refer to Note 3. Acquisitions for additional about the KSP Acquisition and the Saol Acquisition. There were no transfers between levels in the fair value hierarchy during the year ended December 31, 2023. Contingent consideration On April 2, 2021, the Company completed the KSP Acquisition, which provided for contingent milestone payments of up to an aggregate of $8.0 million (undiscounted) upon the achievement of certain regulatory milestones, as well as contingent royalty payments that are tiered depending on the net sales amount of aggregate annual net sales for certain future pharmaceutical products. On February 9, 2022, the Company completed the Saol Acquisition, which provides for contingent royalty payments that are tiered depending on the aggregate annual net sales for certain pharmaceutical products, beginning in 2023. Contingent royalty payments for the year ended December 31, 2023 were not material. The following table provides a reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): Year Ended December 31, 2023 Year Ended Balance, beginning of period $ 15,427 $ 5,900 Addition due to the Saol Acquisition — 8,796 Net change in fair value during period (14,491) 731 Payments (15) — Balance, end of period $ 921 $ 15,427 The fair value measurement of the contingent consideration liabilities was determined based on significant unobservable inputs, including the discount rate, estimated probabilities of success, timing of achieving specified regulatory milestones and the estimated amount of future sales of the acquired products. The contingent consideration liability is estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to fair value of the contingent consideration liabilities can result from changes to one or a number of the aforementioned inputs. If different assumptions were used for various inputs, the estimated fair value could be higher or lower than what the Company determined. The following table summarizes the significant unobservable inputs used in the fair value measurement of our contingent consideration liabilities as of December 31, 2022 (the fair value of contingent consideration was immaterial as of December 31, 2023): Contingent Consideration Liability Fair Value as of December 31, 2022 (in thousands) Unobservable input Range Weighted Average (1) Regulatory Milestones (KSP Acquisition) $ 390 Discount rate 7.2% — 8.5% 7.3 % Probability of payment 1.8% — 20.0% 18.6 % Projected year of payment 2024 — 2026 2024 Royalties (KSP Acquisition) $ 2,900 Discount rate 12.5% — 12.5% 12.5 % Probability of payment 1.8% — 20.0% 18.6 % Projected year of payment 2024 — 2033 2028 Royalties (Saol Acquisition) $ 12,137 Discount rate 17.8% — 17.8% 17.8 % Projected year of payment 2023 — 2033 2027 (1) Unobservable inputs were weighted by the relative fair value of each product candidate acquired. Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying amounts of cash, accounts receivable and accounts payable approximate their fair values due to the short-term maturity of these instruments. The Term Loan Due 2025 is in the Level 2 category within the fair value level hierarchy. The fair value was determined using market data for valuation. The fair value of the Term Loan Due 2025 at December 31, 2023 and 2022 was approximately $190.8 million and $2.3 billion, respectively. The Term Loan Due 2028 is in the Level 2 category within the fair value level hierarchy. The fair value was determined using market data for valuation. The fair value of the Term Loan Due 2028 at December 31, 2023 was approximately $2.3 billion. The Rondo Term Loan is in the Level 2 category within the fair value level hierarchy. The fair value of the Rondo Term Loan at December 31, 2022 was approximately $70.9 million. The Sellers Notes are in the Level 2 category within the fair value level hierarchy. At December 31, 2023 and 2022 the fair value of the Sellers Notes were $41.0 million and $39.1 million, respectively. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis There were no non-recurring fair value measurements during the years ended December 31, 2023 and 2022.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Financial Instruments The Company uses an interest rate swap to manage its exposure to market risks for changes in interest rates. Interest Rate Risk Interest income earned on cash and cash equivalents may fluctuate as interest rates change; however, due to their relatively short maturities, the Company does not hedge these assets or their investment cash flows and the impact of interest rate risk is not material. The Company is exposed to interest rate risk on its debt obligations. The Company's debt obligations consist of variable-rate and fixed-rate debt instruments (for further details, refer to Note 16. Debt ). The Company's primary objective is to achieve the lowest overall cost of funding while managing the variability in cash outflows within an acceptable range. To achieve this objective, the Company initially entered into an interest rate swap on the Term Loan Due 2025. On November 14, 2023, in connection with the refinancing of the Term Loan Due 2025 and the New Credit Facility, the Company novated its swap agreement to another counterparty and, in connection with such novation, amended the interest rate swap agreement. Refer to section “ Interest Rate Derivative - Cash Flow Hedge ” below for additional information. Interest Rate Derivative – Cash Flow Hedge The interest rate swap involves the periodic exchange of payments without the exchange of underlying principal or notional amounts. In October 2019, the Company entered into an interest rate lock agreement for a total notional amount of $1.3 billion to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month LIBOR associated with its Term Loan Due 2025 (the “October 2019 Swap”). On May 31, 2023, the Company executed an amendment to the October 2019 Swap that, among other things, changed the variable reference rate from LIBOR to the one-month SOFR (the “Amended October 2019 Swap”). On November 14, 2023, in connection with the Company’s refinancing of the Term Loan Due 2025 and the New Credit Facility (refer to Note 16. Debt ), the Company novated its Amended October 2019 Swap to another counterparty and subsequently amended the interest rate agreement. Specifically, the amendments modified (i) the fixed rate payable by the counterparty from 1.3660% to a new fixed rate of 2.7877% and (ii) extended the termination date through May 4, 2027 (i.e., one year before the Term Loan Due 2028 matures) (the “November 2023 Swap”). The amendments did not change the notional amount of $1.3 billion. The purpose of the November 2023 Swap is to hedge part of the Company's interest rate exposure associated with the variability in future cash flows from changes in the one-month SOFR associated with the Term Loan Due 2028. The Company used a strategy commonly referred to as “blend and extend,” which allows the existing asset position of the swap agreement to be effectively blended into the new interest rate swap agreement. As a result of this transaction, on November 14, 2023, the Amended October 2019 Swap was de-designated and the unrealized gain of $66.7 million was recorded within accumulated other comprehensive (loss) income and will be amortized as a reduction of interest expense, net, over the original term of the of the Amended October 2019 Swap (until May 2025), as the hedged transactions affect earnings. Additionally, the November 2023 Swap had a fair value of $66.7 million at inception, and will be ratably recorded to accumulated other comprehensive (loss) income and reclassified to interest expense, net, over the term of the November 2023 Swap, as the hedged transactions affect earnings. At the inception of the November 2023 Swap, the Company determined that the swap qualified for cash flow hedge accounting under ASC 815. Therefore, changes in the fair value of the swap, net of taxes, will be recognized in other comprehensive (loss) income each period, then reclassified into the consolidated statements of operations as a component of interest expense, net in the period in which the hedged transaction affects earnings. The November 2023 Swap is the only swap agreement outstanding as of December 31, 2023. The effectiveness of the outstanding November 2023 Swap will be assessed qualitatively by the Company during the life of the hedge by (i) comparing the current terms of the hedge with the related hedged debt to assure they continue to coincide based upon initial quantitative assessment of the amended swap and (ii) through an evaluation of the ability of the counterparty to the hedge to honor its obligations under the hedge. During the year ended December 31, 2023, the Company reclassified a gain of $3.4 million from accumulated other comprehensive income (loss) to interest expense, net. Approximately $26.2 million of net gains included in accumulated other comprehensive loss as of December 31, 2023 are expected to be reclassified into earnings within the next 12 months as interest payments are made on the Company’s Term Loan Due 2028 and amortization of the amounts included in accumulated other comprehensive (loss) income occurs. As of December 31, 2023 , the total gain, net of income taxes, related to the Company’s cash flow hedge of $33.7 million was recognized in accumulated other comprehensive loss. As of December 31, 2022, t he total gain, net of income taxes, related to the Company’s cash flow hedge was $85.6 million, of which $42.3 million was recognized in accumulated other comprehensive (loss) income and $43.3 million was recognized in non-controlling interests. A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands): December 31, 2023 December 31, 2022 Derivatives Designated as Hedging Instruments Balance Sheet Fair Value Balance Sheet Fair Value Variable-to-fixed interest rate swap Other Assets $ 37,089 Other Assets $ 85,586

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments Commercial Manufacturing, Collaboration, License, and Distribution Agreements The Company continues to seek to enhance its product line and develop a balanced portfolio of differentiated products through product acquisitions and in-licensing. Accordingly, the Company, in certain instances, may be contractually obligated to make potential future development, regulatory, and commercial milestone, royalty and/or profit-sharing payments in conjunction with collaborative agreements or acquisitions that the Company has entered with third parties. The Company has also licensed certain technologies or IP from various third parties. The Company is generally required to make upfront payments as well as other payments upon successful completion of regulatory or sales milestones. The agreements generally permit the Company to terminate the agreement with no significant continuing obligation. The Company could be required to make significant payments pursuant to these arrangements. These payments are contingent upon the occurrence of certain future events and, given the nature of these events, it is unclear when, if ever, the Company may be required to pay such amounts. Further, the timing of any future payment is not reasonably estimable. Refer to Note 5. Alliance and Collaboration for additional information. Certain of these arrangements are with related parties. Refer to Note 24. Related Party Transactions for additional information. Contingencies Legal Proceedings The Company's legal proceedings are complex, constantly evolving, and subject to uncertainty. As such, the Company cannot predict the outcome or impact of its significant legal proceedings which are set forth below. Additionally, the Company manufactures and derives a portion of its revenue from the sale of pharmaceutical products in the opioid class of drugs and may therefore face claims arising from the regulation and/or consumption of such products. While the Company believes it has meritorious claims and/or defenses to the matters described below (and intends to vigorously prosecute and defend them), the nature and cost of litigation is unpredictable, and an unfavorable outcome of such proceedings could include damages, fines, penalties and injunctive or administrative remedies. For any proceedings where losses are probable and reasonably capable of estimation, the Company accrues a potential loss. When the Company has a probable loss for which a reasonable estimate of the liability is a range of losses and no amount within that range is a better estimate than any other amount, the Company records the loss at the low end of the range. While these accruals have been deemed reasonable by the Company’s management, the assessment process relies heavily on estimates and assumptions that may ultimately prove inaccurate or incomplete. Additionally, unforeseen circumstances or events may lead the Company to subsequently change its estimates and assumptions. Unless otherwise indicated below, the Company is unable at this time to estimate the possible loss or the range of loss, if any, associated with such legal proceedings and claims. Any such claims, proceedings, investigations or litigation, regardless of the merits, might result in substantial costs to defend or settle, borrowings under the Company’s debt agreements, restrictions on product use or sales, or otherwise harm the Company’s business. The ultimate resolution of any or all claims, legal proceedings or investigations are inherently uncertain and difficult to predict, could differ materially from the Company’s estimates and could have a material adverse effect on its results of operations and/or cash flows in any given accounting period, or on its overall financial condition. The Company currently intends to vigorously prosecute and/or defend these proceedings as appropriate. From time to time, however, the Company may settle or otherwise resolve these matters on terms and conditions that it believes to be in its best interest. An insurance recovery, if any, is recorded in the period in which it is probable the recovery will be realized. For the year ended December 31, 2023, charges related to legal matters, net were $1.8 million, comprised of $3.9 million in charges associated with Generics civil prescription opioid litigation, a $3.0 million charge for the settlement of a Generics customer claim, a $3.0 million charge for the settlement of Generics commercial antitrust litigation, and a $1.9 million charge for the settlement of a corporate stockholder derivative lawsuit, partially offset by a $10.0 million credit from the settlement of Generics patent infringement matters. For the year ended December 31, 2022, the Company recorded charges related to legal matters, net of $269.9 million , primarily for corporate Opana® ER antitrust litigation of $262.8 million and Generics segment civil prescription opioid litigation of $18.0 million, partially offset by corporate insurance recoveries associated with securities class actions of $15.5 million. For the year ended December 31, 2021, charges related to legal matters, net were for the settlement of a corporate securities class action. Liabilities for legal matters were comprised of the following (in thousands): December 31, Matter 2023 2022 Opana ER® antitrust litigation $ 50,000 $ 83,944 Opana ER® antitrust litigation-accrued interest 2,347 1,423 Civil prescription opioid litigation 21,189 17,993 Other 3,452 4,123 Current portion of liabilities for legal matters $ 76,988 $ 107,483 Opana ER® antitrust litigation $ — $ 50,000 Opana ER ® antitrust litigation-imputed interest — (1,405) Opana ER ® antitrust litigation-accrued interest — 847 Civil prescription opioid litigation 316 — Long-term portion of liabilities for legal matters (included in other long-term liabilities) $ 316 $ 49,442 Refer to the respective discussions below for information about the significant matters summarized above. Medicaid Reimbursement and Price Reporting Matters The Company is required to provide pricing information to state agencies, including agencies that administer federal Medicaid programs. Certain state agencies have alleged that manufacturers have reported improper pricing information, which allegedly caused them to overpay reimbursement costs. Other agencies have alleged that manufacturers have failed to timely file required reports concerning pricing information. Liabilities are periodically established by the Company for any potential claims or settlements of overpayment. The Company intends to vigorously defend against any such claims. The ultimate settlement of any potential liability for such claims may be higher or lower than estimated. Patent Litigation There is substantial litigation in the pharmaceutical, biological, and biotechnology industries with respect to the manufacture, use, and sale of new products which are the subject of conflicting patent and IP claims. One or more patents often cover the brand name products for which the Company is developing generic versions and the Company typically has patent rights covering the Company’s branded products. Under federal law, when a drug developer files an Abbreviated New Drug Application (“ANDA”) for a generic drug seeking approval before expiration of a patent which has been listed with the FDA as covering the brand name product, the developer must certify its product will not infringe the listed patent(s) and/or the listed patent is invalid or unenforceable (commonly referred to as a “Paragraph IV” certification). Notices of such certification must be provided to the patent holder, who may file a suit for patent infringement within 45 days of the patent holder’s receipt of such notice. If the patent holder files suit within the 45-day period, the FDA can review and tentatively approve the ANDA, but generally is prevented from granting final marketing approval of the product until a final judgment in the action has been rendered in favor of the generic drug developer, or 30 months from the date the notice was received, whichever is sooner. The Company’s Generics segment is typically subject to patent infringement litigation brought by branded pharmaceutical manufacturers in connection with the Company’s Paragraph IV certifications seeking an order delaying the approval of the Company’s ANDA until expiration of the patent(s) at issue in the litigation. The uncertainties inherent in patent litigation make the outcome of such litigation difficult to predict. For the Company’s Generics segment, the potential consequences in the event of an unfavorable outcome in such litigation include delaying launch of its generic products until patent expiration. If the Company were to launch its generic product prior to successful resolution of a patent litigation, the Company could be liable for potential damages measured by the profits lost by the branded product manufacturer rather than the profits earned by the Company if it is found to infringe a valid, enforceable patent, or enhanced treble damages in cases of willful infringement. For the Company’s Specialty segment, an unfavorable outcome may significantly accelerate generic competition ahead of expiration of the patents covering the Company’s branded products. All such litigation typically involves significant expense. The Company is generally responsible for all of the patent litigation fees and costs associated with current and future products not covered by its alliance and collaboration agreements. The Company has agreed to share legal expenses with respect to third-party and Company products under the terms of certain of the alliance and collaboration agreements. The Company records the costs of patent litigation as expense in the period when incurred for products it has developed, as well as for products which are the subject of an alliance or collaboration agreement with a third-party. Other Litigation Related to the Company’s Business Opana ER® FTC Matters On July 12, 2019, the Company received a Civil Investigative Demand (“CID”) from the Federal Trade Commission (the “FTC”) concerning an August 2017 settlement agreement between Impax Laboratories, Inc. (“Impax”) and Endo Pharmaceuticals Inc. (“Endo”), which resolved a subsequent patent infringement and breach of contract dispute between the parties regarding the June 2010 settlement agreement related to Opana® ER. The Company cooperated with the FTC regarding the CID. On January 25, 2021, the FTC filed a complaint against Endo, Impax and Amneal in the U.S. District Court for the District of Columbia, alleging that the 2017 settlement violated antitrust laws. In April 2021, the Company filed a motion to dismiss the FTC’s complaint, which the District Court granted on March 24, 2022. The FTC appealed the District Court’s decision in May 2022. The D.C. Circuit Court of Appeals affirmed the District Court’s dismissal on August 25, 2023. The FTC did not petition the U.S. Supreme Court for review. Opana ER® Antitrust Litigation From June 2014 to April 2015, a number of complaints styled as class actions on behalf of direct purchasers and indirect purchasers (or end-payors) and several separate individual complaints on behalf of certain direct purchasers (the “opt-out plaintiffs”) of Opana ER® were filed against Endo and Impax and consolidated into multi-district litigation (“MDL”) in the U.S. District Court for the Northern District of Illinois. Impax subsequently entered into settlement agreements with all of the Plaintiffs that were subsequently approved by the court. Pursuant to the settlement agreements, the Company agreed to pay a total of $265.0 million between 2022 and mid-January 2024 to resolve substantially all of the plaintiffs’ claims. The cumulative amount of payments made by the Company pursuant to the settlement agreements was $215.0 million as of December 31, 2023, of which $83.9 million was paid during January 2023, primarily using borrowings under the New Revolving Credit Facility (refer to Note 16. Debt ). As of December 31, 2023, the liability for the remaining settlement payment of $50.0 million, plus 3% stated interest thereon was included in the current portion of liabilities for legal matters and was paid in January 2024 with cash on hand. The settlement agreements are not an admission of liability or fault by Impax, the Company or its subsidiaries. Upon court approval of the final settlement agreements as discussed above, substantially all the claims and lawsuits in the litigation were resolved. 3% interest was payable on the amounts due in January 2023 and January 2024. The Company included the interest accrual on these amounts as a component of the current and long-term portion of liabilities for legal matters. Additional interest of 2.7% was imputed on the $50.0 million long-term liability due in January 2024, resulting in an initial discount of $2.2 million, which was amortized to interest expense over the life of the liability using the effective interest method. United States Department of Justice Investigations On November 6, 2014, Impax disclosed that one of its sales representatives received a grand jury subpoena from the Antitrust Division of the United States Department of Justice (the “DOJ”). On March 13, 2015, Impax received a grand jury subpoena from the DOJ requesting the production of information and documents regarding the sales, marketing, and pricing of four generic prescription medications. Impax cooperated in the investigation and produced documents and information in response to the subpoenas from 2014 to 2016. However, no assurance can be given as to the timing or outcome of the investigation. On April 30, 2018, Impax received a CID from the Civil Division of the DOJ (the “Civil Division”). The CID requests the production of information and documents regarding the pricing and sale of Impax’s pharmaceuticals and interactions with other generic pharmaceutical manufacturers regarding whether generic pharmaceutical manufacturers engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted to the federal government. Impax has cooperated with the Civil Division’s investigation. However, no assurance can be given as to the timing or outcome of the investigation. On May 15, 2023, Amneal received a CID from the Civil Division requesting information and documents related to the manufacturing and shipping of diclofenac sodium 1% gel labeled as “prescription only” after the reference listed drug’s label was converted to over-the-counter. The Company is cooperating with the Civil Division’s investigation. The Civil Division has not made any claim or demand for damages. However, no assurance can be given as to the timing or outcome of the investigation. In Re Generic Pharmaceuticals Pricing Antitrust Litigation Since March 2016, multiple putative antitrust class action complaints have been filed on behalf of direct purchasers, indirect purchasers (or end-payors), and indirect resellers, as well as individual complaints on behalf of certain direct and indirect purchasers, and municipalities (the “opt-out plaintiffs”) against manufacturers of generic drugs, including Impax and the Company. The complaints allege a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for various generic drugs in violation of federal and state antitrust and consumer protection laws. Plaintiffs seek unspecified monetary damages and equitable relief, including disgorgement and restitution. The lawsuits have been consolidated in an MDL in the United States District Court for the Eastern District of Pennsylvania ( In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2724, (E.D. Pa . )). On May 10, 2019, Attorneys General of 43 States and the Commonwealth of Puerto Rico filed a complaint in the United States District Court for the District of Connecticut against various manufacturers and individuals, including the Company, alleging a conspiracy to fix, maintain, stabilize, and/or raise prices, rig bids, and allocate markets or customers for multiple generic drugs. On November 1, 2019, the State Attorneys General filed an Amended Complaint on behalf of nine additional states and territories. On June 10, 2020, Attorneys General of 46 States, the Commonwealth of Puerto Rico, the Commonwealth of the Northern Mariana Islands, the Territory of Guam, the U.S. Virgin Islands, and the District of Columbia filed a new complaint against various manufacturers and individuals, including the Company, alleging a conspiracy to fix prices, rig bids, and allocate markets or customers for additional generic drugs. Plaintiff states seek unspecified monetary damages and penalties and equitable relief, including disgorgement and restitution. On September 9, 2021, the State Attorneys General filed an Amended Complaint on behalf of California in addition to the original plaintiff states. Both the May 10, 2019 and June 10, 2020 lawsuits have been incorporated into MDL No. 2724, and the June 10, 2020 lawsuit has been selected for bellwether status. The States of Alabama, Hawaii and Arkansas, and the Territory of Guam voluntarily dismissed all of their claims in the two actions against all defendants, including the Company. American Samoa voluntarily dismissed its claims in the May 10, 2019 action and was not named as a plaintiff in the June 10, 2020 action. On February 27, 2023, the Court addressed defendants’ motions to dismiss the bellwether action filed on June 10, 2020, holding that the states may not pursue certain federal remedies, and otherwise denying Amneal’s joint and individual motion to dismiss. On November 1, 2023, the Attorneys General filed a Motion to Remand their cases to the State of Connecticut. On January 21, 2024, the Joint Panel on Multidistrict Litigation (“JPML”) granted the Motion. However, the JPML stayed the remand order in light of certain defendants’ anticipated petition for a Writ of Mandamus, which defendants filed in the United States Court of Appeals for the Third Circuit on February 22, 2023. Fact discovery in MDL No. 2724 is proceeding as to both bellwether and non-bellwether cases, and expert discovery as to bellwether cases is also underway. No trial date has been set. On June 3, 2020, the Company and Impax were also named in a putative class action complaint filed in the Federal Court of Canada in Toronto, Ontario against numerous generic pharmaceutical manufacturers, on behalf of a putative class of individuals who purchased generic drugs in the private sector from 2012 to the present ( Kathryn Eaton v. Teva Canada Limited, et. al., No. T-607-20). The complaint alleges price fixing, among other claims. On August 23, 2022, the plaintiff filed a second amended complaint. On May 30, 2023, the plaintiff served materials for their motion to certify the action as a class proceeding, define the class and certify the common questions to be decided, among other things. The certification hearing date is scheduled for December 2024 and the Company is preparing a response to the motion to certify in advance of that date. Civil Prescription Opioid Litigation The Company and certain of its affiliates are named as defendants in over 900 cases filed in state and federal courts relating to the sale of prescription opioid pain relievers. Plaintiffs in these actions include county and municipal governments, hospitals, Native American tribes, pension funds, third-party payors, and individuals. Plaintiffs seek unspecified monetary damages and other forms of relief based on various causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleged violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”), state and federal controlled substances laws and other statutes. All cases involving the Company also name other manufacturers, distributors, and retail pharmacies as defendants, and there have been numerous other cases involving allegations relating to prescription opioid pain relievers against other manufacturers, distributors, and retail pharmacies in which the Company and its affiliates are not named. Nearly all cases pending in federal district courts have been consolidated for pre-trial proceedings in an MDL in the United States District Court for the Northern District of Ohio (In re: National Prescription Opiate Litigation, Case No. 17-mdl-2804). The Company is also named in various state court cases pending in seven states. No firm trial dates have been set except in Alabama (August 12, 2024 (Mobile County Board of Health)) and Texas (January 31, 2025, trial-ready date (Dallas County)). The Company reached a settlement agreement with the New Mexico Attorney General to resolve its claims against the Company, which was finalized on April 24, 2023. A Consent Judgment dismissing the case was entered on May 15, 2023. The Company reached a settlement agreement to resolve all pending litigation brought by West Virginia political subdivisions, which was signed on May 25, 2023. The two neonatal abstinence syndrome cases in West Virginia state court were dismissed on May 31, 2023 and were subsequently appealed by the plaintiffs. These appeals remain pending. The hospital cases pending in West Virginia state court were dismissed on May 2, 2023. The Company reached a preliminary settlement with a group of private hospitals in Alabama (the “Alabama Hospitals”) in June 2023 to resolve the hospitals’ claims against the Company. The Company anticipates a final determination approving the settlement by the end of the second quarter of 2024. On January 13, 2023, the Company re ceived a subpoena from the New York Attorney General, seeking information regarding its business concerning opioid-containing products. The Company is cooperating with the request and providing responsive information. On January 4, 2024, the Company received a CID issued by the Alaska Attorney General seeking information regarding its business concerning opioid-containing products. The Company is evaluating the CID. Based on the settlement agreements with the states of New Mexico and West Virginia and an assessment of the information available, the Company recorded an $18.0 million charge for the year ended December 31, 2022, related to the majority of the MDL and state court cases. Based on an increase in the number of political subdivision cases and the preliminary settlement with the Alabama Hospitals, the Company recorded charges of $3.9 million for the year ended December 31, 2023. For the remaining cases, primarily brought by other hospitals, pension funds, third-party payors and individuals, the Company has not recorded a liability as of December 31, 2023 or December 31, 2022, because it concluded that a loss was not probable and estimable. United States Department of Justice / Drug Enforcement Administration Subpoenas On July 7, 2017, Amneal New York received an administrative subpoena issued by the Long Island, NY District Office of the Drug Enforcement Administration (the “DEA”) requesting information related to compliance with certain recordkeeping and reporting requirements. On or about April 12, 2019 and May 28, 2019, the Company received grand jury subpoenas from the U.S. Attorney’s Office for the Eastern District of New York (the “USAO”) relating to similar topics concerning the Company’s suspicious order monitoring program and its compliance with the Controlled Substances Act. The Company is cooperating with the USAO in responding to the subpoenas and has entered civil and criminal tolling agreements with the USAO through May 15, 2024. It is not possible to determine the exact outcome of these investigations. On March 14, 2019, Amneal received a subpoena from an Assistant U.S. Attorney for the Southern District of Florida (the “AUSA”). The subpoena requested information and documents generally related to the marketing, sale, and distribution of oxymorphone. The Company intends to cooperate with the AUSA regarding the subpoena. However, no assurance can be given as to the timing or outcome of its underlying investigation. On October 7, 2019, Amneal received a subpoena from the New York State Department of Financial Services seeking documents and information related to sales of opioid products in the state of New York. The Company is cooperating with the request and providing responsive information. It is not possible to determine the exact outcome of this investigation. Ranitidine Litigation The Company and its affiliates were named as defendants, along with numerous other brand and generic pharmaceutical manufacturers, wholesale distributors, retail pharmacy chains, and repackagers of ranitidine-containing products, in In re Zantac/Ranitidine NDMA Litigation (MDL No. 2924), in the Southern District of Florida. Plaintiffs allege that defendants failed to disclose and/or concealed the alleged inherent presence of N-Nitrosodimethylamine (or “NDMA”) in brand-name Zantac® or generic ranitidine and the alleged associated risk of cancer. On July 8, 2021, the MDL Court dismissed all claims by all plaintiffs against the generic drug manufacturers, including the Company, without leave to file further amended complaints, holding all claims were preempted. Plaintiffs appealed the MDL Court’s dismissals to the 11th Circuit Court of Appeals. On November 7, 2022, the 11th Circuit affirmed the MDL Court’s dismissal of cases brought by third-party payors. The 11th Circuit raised questions in the appeals of the other cases about the finality of the MDL Court’s judgments, which were resolved in September 2023. Merits briefs are expected to be filed during the second quarter of 2024. The Company and its affiliates have also been named as defendants in various state lawsuits in five states in which the Company has filed motions to dismiss or plans to file motions to dismiss in the future. On August 17, 2023, the judge in the consolidated Illinois state court cases granted a motion to dismiss all such cases in which the Company and affiliates had been named, holding all claims preempted. There are no trial dates involving the Company in any of the state court cases. Metformin Litigation Amneal and AvKARE, LLC (improperly named as AvKARE, Inc.) were named as defendants, along with numerous other manufacturers, retail pharmacies, and wholesalers, in several putative class action lawsuits pending in the United States District Court for the District of New Jersey, consolidated as In Re Metformin Marketing and Sales Practices Litigation (No. 2:20-cv-02324-MCA-MAH). The lawsuits allege economic loss in connection with their purchase or reimbursements due to the alleged contamination of generic metformin products with NDMA. Plaintiffs have voluntarily dismissed their claims seeking medical monitoring or evaluation due to their consummation of allegedly contaminated metformin. The parties are currently engaged in discovery. On October 17, 2023, co-defendant Rite-Aid filed a suggestion of bankruptcy and automatic stay of proceeding. Two additional similar putative class action lawsuits were filed against Amneal and/or AvKARE in the United States District Court for the District of New Jersey and have not been consolidated with In re Metformin: County of Monmouth, et al. v. Apotex Inc., et al. , No. 2:23-cv-21001-MAC0MAH (D.N.J.) and Michael Hann v. Amneal Pharmaceuticals of New York, LLC et al ., No. 2:23-cv-22902 (D.N.J.). In County of Monmouth , filed against Amneal, AvKARE and numerous other manufacturers and retail pharmacies, Amneal’s response to plaintiffs’ first amended complaint is due March 20, 2024. On February 23, 2024, a stipulation and order was entered which among other things, dismissed specially appearing Amneal Pharmaceuticals Pvt. Ltd. and ordered that the only remaining defendant, Amneal Pharmaceuticals of New York LLC, respond to the complaint within 45 days of the execution of the stipulation on February 22, 2024. On March 29, 2021, a plaintiff filed a complaint in the United States District Court for the Middle District of Alabama asserting claims against manufacturers of valsartan, losartan, and metformin based on the alleged presence of nitrosamines in those products. The only allegations against the Company concern metformin ( Davis v. Camber Pharmaceuticals, Inc. , et al., C.A. No. 2:21-00254 (M.D. Ala.) (the “Davis Action”)). On May 5, 2021, the United States Judicial Panel on Multidistrict Litigation transferred the Davis Action into the In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation multi-district litigation for pretrial proceedings. Xyrem® (Sodium Oxybate) Antitrust Litigation Amneal was named as a defendant, along with Jazz Pharmaceuticals, Inc. (“Jazz”) and numerous other manufacturers of generic versions of Jazz’s Xyrem® (sodium oxybate), in several class action lawsuits filed in the United States District Court for the Northern District of California and the United States District Court for the Southern District of New York, alleging that the generic manufacturers entered into anticompetitive agreements with Jazz in connection with the settlement of patent litigation related to Xyrem®. The actions have been consolidated in the United States District Court for the Northern District of California for pretrial proceedings ( In re Xyrem (Sodium Oxybate) Antitrust Litigation , No. 5:20-md-02966-LHK (N.D. Cal.)). Amneal was also named as a defendant in a similar action filed by Aetna Inc. (“Aetna”) in California state court (Aetna Inc. v. Jazz Pharms., Inc. et. All , No. 22CV010951 (Cal. Super. Ct.). The California state court held that it lacks jurisdiction over several defendants, including Amneal, on December 27, 2022, and later issued an order dismissing Amneal without prejudice. On August 25, 2023, Aetna filed a motion seeking leave to file a second amended complaint adding Amneal as a defendant, which the Court tentatively granted on October 20, 2023. Aetna filed a second amended complaint naming Amneal on November 17, 2023. On February 28, 2023, Amneal executed a $1.9 million settlement agreement with class plaintiffs in the federal litigation. Class plaintiffs filed a motion for final approval of the settlement on November 10, 2023, and a hearing on the issue is scheduled for April 17, 2024. On December 18, 2023, Amneal executed a $4.0 million settlement with Aetna, United Healthcare Services, Inc. (“United”), Humana Inc. (“Humana”), Molina Healthcare Inc. (“Molina”), and Health Care Service Corporation (“HCSC”). Pursuant to that settlement, the federal court dismissed United, Humana, Molina and HCSC’s claims against Amneal, with prejudice, on February 26, 2024, and the California state court dismissed Aetna’s claims against Amneal, with prejudice, on February 29, 2024. For the years ended December 31, 2023 and 2022, the Company recorded $3.0 million and $2.9 million, respectively, for the settlement of claims associated with Xyrem® antitrust litigation. Value Drug Company v. Takeda Pharmaceuticals U.S.A., Inc. On August 5, 2021, Value Drug Company filed a purported class action lawsuit in the United States District Court for the Eastern District of Pennsylvania against Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) and numerous other manufacturers of generic versions of Takeda’s Colcrys® (colchicine), including Amneal, seeking to represent a class of direct purchasers and alleging that the generic manufacturers conspired with Takeda to restrict output of generic Colcrys® in order to maintain higher prices, in violation of the antitrust laws. On April 10, 2023, plaintiff filed a motion for leave to amend its complaint to add 18 former direct purchaser class members as plaintiffs, which the Court subsequently granted. Plaintiffs’ second amended complaint did not add any new legal theories or allegations. On April 14, 2023, the Court entered a scheduling order setting a 22-day jury trial to begin on September 5, 2023. On September 5, 2023, Amneal entered into a settlement agreement with plaintiffs, pursuant to which plaintiffs dismissed with prejudice all claims against Amneal. During the year ended December 31, 2023, the Company recorded a $3.0 million charge for the settlement of this claim. UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc. On November 14, 2023, UFCW Local 1500 Welfare Fund and other health plans filed a purported class action lawsuit in the United States District Court for the Southern District of New York against Takeda and numerous other manufacturers of gene

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity On November 7, 2023, the Company implemented the Reorganization, a plan pursuant to which the Company and Amneal reorganized and simplified the Company’s corporate structure by eliminating its umbrella partnership-C-corporation structure and converting to a more traditional C-corporation structure whereby all stockholders hold their voting and economic interests directly through the public company. Effective with the Reorganization, the Company holds 100% of the Amneal Common Units. Refer to Note 1. Nature of Operations for additional information on the Reorganization. In connection with the Reorganization, the Company amended and restated its certificate of incorporation (“Charter”). The voting rights, dividend rights and participation rights of holders of Class A common stock of the Company did not materially change as a result of the amendment. There were no shares of Class B common stock of the Company outstanding as of December 31, 2023. Voting Rights Holders of Class A common stock and Class B common stock are entitled to one vote for each share of stock held, except as required by law. Holders of Class A common stock and Class B common stock vote together as a single class on each matter submitted to a stockholder vote, including to elect, remove or replace all other directors to the Board subject to rights of holders of any preferred stock. Holders of Class A common stock and Class B common stock are not entitled to vote on any amendment to the Company’s Charter that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote on such terms pursuant to the Company’s Charter or law. Holders of Class A common stock do not have cumulative voting rights. Dividend Rights The holders of Class A common stock are entitled to receive dividends, if any, payable in cash, property, or securities of the Company, as may be declared by the Company's board of directors, out of funds legally available for the payment of dividends, subject to any preferential or other rights of the holders of any outstanding shares of preferred stock. The holders of Class B common stock will not be entitled to receive any dividends. Participation Rights The holders of Class A common stock and Class B common stock have no participation rights. Issuance and Restrictions on Company Common Stock No shares of Class B common stock may be issued except to a holder of Common Units or its affiliates. Liquidation Rights On the liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Class A common stock are entitled to share equally in all assets of the Company available for distribution among the stockholders of the Company after payment to all creditors and subject to any preferential or other rights of the holders of any outstanding shares of preferred stock. The holders of Class B common stock are not entitled to share in such net assets. Preferred Stock Under the Company’s Charter, the Company’s Board of Directors has the authority to issue preferred stock and set its rights and preferences. As of December 31, 2023 and 2022, no preferred stock had been issued. Non-Controlling Interests As discussed in Note 2. Summary of Significant Accounting Policies , the consolidated financial statements of the Company include the accounts of all entities controlled by the Company, including Amneal and its subsidiaries, through the Company’s direct or indirect ownership of a majority voting interest. The Company records non-controlling interests for the portion of its subsidiaries’ economic interests that it does not hold. Prior to the Reorganization, non-controlling interests were adjusted for capital transactions that impact the non-publicly held economic interests in Amneal. Prior to the Reorganization, Amneal was obligated to make tax distributions to the Members. For the years ended December 31, 2023, 2022, and 2021, the Company recorded net tax distributions of $56.7 million, $10.6 million, and $53.5 million, respectively, as a reduction of non-controlling interests. Subsequent to the Reorganization, the Company is no longer obligated to make tax distributions to the Members. There was no liability for tax distributions payable to Members as of December 31, 2023 and 2022. As discussed in Note 3. Acquisitions , the Company acquired a 98% interest in KSP on April 2, 2021. The sellers of KSP, a related party, hold the remaining interest. The Company attributes 2% of the net income or loss of KSP to these non-controlling interests. Redeemable Non-Controlling Interests - AvKARE, LLC and R&S The Company acquired a 65.1% interest in both AvKARE, LLC and R&S on January 31, 2020. The sellers hold the remaining 34.9% interest (“Rondo Class B Units”) in the holding company that directly owns the acquired companies (“Rondo”). Beginning on January 1, 2026, the holders of the Rondo Class B Units have the right (“Put Right”) to require the Company to acquire the Rondo Class B Units for a purchase price that is based on a multiple of Rondo’s earnings before income taxes, depreciation, and amortization (EBITDA) if certain financial targets and other conditions are met. Additionally, beginning on January 31, 2020, the Company has the right to acquire the Rondo Class B Units based on the same value and conditions as the Put Right. The Rondo Class B Units are also redeemable by the holders upon a change in control. Since the redemption of the Rondo Class B Units is outside of the Company’s control, the units have been presented outside of stockholders’ equity as redeemable non-controlling interests. The Company attributes 34.9% of the net income of Rondo to the redeemable non-controlling interests. The Company will also accrete the redeemable non-controlling interests to redemption value upon an event that makes redemption certain. For the years ended December 31, 2023, 2022 and 2021, tax distributions of $14.2 million, $6.9 million and $3.6 million, respectively, were recorded as reductions of redeemable non-controlling interests . As of December 31, 2023 and 2022, there were no amounts due for tax distributions related to these redeemable non-controlling interests. Redeemable Non-Controlling Interests - Puniska As discussed in Note 3 . Acquisitions , the Company acquired a 74% interest in Puniska on November 2, 2021. Amneal was required pursuant to the purchase agreement to acquire the remaining 26% of Puniska upon approval of the transaction by the government of India. Since approval of the government of India was outside of the Company’s control, upon closing of the Puniska Acquisition, the equity interests of Puniska that the Company did not own were presented outside of stockholders' equity as redeemable non-controlling interests. The Company attributed 26% of the net losses of Puniska to the redeemable non-controlling interests. Upon approval of the transaction by the government of India in March 2022, the Company paid the $1.7 million redemption value for the remaining 26% of the equity interests of Puniska. For the year ended December 31, 2022 , t he Company recorded accretion of $0.9 million to increase the redeemable non-controlling interests to redemption value. Changes in Accumulated Other Comprehensive Loss by Component (in thousands): Foreign Unrealized (loss) gain on cash flow hedge, net of tax Accumulated Balance December 31, 2021 $ (18,845) $ (5,982) $ (24,827) Other comprehensive income before reclassification (13,394) 48,270 34,876 Reallocation of ownership interests (143) 33 (110) Balance December 31, 2022 (32,382) 42,321 9,939 Other comprehensive income before reclassification (433) (39,248) (39,681) Reallocation of ownership interests (33,257) 34,016 759 Reclassification of cash flow hedge to earnings, net of tax — (3,366) (3,366) Balance December 31, 2023 $ (66,072) $ 33,723 $ (32,349)

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan In May 2018, the Company adopted the Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan (“2018 Plan”) under which the Company may grant stock options, restricted stock units and other equity-based awards to employees and non-employee directors providing services to the Company and its subsidiaries. The stock option, RSU and MPRSU award grants are made in accordance with the Company’s 2018 Plan and are subject to forfeiture if the vesting conditions are not met. On May 5, 2020, the stockholders of the Company approved an amendment to the 2018 Plan, which authorized an additional 14 million shares of Class A common stock available for issuance under the 2018 Plan. On May 9, 2023, the stockholders of the Company approved an amendment and restatement of the 2018 Plan, which authorized an additional 20 million shares of Class A common stock available for issuance under the 2018 Plan, resulting in a total shares reserved under the Stock Plan of 57 million shares, and extends the term of the 2018 Plan until May 9, 2033. As of December 31, 2023, the Company had 26,764,218 shares available for issuance under the 2018 Plan. The Company recognizes the grant date fair value of each option and share of restricted stock unit over its vesting period. Stock options and RSU awards are granted under the Company’s 2018 Plan and generally vest over a 4 year period and, in the case of stock options, have a term of 10 years. The following table summarizes all of the Company’s stock option activity for the years ended December 31, 2023, 2022, and 2021: Stock Options Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2020 3,811,229 $ 4.80 Options exercised (342,350) 2.76 Options forfeited (417,379) 11.09 Outstanding at December 31, 2021 3,051,500 $ 4.17 7.0 $ 5.3 Options exercised (207,452) 2.75 Options forfeited (195,607) 2.77 Outstanding at December 31, 2022 2,648,441 $ 4.38 6.0 $ — Options exercised (163,824) 2.75 Options forfeited (68,252) 2.75 Outstanding at December 31, 2023 2,416,365 $ 4.54 5.0 $ 6.6 Options exercisable at December 31, 2023 2,416,365 $ 4.54 5.0 $ 6.6 The intrinsic value of options exercised during the year ended December 31, 2023 was approximately $0.2 million. There were no options granted in the years ended December 31, 2023, 2022 and 2021. The following table summarizes all of the Company's restricted stock unit activity for the years ended December 31, 2023, 2022, and 2021: Restricted Stock Units Number of Weighted- Weighted- Aggregate Non-vested at December 31, 2020 9,132,552 $ 5.09 Granted 6,870,481 5.86 Vested (1,906,607) 5.97 Forfeited (912,826) 6.68 Non-vested at December 31, 2021 13,183,600 $ 5.25 1.4 $ 63.7 Granted 10,117,037 4.54 Vested (2,697,134) 5.95 Forfeited (2,674,890) 5.07 Non-vested at December 31, 2022 17,928,613 $ 4.77 1.3 $ 35.7 Granted 7,519,565 1.91 Vested (3,888,602) 4.53 Forfeited (4,104,873) 3.41 Non-vested at December 31, 2023 17,454,703 $ 3.92 1.2 $ 105.4 The table above includes 2,431,521 MPRSUs granted to executives during March and April 2023. Vesting of the March 2023 awards is contingent upon the Company’s achievement of stock price hurdles over the performance period starting March 3, 2023 and requires the employee’s continued employment or service through February 28, 2026. Vesting of the April 2023 awards is contingent upon the Company’s achievement of stock price hurdles over the performance period starting April 28, 2023 and requires the employee’s continued employment or service through February 28, 2026. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (4,863,042 shares) based on the Company's stock price performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated fair value per share of the MPRSUs ranged from $1.81 and $2.17 and was calculated using a Monte Carlo simulation model. 2,375,711 of these MPRSUs remain outstanding and unvested at December 31, 2023. The table above includes 3,053,738 MPRSUs granted to executives during 2022. Vesting of these awards is contingent upon the Company’s achievement of stock price hurdles over the performance period starting March 1, 2022 and requires the employee’s continued employment or service through February 28, 2025. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (6,107,476 shares) based on the Company's stock price performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated fair value per share of the MPRSUs was $6.22 and was calculated using a Monte Carlo simulation model. 2,627,349 of these MPRSUs remain outstanding and unvested at December 31, 2023. The table above also includes 2,331,211 MPRSUs granted to executives during 2021. Vesting of these awards is contingent upon the Company’s achievement of stock price hurdles over the performance period starting March 1, 2021 and requires the employee’s continued employment or service through February 29, 2024. The MPRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (4,662,422 shares) based on the Company's stock price performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated fair value per share of the MPRSUs ranged from $5.31 and $8.58 and was calculated using a Monte Carlo simulation model. 1,940,739 of these MPRSUs remained outstanding and unvested at December 31, 2023. As of December 31, 2023, the Company had total unrecognized stock-based compensation expense of $32.3 million related to all of its stock-based awards, which is expected to be recognized over a weighted average period of 1.5 years. The amount of stock-based compensation expense recognized by the Company was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Cost of goods sold $ 3,561 $ 4,811 $ 4,688 Selling, general and administrative 18,922 20,746 18,718 Research and development 4,339 6,290 5,006 Total $ 26,822 $ 31,847 $ 28,412

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions The Company has various business agreements with certain third-party companies in which there is some common ownership and/or management between those entities, on the one hand, and the Company, on the other hand. The Company has no direct ownership or management in any of such related party companies. The following table summarizes the Company’s related party transactions (in thousands): Year ended December 31, Related Party and Nature of Transaction Caption in Balance Sheet and Statement of Operations 2023 2022 2021 A Kashiv Biosciences LLC i. Parking space lease Research and development $ 100 $ 100 $ 99 ii. License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Filgrastim Selling, general and administrative $ — $ 5,000 $ — ii. License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for P egfilgrastim-pbbk Intangible asset $ — $ 15,000 $ — ii. Inventory purchases under license and commercialization agreement - Filgrastim and Pegfilgrastim Inventory and cost of goods sold $ — $ 260 $ — ii. Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko) Cost of goods sold $ 5,114 $ — $ — ii. Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko) Inventory and cost of goods sold $ 1,022 $ — $ — iii. Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate Research and development $ (25) $ 1,761 $ 1,362 iv. Transition services associated with the KSP Acquisition Selling, general and administrative $ — $ — $ 255 v. Development and commercialization - consulting - various products Research and development $ — $ 2 $ 628 vi. Generic development supply agreement - research and development material Research and development $ (2,809) $ — $ — vi. Generic development supply agreement - development activity deferred income Deferred revenue $ (246) $ — $ — vii. K127 development and commercialization agreement* Research and development $ — $ — $ 3,000 viii. Commercial product support for EluRyng and other products* Cost of goods sold and research and development $ — $ — $ 1,239 ix. Profit sharing - various products* Cost of goods sold $ — $ — $ 2,680 x. Development and commercialization agreements - various products* Research and development $ — $ — $ 150 B LAX Hotel, LLC Financing lease Inventory and cost of goods sold $ — $ — $ 217 Interest component of financing lease Interest expense — — 362 Total $ — $ — $ 579 C Kanan, LLC - operating lease Inventory and cost of goods sold $ 2,540 $ 2,104 $ 2,103 D Sutaria Family Realty, LLC - operating lease Inventory and cost of goods sold $ 1,352 $ 1,211 $ 1,179 E PharmaSophia, LLC - research and development services income Research and development $ — $ (45) $ (329) E PharmaSophia, LLC - license and commercialization agreement Research and development $ — $ 1,093 $ — F Fosun International Limited - license and supply agreement Net revenue $ (80) $ — $ — F Fosun International Limited - API co-development agreement Net revenue $ — $ — $ (200) G Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement Inventory and cost of goods sold $ 15,873 $ 2,742 $ 11,380 H Tracy Properties LLC - operating lease Selling, general and administrative $ 625 $ 565 $ 532 I AzaTech Pharma LLC - supply agreement Inventory and cost of goods sold $ 8,746 $ 4,963 $ 5,156 J AvPROP, LLC - operating lease Selling, general and administrative $ 167 $ 178 $ 165 K Tarsadia Investments, LLC - financial consulting services Selling, general and administrative $ — $ — $ — L Avtar Investments, LLC - consulting services Research and development $ 321 $ 216 $ 361 M TPG Operations, LLC - consulting services Selling, general and administrative $ — $ 19 $ 249 N TPG Capital BD, LLC Loss on refinancing $ 3,000 $ — $ — O Alkermes Plc Inventory and cost of goods sold $ 464 $ 235 $ 138 P R&S Solutions LLC - logistics services Selling, general and administrative $ 102 $ 85 $ 183 Q Asana Biosciences, LLC Research and development $ — $ (5) $ (4) S Members - tax receivable agreement Other expense $ 3,126 $ 631 $ — *Agreement between Amneal and Kashiv was acquired with KSP and has become a transaction among Amneal’s consolidated subsidiaries subsequent to the transaction closing on April 2, 2021. The disclosure relates to the historical agreement as a related party transaction through April 2, 2021 (refer to Note 3. Acquisitions for additional information). The following table summarizes the amounts due to or from the Company for related party transactions (in thousands): December 31, 2023 December 31, 2022 R Sellers of AvKARE LLC and R&S - state tax indemnification $ — $ 486 A Kashiv - various agreements 954 12 Q Asana BioSciences, LLC — 2 O Alkermes 1 — Related party receivables - short term $ 955 $ 500 A Kashiv - various agreements $ 3,179 $ 110 G Apace Packaging, LLC - packaging agreement 1,091 756 I AzaTech Pharma LLC - supply agreement 1,958 863 L Avtar Investments LLC - consulting services 100 72 R Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 442 442 S Members - tax receivable agreement 549 201 P R&S Solutions LLC - logistics services — 7 O Alkermes Plc 2 28 Related party payables - short term $ 7,321 $ 2,479 A Kashiv - contingent consideration $ 430 $ 3,290 R Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 8,139 5,929 S Members - tax receivable agreement 3,207 430 Related party payables - long term $ 11,776 $ 9,649 Related Party Descriptions (A) Kashiv Biosciences LLC Kashiv is an independent contract development organization focused primarily on the development of 505(b)(2) NDA products. Amneal has various business agreements with Kashiv. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Kashiv. In addition, they serve on the Board of Managers of Kashiv. On January 11, 2021, the Company and Kashiv entered into a definitive agreement for Amneal to acquire a 98% interest in KSP, which was a subsidiary of Kashiv and focuses on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs. The acquisition closed on April 2, 2021 and included contingent payments for achievement of certain regulatory milestones and potential royalty payments base on annual net sales for certain future pharmaceutical products. Certain of the contracts between Amneal and Kashiv were acquired in this transaction and have become transactions among Amneal’s consolidated subsidiaries subsequent to the transaction closing. Refer to Note 3. Acquisitions for further details on the KSP acquisition. Below is a summary of the related party arrangements held between the Company and Kashiv that were not impacted by the KSP Acquisition: i. The parties entered into a lease for parking spaces in Piscataway, NJ. The annual lease cost is $0.1 million per year. ii. In 2017 Kashiv and Amneal entered into an exclusive license and commercialization agreement (the “Kashiv Biosimilar Agreement”) to distribute and sell two biosimilar products, Filgrastim and Pegfilgrastim, in the U.S. Kashiv is responsible for development, regulatory filings, obtaining FDA approval, and manufacturing, and Amneal is responsible for marketing, selling, and pricing activities. The term of the agreement is 10 years from the respective product’s launch date. The Kashiv Biosimilar Agreement provided for potential future milestone payments to Kashiv of up to $183.0 million, as follows: (i) up to $22.5 million relating to regulatory approval and execution, (ii) up to $43.0 million for successful delivery of commercial launch inventory, (iii) up to $50.0 million depending on the number of competitors at launch for one product, and (iv) between $15.0 million and $67.5 million for the achievement of cumulative net sales for both products. In July 2022, the Company and Kashiv amended the Kashiv Biosimilar Agreement to, among other things, (i) eliminate milestones related to the manufacturing and delivery of the Kashiv products, (ii) revise the net sales milestones to provide for future milestone payments by the Company to Kashiv of up to $37.5 million for the achievement of cumulative combined net sales goals for both products, and (iii) adjust the supply price of product that Kashiv manufacturers and supplies to the Company, which will lower the cost per unit of both products. The remaining milestones are subject to reaching certain commercial sales volume objectives. In addition, the agreement provides for Amneal to pay a profit share equal to 50% of net profits, after considering manufacturing and marketing costs. On May 27, 2022, the FDA approved the Company’s biologic license application, associated with the amended Kashiv Biosimilar Agreement, for Pegfilgrastim-pbbk. In connection with this regulatory approval and associated activity, the Company incurred a milestone of $15.0 million during the year ended December 31, 2022, payable to Kashiv. The milestone was capitalized as an intangible asset and will be amortized to cost of sales over an estimated useful life of 8.3 years. The Company paid Kashiv $15.0 million in August 2022 related to this milestone. The Company recognized a $5.0 million milestone in selling, general and administrative expense upon FDA approval of Filgrastim in February 2022. iii. Amneal and Kashiv entered into a product development agreement for the development and commercialization of two generic peptide products, Ganirelix Acetate and Cetrorelix Acetate. Under the agreement, the IP and abbreviated new drug application for these products are owned by Amneal, and Kashiv will receive a profit share for all sales of the products made by Amneal. In connection with the agreement, Amneal made an upfront payment of $1.1 million in August 2020. The agreement also provides for potential future milestone payments to Kashiv of (i) up to $2.1 million relating to development milestones, and (ii) up to $0.3 million relating to regulatory filings. The milestones are subject to certain performance conditions which may or may not be achieved, including FDA filings. In addition, Amneal agreed to pay $2.6 million of development fees to Kashiv as the development work is completed. iv. As discussed in Note 3. Acquisitions, the purchase price for the KSP Acquisition included contingent consideration. As of December 31, 2023 and 2022 , a contingent consideration liability of $0.4 million and $3.3 million, respectively, associated with the KSP Acquisition was recorded in related party payable-long term. For the year ended December 31, 2021, the Company recorded $0.3 million of expenses for transition services associated with the KSP Acquisition provided by Kashiv. v. Amneal has various consulting arrangements with Kashiv to collaborate on the development and commercialization of certain generic pharmaceutical products. vi. In December 2022, Amneal and Kashiv entered into a development supply agreement specific to four generic product candidates. Amneal will be responsible to manufacture batch products, as well as to perform certain developmental activities on behalf of Kashiv. Kashiv, as owner of the IP, will be responsible for regulatory filings, obtaining FDA approval, marketing, selling, and pricing activities. Pursuant to the terms of the development supply agreement, Amneal is eligible to earn up to $2.4 million related to the aforementioned services. During the years ended December 31, 2023, 2022 and 2021, the Company did not record any revenue related to this agreement. The following disclosures relate to agreements between Amneal and Kashiv that were acquired as part of the KSP Acquisition. These agreements became a transaction among Amneal’s consolidated subsidiaries subsequent to the closing of the KSP Acquisition on April 2, 2021. These below transactions were considered related party transactions through April 2, 2021 (refer to Note 3. Acquisitions for additional information). vii. Amneal and Kashiv entered into a licensing agreement for the development and commercialization of Kashiv’s orphan drug K127 (pyridostigmine) for the treatment of Myasthenia Gravis. Under the terms of the agreement, Kashiv was responsible for all development and clinical work required to secure Food and Drug Administration approval and Amneal was responsible for filing the NDA and commercializing the product. The Company made an upfront payment of approximately $1.5 million to Kashiv in December 2019, and Kashiv was eligible to receive development and regulatory milestones totaling approximately $16.5 million. Kashiv was also eligible to receive tiered royalties from the low double-digits to mid-teens on net sales of K127. viii. On February 20, 2020, the Company and Kashiv entered into a master services agreement covering certain services that Kashiv provided the Company for commercial product support related to EluRyng and other products, including Ranitidine and Nitrofurantoin. ix. Amneal had various development, commercialization and consulting arrangements with Kashiv to collaborate on the development and commercialization of certain generic pharmaceutical products. Kashiv received a percentage of net profits with respect to Amneal’s sales of these products. x. Amneal had various development, commercialization and consulting arrangements with Kashiv to collaborate on the development and commercialization of certain generic pharmaceutical products. This activity related to the total reimbursable expenses associated with these arrangements. Refer to Note 21. Commitments and Contingencies for information on an amendment to the Membership Interest Purchase Agreement associated with the acquisition of KSP from Kashiv, resulting from the settlement of litigation. (B) LAX Hotel, LLC The Company had a financing lease with LAX Hotel, LLC for two buildings located in Long Island, New York, which are used as an integrated manufacturing and office facility. The Company leased these buildings from LAX Hotel, LLC from 2012 until January 2021. LAX Hotel, LLC had been controlled by a member of the Amneal Group, who also serves as observer on the Company's Board of Directors. As a result, this lease had been historically accounted for as a related party financing lease. During January 2021, LAX Hotel, LLC sold its interests in the leased buildings to an unrelated third-party. (C) Kanan, LLC Kanan, LLC (“Kanan”) is a real estate company that owns Amneal’s manufacturing facilities located at 65 Readington Road, Branchburg, New Jersey, 131 Chambers Brook Road, Branchburg, New Jersey and 1 New England Avenue, Piscataway, New Jersey. Certain executive officers of the Company beneficially own, through certain revocable trusts, equity securities of Kanan. In addition, they serve on the Board of Managers of Kanan. Amneal leases these facilities from Kanan under two separate triple-net lease agreements that expire in 2027 and 2031, respectively, at an annual rental cost of approximately $2.0 million combined, subject to CPI rent escalation adjustments as provided in the lease agreements. (D) Sutaria Family Realty, LLC Industrial Real Estate Holdings NY, LLC (“IRE”) is a real estate management entity, which was the sub-landlord of Amneal’s leased manufacturing facility located at 75 Adams Avenue, Hauppauge, New York. IRE is controlled by a member of the Amneal Group who also serves as an observer on our Board of Directors. Effective June 1, 2020, the lease was assigned to the Company with the consent of the landlord, Sutaria Family Realty, LLC, which is also a related party because a member of Company management is a beneficial owner. Concurrently with the assignment of the lease, the Company exercised a renewal option for $0.1 million to extend the lease by 5 years until March 31, 2026. Monthly rent payments are $0.1 million and increase by 3% annually. (E) PharmaSophia, LLC PharmaSophia, LLC (“PharmaSophia”) is a joint venture formed by Nava Pharma, LLC (“Nava”) and Oakwood Laboratories, LLC for the purpose of developing certain products. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Nava. Nava beneficially owns 50% of the outstanding equity securities of PharmaSophia. In addition, these executive officers also serve on the Board of Managers of PharmaSophia. PharmaSophia and Nava are parties to an R&D agreement pursuant to which Nava provides R&D services to PharmaSophia (the “Nava Agreement”). Nava subcontracted this obligation to Amneal under a subcontract R&D services agreement pursuant to which Amneal provides R&D services to Nava in connection with the products being developed by PharmaSophia. On August 28, 2023, Amneal and Nava terminated the subcontract R&D services agreement by mutual consent. In October 2022, PharmaSophia and Amneal entered into an exclusive license and commercialization agreement (the “PharmaSophia Agreement”) to develop, manufacture, and sell one injectable product. Under the terms of the agreement, Amneal committed to spend up to $6.0 million to further develop the product, including all related expenses up to submission of the ANDA, which will be owned by Amneal. Also under the terms of the PharmaSophia Agreement, PharmaSophia settled a liability of $1.1 million payable to Amneal under the terms of the Nava Agreement by reducing the amount of Amneal’s committed spending under the terms of the PharmaSophia Agreement to $4.9 million. Amneal recorded $1.1 million of research and development expense for the year ended December 31, 2022 as a result of the settlement. PharmaSophia will receive a 50% profit share for all sales of product made by Amneal under the PharmaSophia Agreement. (F) Fosun International Limited Fosun International Limited (“Fosun”) is a Chinese international conglomerate and investment company that is a shareholder of the Company. On June 6, 2019, the Company entered into a license and supply agreement with a subsidiary of Fosun, which is a Chinese pharmaceutical company. Under the terms of the agreement, the Company will hold the imported drug license required for pharmaceutical products manufactured outside of China and will supply Fosun with finished, packaged products for Fosun to then sell in the China market. Fosun will be responsible for obtaining regulatory approval in China and for shipping the product from Amneal’s facility to Fosun’s customers in China. In consideration for access to the Company's U.S. regulatory filings to support its China regulatory filings and for the supply of product, Fosun paid the Company a $1.0 million non-refundable fee, net of tax, in July 2019 and was required to pay the Company $0.3 million for each of eight products upon the first commercial sale of each in China in addition to a supply price and a profit share. On August 11, 2023, the Company and Fosun amended the license and supply agreement to, among other things, (i) increase the products in the agreement from eight to ten, (ii) eliminate the first commercial sales milestone of $0.3 million for each product and (iii) decrease the profit share percentage applicable to all products. On August 12, 2021, the Company entered into an active pharmaceutical ingredient (“API”) co-development agreement with a subsidiary of Fosun. Under the terms of the agreement, the Company provided Fosun a license to manufacture and sell two pharmaceutical products outside of the U.S. Fosun will be responsible for obtaining regulatory approval outside the U.S. Fosun paid the Company a $0.2 million non-refundable fee which was recognized in 2021 as revenue and will be required to pay the Company $0.1 million for each of the two products upon the first commercial sale of each in China in addition to a profit share. (G) Apace KY, LLC d/b/a Apace Packaging LLC Apace KY, LLC d/b/a Apace Packaging LLC (“Apace”) provides packaging solutions pursuant to a packaging agreement. Apace markets its services which include bottling and blistering for the pharmaceutical industry. A member of Company management beneficially owns outstanding equity securities of Apace. (H) Tracy Properties LLC R&S leases operating facilities, office and warehouse space from Tracy Properties LLC (“Tracy”). A member of Company management beneficially owns outstanding equity securities of Tracy. (I) AzaTech Pharma, LLC R&S purchases inventory from AzaTech Pharma LLC (“AzaTech”) for resale. A member of Company management beneficially owns outstanding equity securities of AzaTech. (J) AvPROP, LLC AvKARE LLC leases its operating facilities from AvPROP, LLC (“AvPROP”). A member of Company management beneficially owns outstanding equity securities of AvPROP. (K) Tarsadia Investments, LLC Tarsadia Investments, LLC (“Tarsadia”) is a private investment firm that provides financial services and is a significant shareholder of the Company. A member of Amneal Group, and an observer to the Board, is the Chairman and Founder of Tarsadia. Another member of the Amneal Group, and a member of the Board, is a Managing Director of Tarsadia. Tarsadia offers capital and strategic support for companies with substantial growth potential primarily in the healthcare, financial services, real estate, and clean technology sectors. The Company entered into an agreement in which Tarsadia will provide financial consulting services. The services are not expected to have a material impact to the Company’s financial statements. (L) Avtar Investments, LLC Avtar Investments, LLC (“Avtar”) is a private investment firm. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Avtar. During April 2020, the Company entered into an agreement under which Avtar will provide R&D consulting services. (M) TPG Operations, LLC TPG Operations LLC (“TPG”) is a private investment firm that provides financial services and is a significant stockholder of the Company. An observer of our Board is a managing director of TPG. In March 2020, the Company entered into an agreement in which TPG provided financial consulting services for a period of 7 months. The agreement was subsequently extended until March 2022. (N) TPG Capital BD, LLC TPG Capital BD, LLC (“TPG Capital”), an affiliate of TPG, provided the Company with advice and assistance with respect to the refinancing of the Term Loan Due 2025 and the Amended New Revolving Credit Facility for which the Company paid TPG Capital $3.0 million. Refer to Note 16. Debt for additional information on the refinancing of the Company’s debt. (O) Alkermes Plc Rondo Partners LLC purchases inventory from Alkermes Plc for resale. A member of the Board of Directors of the Company is also a member of the Board of Directors of Alkermes Plc. (P) R&S Solutions LLC R&S Solutions LLC provides logistic services to the Company. A member of Company management beneficially owns outstanding equity securities of R&S Solutions LLC. (Q) Asana Biosciences, LLC Asana Biosciences, LLC (“Asana”) is an early-stage drug discovery and R&D company focusing on several therapeutic areas, including oncology, pain and inflammation. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Asana. In addition, they serve on the Board of Managers of Asana. From time to time, Amneal provides R&D services to Asana under a development and manufacturing agreement and storage services under a storage agreement. (R) Sellers of AvKARE LLC and R&S Tax Indemnification – Rondo Acquisitions In accordance with the Rondo Equity Purchase Agreement, the Company was indemnified by the sellers of AvKARE, LLC and R&S for $0.5 million of state taxes paid on behalf of the sellers for a tax period prior to the closing of the Rondo Acquisition. As a result, the Company recorded $0.5 million of related party receivables - short term as of December 31, 2022. Notes Payable – Related Party Certain holders of the Rondo Class B Units are also holders of the Sellers Notes and were holders of the Short-Term Sellers Note, which Amneal repaid in 2021. For additional information, refer to Note 16. Debt . Refer to Note 22. Stockholders’ Equity for related party transactions associated with the Rondo Acquisitions . Tax Distributions Under the terms of the limited liability company agreement between the Company and the holders of the Rondo Class B Units, Rondo is obligated to make tax distributions to those holders, subject to certain limitations as defined in the Rondo Credit Facility. For further details, refer to Note 22. Stockholders' Equity . (S) Tax Receivable Agreement In connection with the acquisition of Impax, the Company entered into a tax receivable agreement, for which it was generally required to pay the other holders of Amneal Common Units 85% of the applicable tax savings, if any, in U.S. federal and state income tax that it is deemed to realize as a result of certain tax attributes of their Amneal Common Units sold to the Company (or exchanged in a taxable sale) and that are created as a result of (i) the sales of their Amneal C ommon Units for shares of Class A Common Stock and (ii) tax benefits attributable to payments made under the TRA. In connection with the Reorganization, the TRA was amended to reduce the Company’s future obligation to pay 85% of the realized tax benefits subject to the TRA to 75% of such realized benefits. Refer to Note 7. Income Taxes for additional information. (T) Tax Distributions to Members Prior to the Reorganization, Amneal was obligated to make tax distributions to the Members, which were also holders of non-controlling interests in the Company. For further details, refer to Note 22. Stockholders' Equity and Note. 7 Income Taxes . (U) Puniska Acquisition The purchase price for the Puniska Acquisition included $14.2 million due to the sellers, which was outstanding at December 31, 2021 (paid by Amneal in 2022), for the satisfaction of a preexisting payable upon approval of the transaction by the government of India. Further, the Company paid $1.7 million for the remaining 26% equity interest of Puniska (included in redeemable non-controlling interests in the Company’s consolidated balance sheet as of December 31, 2021) upon approval of the Puniska Acquisition by the government of India in 2022. Refer to Note. 3 Acquisitions and Note 22. Stockholders’ Equity for additional information.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Employee Benefit Plans	Employee Benefit Plans The Company has voluntary defined contribution plans covering eligible employees in the U.S. which provide for a Company match. For the years ended December 31, 2023, 2022 and 2021, the Company made matching contributions of $9.9 million, $9.5 million and $8.9 million, respectively. The Company also has a deferred compensation plan for certain former executives and employees of Impax, some of whom are currently employed by the Company. In January 2019, the Company announced that it will no longer accept contributions from employees or make matching contributions for the deferred compensation plan. Deferred compensation liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived by reference to hypothetical investments selected by the participants and is included in accounts payable and accrued expenses and other long-term liabilities. Refer to Note 17. Other Long-Term Liabilities and Note 19. Fair Value Measurements for additional information.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Segment Information	Segment Information The Company has three reportable segments: Generics, Specialty, and AvKARE. Generics The Company’s Generics segment includes a retail and institutional portfolio of over 260 product families covering an extensive range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals. Specialty The Company’s Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease, and endocrine disorders. AvKARE The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies. AvKARE is a re-packager of bottle and unit dose pharmaceuticals under the registered names of AvKARE and AvPAK, which service the Department of Defense and Department of Veteran Affairs. AvKARE is also a wholesale distributor of pharmaceuticals, over the counter drugs and medical supplies to its retail and institutional customers that are located throughout the U.S. focused primarily on offering 340b-qualified entities products to provide consistency in care and pricing. Chief Operating Decision Makers The Company’s chief operating decision makers evaluate the financial performance of the Company’s segments based upon segment operating income (loss). Items below operating income (loss) are not reported by segment, since they are excluded from the measure of segment profitability reviewed by the Company’s chief operating decision maker. Additionally, general and administrative expenses, certain selling expenses, certain litigation settlements, and non-operating income and expenses are included in “Corporate and Other.” The Company does not report balance sheet information by segment since it is not reviewed by the Company’s chief operating decision makers. The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, R&D expenses, and other operating expenses to the extent specifically identified by segment (in thousands): Year Ended December 31, 2023 Generics Specialty AvKARE Corporate Total Net revenue (1) $ 1,471,401 $ 390,457 $ 531,749 $ — $ 2,393,607 Cost of goods sold 913,869 214,277 444,896 — 1,573,042 Gross profit 557,532 176,180 86,853 — 820,565 Selling, general and administrative 119,912 88,137 55,341 166,285 429,675 Research and development 132,233 31,717 — — 163,950 In-process research and development impairment charges 26,500 4,300 — — 30,800 Intellectual property legal development expenses 3,708 120 — — 3,828 Restructuring and other charges 211 1,105 — 433 1,749 Change in fair value of contingent consideration — (14,497) — — (14,497) (Credit) charges related to legal matters, net (64) — — 1,888 1,824 Other operating income (1,138) — — — (1,138) Operating income (loss) $ 276,170 $ 65,298 $ 31,512 $ (168,606) $ 204,374 Year Ended December 31, 2022 Generics Specialty AvKARE Corporate Total Net revenue (1) $ 1,432,073 $ 374,121 $ 406,110 $ — $ 2,212,304 Cost of goods sold 896,031 182,432 349,133 — 1,427,596 Gross profit 536,042 191,689 56,977 — 784,708 Selling, general and administrative 109,781 90,031 53,659 146,229 399,700 Research and development 167,509 28,179 — — 195,688 In-process research and development impairment charges 12,970 — — — 12,970 Intellectual property legal development expenses 4,251 107 — — 4,358 Acquisition, transaction-related and integration expenses 25 49 — 635 709 Restructuring and other charges 821 — — 600 1,421 Change in fair value of contingent consideration — 731 — — 731 Insurance recoveries for property losses and associated expenses, net (1,911) — — — (1,911) Charges related to legal matters, net 22,400 — — 247,530 269,930 Other operating income (3,960) — — — (3,960) Operating income (loss) $ 224,156 $ 72,592 $ 3,318 $ (394,994) $ (94,928) Year Ended December 31, 2021 Generics Specialty AvKARE Corporate Total Net revenue (1) $ 1,366,338 $ 378,319 $ 349,012 $ — $ 2,093,669 Cost of goods sold 848,260 193,562 282,874 — 1,324,696 Gross profit 518,078 184,757 66,138 — 768,973 Selling, general and administrative 64,500 84,481 57,918 158,605 365,504 Research and development 158,365 43,482 — — 201,847 In-process research and development impairment charges 710 — — — 710 Intellectual property legal development expenses 7,562 154 — — 7,716 Acquisition, transaction-related and integration expenses — 16 1,422 6,617 8,055 Restructuring and other charges 80 — — 1,777 1,857 Change in fair value of contingent consideration — 200 — — 200 Charges for property losses and associated expenses, net 5,368 — — — 5,368 Charges related to legal matters, net — — — 25,000 25,000 Operating income (loss) $ 281,493 $ 56,424 $ 6,798 $ (191,999) $ 152,716 (1) Net revenue from external customers is attributed to countries based on the location of the product shipment. For the years ended December 31, 2023, 2022, and 2021, net revenue from external customers attributed to foreign countries was immaterial. Long-Lived Assets Long-lived assets, which are comprised of property, plant and equipment, net and operating and financing lease right-of-use assets, are attributed based on physical location. Long-lived assets by country were as follows (in thousands): December 31, 2023 December 31, 2022 United States $ 316,947 $ 354,504 India 179,401 180,325 Ireland 53,789 54,531 $ 550,137 $ 589,360

(Insurance Recoveries) Charges

(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net	12 Months Ended
	Dec. 31, 2023
Unusual or Infrequent Items, or Both [Abstract]
(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net	(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net On September 1, 2021, Tropical Storm Ida brought extreme rainfall and flash flooding to New Jersey that caused damage to two of the Company’s facilities. The Company concluded that all inventory on-hand at the time of the flooding was damaged and unsellable and that a majority of the equipment was damaged beyond repair. In addition, the Company incurred significant costs to repair both facilities. Accordingly, the Company recorded $10.4 million of charges for property losses and associated expenses for the year ended December 31, 2021. The Company has insurance policies for property damage, inventory losses and business interruption. Insurance recoveries are recorded in the periods when it is probable they will be realized. During the year ended December 31, 2022 and 2021, insurance recoveries of $1.9 million and $5.0 million, respectively, associated with property damage and equipment losses were received and recorded as a reduction of property losses and associated expenses. (Insurance recoveries) charges for property losses and associated expenses was comprised of the following (in thousands): Year Ended December 31, 2023 2022 2021 Impairment of equipment $ — $ — $ 4,202 Impairment of inventory — — 950 Repairs and maintenance expenses — — 3,716 Salaries and benefits — — 1,500 Total property losses and associated expenses $ — $ — $ 10,368 Less: Insurance recoveries received — (1,911) (5,000) (Insurance recoveries) charges for property losses and associated expenses, net $ — $ (1,911) $ 5,368

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Knight Therapeutics International S.A. License Agreement On January 24, 2024, the Company entered into a 15-year license, distribution and supply agreement with Knight Therapeutics International S.A. (“Knight”) granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America (the “Knight License Agreement”). The Knight License Agreement will automatically renew for successive two-year periods unless either party provides notice declining such renewal at least one year in advance of any such renewal. Knight will be responsible for the performance of all R&D activities, regulatory approval, commercialization, and marketing activities for the territories in the agreement to be conducted to obtain regulatory approval for each product. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Knight. On February 26, 2024, the Company received a nonrefundable license fee of $1.0 million from Knight. The Knight License Agreement provides for potential future milestone payments totaling $10.5 million, contingent upon regulatory approval, launch dates and cumulative net sales targets by Knight. The agreement also includes low-double digit royalty payments based on net sales of IPX203. License Agreement with Zambon Biotech On February 23, 2024, the Company entered into a 15-year license, distribution and supply agreement with Zambon Biotech S.A. (“Zambon”) granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Europe (the “Zambon License Agreement”). The Zambon License Agreement will automatically renew for successive two-year periods unless either party provides notice declining such renewal at least one year in advance of any such renewal. Zambon will be responsible for the performance of all R&D activities, regulatory approval, commercialization, and marketing activities for the territories in the agreement to be conducted to obtain regulatory approval for each product. Upon achieving regulatory approval for products, Amneal will be responsible for manufacturing and supplying products to Zambon.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Accounting Principles	Accounting Principles The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of all entities controlled by the Company, including Amneal and its subsidiaries, through the Company’s direct or indirect ownership of a majority voting interest. The Company records non-controlling interests for the portion of its subsidiaries’ economic interests that it does not hold.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the reported financial position at the date of the financial statements and the reported results of operations during the reporting period. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The following are some, but not all, of such estimates: the determination of chargebacks, sales returns, rebates, billbacks, valuation of intangible and other assets acquired in business combinations, allowances for accounts receivable, accrued liabilities, liabilities for legal matters, contingent liabilities, initial and subsequent valuation of contingent consideration recognized in business combinations, stock-based compensation, valuation of inventory balances, the determination of useful lives for product rights and the assessment of expected cash flows used in evaluating goodwill and other long-lived assets for impairment. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition When assessing its revenue recognition, the Company performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the performance obligation. The Company recognizes revenue when it transfers control of its products to customers, in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those products. From time to time, the Company may enter into arrangements where it licenses certain products to a third-party distributor. Licensing arrangement performance obligations generally include intellectual property (“IP”) rights and research and development (“R&D”) and contract manufacturing services. The Company accounts for IP rights and services separately if they are distinct. The consideration is allocated between IP rights and services based on their relative stand-alone selling prices. Revenue for distinct IP rights is accounted for based on the nature of the promise to grant the license. In determining whether the Company’s promise is to provide a right to access its IP or a right to use its IP, the Company considers the nature of the IP to which the customer will have rights. IP is either functional IP which has significant standalone functionality or symbolic IP which does not have significant standalone functionality. Revenue from functional IP is recognized at the point in time when control of the distinct license is transferred to the customer. Revenue from symbolic IP is recognized over the access period to the Company’s IP. Revenue from sales-based milestones and royalties promised in exchange for a license of IP is recognized only when, or as, the later of subsequent sale or the performance obligation to which some or all of the sales-based royalty has been allocated, is satisfied. Pharmaceutical Product Sales Performance Obligations The Company’s performance obligation is the supply of finished pharmaceutical products to its customers. The Company’s customers consist primarily of major wholesalers, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions and pharmaceutical companies. The Company’s customer contracts generally consist of both a master agreement, which is signed by the Company and its customer, and a customer submitted purchase order, which is governed by the terms and conditions of the master agreement. Customers purchase product by direct channel sales from the Company or by indirect channel sales through various distribution channels. Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time. The Company offers standard payment terms to its customers and has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing, since the period between when the Company transfers the product to the customer and when the customer pays for that product is one year or less. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenues. The consideration amounts due from customers as a result of product sales are subject to variable consideration, as described further below. The Company offers standard product warranties which provide assurance that the product will function as expected and in accordance with specifications. Customers cannot purchase warranties separately and these warranties do not give rise to a separate performance obligation. The Company permits the return of product under certain circumstances, mainly upon product expiration, instances of shipping errors or where product is damaged in transit. The Company accrues for the customer’s right to return as part of its variable consideration. See below for further details. Variable Consideration The Company includes an estimate of variable consideration in its transaction price at the time of sale, when control of the product transfers to the customer. Variable consideration includes but is not limited to: chargebacks, distribution fees, rebates, group purchasing organization (”GPO”) fees, prompt payment (cash) discounts, consideration payable to the customer, billbacks, Medicaid and other government pricing programs, price protection and shelf stock adjustments, sales returns, and profit shares. The Company assesses whether or not an estimate of its variable consideration is constrained and has determined that the constraint does not apply, since it is probable that a significant reversal in the amount of cumulative revenue will not occur in the future when the uncertainty associated with the variable consideration is subsequently resolved. The Company’s estimates for variable consideration are adjusted as required at each reporting period for specific known developments that may result in a change in the amount of total consideration it expects to receive. Chargebacks In the case an indirect customer purchases product from their preferred wholesaler instead of directly from the Company, and the contract price charged to the indirect customer is lower than the wholesaler pricing, the Company pays the direct customer (wholesaler) a chargeback for the price differential. The Company estimates its chargeback accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to chargebacks, current contract terms and historical experience. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Rebates The Company pays fixed or volume-based rebates to its customers based on a fixed amount, fixed percentage of product sales or based on the achievement of a specified level of purchases. The Company’s rebate accruals are based on actual net sales, contractual rebate rates negotiated with customers, and expected purchase volumes / corresponding tiers based on actual sales to date and forecasted amounts. Group Purchasing Organization Fees The Company pays fees to GPOs for administrative services that the GPOs perform in connection with the purchases of product by the GPO participants who are the Company’s customers. The Company’s GPO fee accruals are based on actual net sales, contractual fee rates negotiated with GPOs and the mix of the products in the distribution channel that remain subject to GPO fees. Prompt Payment (Cash) Discounts The Company provides customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The Company’s prompt payment discount accruals are based on actual net sales and contractual discount rates. Consideration Payable to the Customer The Company pays administrative and service fees to its customers based on a fixed percentage of the product price. These fees are not in exchange for a distinct good or service and therefore are recognized as a reduction of the transaction price. The Company accrues for these fees based on actual net sales, contractual fee rates negotiated with the customer and the mix of the products in the distribution channel that remain subject to fees. Billbacks In the case an indirect customer purchases product from their preferred wholesaler instead of directly from the Company, and the contract price charged to the indirect customer is higher than contractual pricing, the Company pays the indirect customer a billback for the price differential. The Company estimates its billback accrual based on its estimates of the level of inventory of its products in the distribution channel that remain subject to billbacks, current contract terms and historical experience. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Medicaid and Other Government Pricing Programs The Company complies with required rebates mandated by law under Medicaid and other government pricing programs. The Company estimates its government pricing accruals based on monthly sales, historical experience of claims submitted by the various states and jurisdictions, historical rates and estimated lag time of the rebate invoices. Price Protection and Shelf Stock Adjustments The Company provides customers with price protection and shelf stock adjustments which may result in an adjustment to the price charged for the product transferred, based on differences between old and new prices which may be applied to the customer’s on-hand inventory at the time of the price change. The Company accrues for these adjustments when its expected value of an adjustment is greater than zero, based on contractual pricing, actual net sales, accrual rates based on historical average rates, and estimates of the level of inventory of its products in the distribution channel that remain subject to these adjustments. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Sales Returns The Company permits the return of product under certain circumstances, mainly due to product expiration, instances of shipping errors or where product is damaged in transit, and occurrences of product recalls. The Company’s product returns accrual is primarily based on estimates of future product returns based generally on actual net sales, estimates of the level of inventory of its products in the distribution channel that remain subject to returns, estimated lag time of returns and historical return rates. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers. Profit Shares For certain product sale arrangements, the Company earns a profit share upon the customer’s sell-through of the product purchased from the Company. The Company estimates its profit shares based on actual net sales, estimates of the level of inventory of its products in the distribution channel that remain subject to profit shares, and historical rates of profit shares earned. The estimate of the level of products in the distribution channel is based primarily on data provided by key customers.
Stock-Based Compensation	Stock-Based Compensation The Company’s stock-based compensation consists of stock options, restricted stock units (“RSUs”) and market performance-based restricted stock units (“MPRSUs”) awarded to employees and non-employee directors. Stock options are measured at their fair value on the grant date or date of modification, as applicable. RSUs, including MPRSUs, are measured at the stock price on the grant date or date of modification, as applicable. The Company recognizes compensation expense on a straight-line basis over the requisite service and/or performance period, as applicable. Forfeitures of awards are accounted for as a reduction in stock-based compensation expense in the period such awards are forfeited. The Company's policy is to issue new shares upon option exercises and the vesting of RSUs and MPRSUs.
Contingent consideration	Contingent consideration
Foreign Currencies	Foreign Currencies The Company has operations in the U.S., India, Ireland, and other foreign jurisdictions. Generally, the Company’s foreign operating subsidiaries’ functional currency is the local currency. The results of its non-U.S. dollar based operations are translated to U.S. dollars at the average exchange rates during the period. Assets and liabilities are translated at the rate of
Business Combinations	Business Combinations Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, the acquiring entity in a business combination records the assets acquired and liabilities assumed at the date of acquisition at their fair values. Any excess of the purchase price over the fair value of net assets and other identifiable intangible assets acquired is recorded as goodwill. Acquisition-related costs, primarily professional fees, are expensed as incurred.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of cash on deposit and highly liquid investments with original maturities of three months or less. A portion of the Company’s cash flows are derived outside the U.S. As a result, the Company is subject to market risk associated with changes in foreign exchange rates. The Company maintains cash balances at both U.S.-based and international-based commercial banks. At various times during the year, cash balances in the U.S. may exceed amounts that are insured by the Federal Deposit Insurance Corporation.
Restricted Cash	Restricted Cash At December 31, 2023 and 2022, respectively, the Company had restricted cash balances of $7.6 million and $9.3 million, respectively, in its bank accounts primarily related to the purchase of certain land and equipment in India.
Accounts Receivable and Allowance for Credit Losses	Accounts Receivable and Allowance for Credit Losses Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary. The Company does not require collateral to secure amounts owed to it by its customers. Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects the best estimate of expected credit losses of the accounts receivable portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. The Company determines its allowance methodology by pooling receivable balances at the customer level. The Company consider various factors, including its previous loss history, individual credit risk associated to each customer, and the current and future condition of the general economy. These credit risk factors are monitored on a quarterly basis and updated as necessary. To the extent that any individual debtor is identified whose credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of such customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, account balances are charged off against the allowance when management believes it is probable the receivable will not be recovered. The Company does not have any off-balance-sheet credit exposure related to customers.
Chargebacks Received From Manufacturers	Chargebacks Received from Manufacturers
Inventories	Inventories Inventories consist of finished goods held for sale, raw materials, and work in process. Inventories are stated at net realizable value, with cost determined using the first-in, first-out method. Adjustments for excess and obsolete inventories are established based upon historical experience and management’s assessment of current product demand. These assessments include inventory obsolescence based on its expiration date, damaged or rejected product, and slow-moving products.
Property, Plant and Equipment	Upon retirement or disposal, the cost of the asset disposed and the accumulated depreciation are removed from the accounts, and any gain or loss is reflected as part of operating income (loss) in the period of disposal. Expenditures that significantly increase value or extend useful lives of property, plant, and equipment are capitalized, whereas those for normal maintenance and repairs are expensed. The Company capitalizes interest on borrowings during the construction period of major capital projects as part of the related asset and amortizes the capitalized interest into earnings over the related asset’s remaining useful life.
Leases	Leases All significant lease arrangements are recognized as right-of-use (“ROU”) assets and lease liabilities at lease commencement. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of the future lease payments using the Company's incremental borrowing rate. Operating lease expense is recognized on a straight-line basis over the lease term. At each balance sheet date, operating and financing lease liabilities continue to represent the present value of the future payments. Financing lease ROU assets are expensed using the straight-line method, unless another basis is more representative of the pattern of economic benefit, to lease expense. Interest on financing lease liabilities is recognized in interest expense. Leases with an initial term of 12 months or less (short-term leases) are not recognized in the balance sheet and the related lease payments are recognized as incurred over the lease term. The Company separates lease and non-lease components. A portion of the Company's real estate leases are subject to periodic changes in the Consumer Price Index (“CPI”). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.
In-Process Research and Development	In-Process Research and Development The fair value of in-process research and development (“IPR&D”) acquired in a business combination is determined based on the present value of each research project’s projected cash flows using an income approach. Revenues are estimated based on relevant market size and growth factors, expected industry trends, individual project life cycles and the life of each research project’s underlying marketability. In determining the fair value of each research project, expected cash flows are adjusted for certain risks of completion, including technical and regulatory risk. The value attributable to IPR&D projects at the time of acquisition is capitalized as an indefinite-lived intangible asset and tested for impairment until the project is completed or abandoned. Upon completion of the project, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized over the estimated useful life of the asset based on the pattern in which the economic benefits are expected to be consumed or otherwise used up or, if that pattern is not readily determinable, on a straight-line basis. If the project is abandoned, the indefinite-lived intangible asset is charged to expense. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance.
Goodwill	Goodwill Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. The Company reviews goodwill for possible impairment annually during the fourth quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable. In order to test goodwill for impairment, an entity is permitted to first assess qualitative factors to determine whether a quantitative assessment of goodwill is necessary. The qualitative factors considered by the Company may include, but are not limited to, general economic conditions, the Company’s outlook, market performance of the Company’s industry and recent and forecasted financial performance. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that a reporting unit’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. If a quantitative assessment is required, the Company determines the fair value of its reporting unit using a combination of the income and market approaches. If the net book value of the reporting unit exceeds its fair value, the Company recognizes a goodwill impairment charge for the reporting unit equal to the lesser of (i) the total goodwill allocated to that reporting unit and (ii) the amount by which that reporting unit’s carrying amount exceeds its fair value. See Note 13. Goodwill and Other Intangible Assets , for further discussion of the Company's qualitative and quantitative assessments of goodwill. Assumptions and estimates used in the evaluation of impairment may affect the carrying value of long-lived assets, which could result in impairment charges in future periods. Such assumptions include projections of future cash flows and the current fair value of the asset.
Amortization of Intangible Assets with Finite Lives	Amortization of Intangible Assets with Finite Lives Intangible assets, other than indefinite-lived intangible assets, are amortized over the estimated useful life of the asset based on the pattern in which the economic benefits are expected to be consumed or otherwise used up or, if that pattern is not readily determinable, on a straight-line basis. The useful life is the period over which the assets are expected to contribute directly or indirectly to future cash flows. Intangible assets are not written-off in the period of acquisition unless they become impaired during that period.
Impairment of Long-Lived Assets (Including Intangible Assets with Finite Lives)	Impairment of Long-Lived Assets (Including Intangible Assets with Finite Lives)
Financial Instruments	Financial Instruments The Company minimizes its risks from interest fluctuations through its normal operating and financing activities and, when deemed appropriate through the use of derivative financial instruments. Derivative financial instruments are used to manage risk and are not used for trading or other speculative purposes. The Company does not use leveraged derivative financial instruments. Derivative financial instruments that qualify for hedge accounting must be designated and effective as a hedge of the identified risk exposure at the inception of the contract. Accordingly, changes in fair value of the derivative contract must be highly correlated with changes in fair value of the underlying hedged item at inception of the hedge and over the life of the hedge contract. All derivatives are recorded on the balance sheet as assets or liabilities and measured at fair value. For derivatives designated as cash flow hedges, the effective portion of the changes in fair value of the derivatives are recorded in accumulated other comprehensive (loss) income net of income taxes and subsequently amortized as an adjustment to interest expense over the period during which the hedged forecasted transaction affects earnings, which is when the Company recognizes interest expense on the hedged cash flows. Cash flows of such derivative financial instruments are classified consistent with the underlying hedged item. Highly effective hedging relationships that use interest rate swaps as the hedging instrument and that meet criteria under ASC 815, Derivatives and Hedging (“ASC 815”), may qualify for the “short-cut method” of assessing effectiveness. The short-cut method allows the Company to make the assumption of no ineffectiveness, which means that the change in fair value of the hedged item can be assumed to be equal to the change in fair value of the derivative. Unless critical terms change, no further evaluation of effectiveness is performed for these hedging relationships unless a critical term is changed. For a hedging relationship that does not qualify for the short-cut method, the Company measures its effectiveness using the “hypothetical derivative method”, in which the change in fair value of the hedged item must be measured separately from the change in fair value of the derivative. At inception and quarterly thereafter, the Company formally assesses whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. The Company compares the change in the fair value of the actual interest rate derivative to the change in the fair value of a hypothetical interest rate derivative with critical terms that match the hedged interest rate payments. After the initial quantitative assessment, this analysis is performed on a qualitative basis and, if it is determined that the hedging relationship was and continues to be highly effective, no further analysis is required. All components of each derivative financial instrument's gain or loss are included in the assessment of hedge effectiveness. If it is determined that a derivative ceases to be a highly effective hedge, the Company discontinues hedge accounting and any deferred gains or losses related to a discontinued cash flow hedge shall continue to be reported in accumulated other comprehensive (loss) income net of income taxes, unless it is probable that the forecasted transaction will not occur. If it is probable that the forecasted transaction will not occur by the originally specified time period, the Company discontinues hedge accounting, and any deferred gains or losses reported in accumulated other comprehensive (loss) income are reclassified into earnings immediately. The Company is subject to credit risk as a result of nonperformance by counterparties to the derivative agreements. Upon inception and quarterly thereafter, the Company makes judgments on each counterparty’s creditworthiness for nonperformance by counterparties.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Accounting for Income Taxes (“ASC 740”), which requires the recognition of tax benefits or expenses on temporary differences between the financial reporting and tax bases of its assets and liabilities by applying the enacted tax rates in effect for the year in which the differences are expected to reverse. Such net tax effects on temporary differences are reflected on the Company’s consolidated balance sheets as deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when the Company believes that it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. ASC 740-10 prescribes a two-step approach for the recognition and measurement of tax benefits associated with the positions taken or expected to be taken in a tax return that affect amounts reported in the financial statements. The Company has reviewed and will continue to review the conclusions reached regarding uncertain tax positions, which may be subject to review and adjustment at a later date based on ongoing analyses of tax laws, regulations and interpretations thereof. To the extent that the Company’s assessment of the conclusions reached regarding uncertain tax positions changes as a result of the evaluation of new information, such change in estimate will be recorded in the period in which such determination is made. The Company reports income tax-related interest and penalties relating to uncertain tax positions, if applicable, as a component of income tax expense.
Comprehensive (Loss) Income	Comprehensive (Loss) Income Comprehensive (loss) income includes net (loss) income and all changes in stockholders’ equity (except those arising from transactions with stockholders) including foreign currency translation adjustments resulting from the consolidation of foreign subsidiaries’ financial statements and unrealized gains (losses) on cash flows hedges, net of income taxes.
Research and Development and Intellectual Property Legal Development Expenses	Research and Development R&D activities are expensed as incurred. R&D expenses primarily consist of direct and allocated expenses incurred with the process of formulation, clinical research, and validation associated with new product development. Upfront and milestone payments made to third parties in connection with R&D collaborations are expensed as incurred up to the point of regulatory approval or when there is no alternative future use. Intellectual Property Legal Development Expenses The Company expenses external IP legal development expenses as incurred. These costs relate to legal challenges of innovator’s patents for invalidity or non-infringement, which are customary in the generic pharmaceutical industry, and are incurred predominately during development of a product and prior to regulatory approval. Associated costs include, but are not limited to, formulation assessments, patent challenge opinions and strategy, and litigation expenses to defend the IP supporting the Company's regulatory filings.
Shipping Costs	Shipping Costs
Advertising Costs	Advertising Costs
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”) , which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers (“ASC 606”). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. ASU 2021-08 was effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective January 1, 2023 and will apply the guidance to subsequent acquisitions. The adoption of ASU 2021-08 did not have an impact on the Company’s consolidated financial statements because the Company did not acquire a business the during the year ended December 31, 2023. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference the London interbank offered rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848) , to expand and clarify the scope of Topic 848 to include derivative instruments on discounting transactions. In December 2022, the FASB issued ASU 2022-06, Reference Rate reform (Topic 848): Deferral of the Sunset Date of Topic 848 , which deferred the sunset date of Topic 848, Reference Rate Reform to December 31, 2024. The Company adopted ASU 2020-04 during the three months ended June 30, 2023 (refer to Note 16. Debt for additional information). The adoption of ASU 2020-04 did not have a material impact on the Company’s consolidated financial statements. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which provides improvements to reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 requires disclosures to include the title and position of the chief operating decision maker (“CODM”), significant segment expenses that are regularly provided to the CODM, a description of other segment items by reportable segment, and any additional measures of a segment’s profit or loss used by the CODM when deciding how to allocate resources. ASU 2023-07 also requires all annual disclosures currently required by Topic 280 to be included in interim periods. The update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which enhances the transparency and usefulness of income tax disclosures. ASU 2023-09 requires that public business entities on an annual basis disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The update is effective for fiscal years beginning after December 15, 2024, with early adoption permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.
Reclassification	Reclassification The prior period balances related to cost of goods sold impairment charges of $11.1 million and $22.7 million, formerly included in a separate caption in the consolidated statements of operations for the years ended December 31, 2022 and 2021, respectively, have been reclassified to be included within the caption cost of goods sold in the consolidated statements of operations to conform with the current period presentation. This reclassification did not impact gross profit or net income.
Fair Value Measurements	Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. Valuation techniques used to measure fair value should maximize the use of observable inputs and minimize the use of unobservable inputs. To measure fair value, the Company uses the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data by correlation or other means. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Value is determined using pricing models, discounted cash flow methodologies, or similar techniques and also includes instruments for which the determination of fair value requires significant judgment or estimation.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Property, Plant, and Equipment Estimated Useful Lives	Depreciation expense is computed primarily using the straight-line method over the estimated useful lives of the assets, which are as follows: Asset Classification Estimated Useful Life Buildings 30 years Computer equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of asset's useful life or remaining life of lease Machinery and equipment 5 - 10 years Vehicles 5 years Property, plant, and equipment, net was comprised of the following (in thousands): December 31, December 31, Land $ 9,024 $ 10,706 Buildings 227,837 225,630 Leasehold improvements 126,461 124,668 Machinery and equipment 443,532 411,572 Furniture and fixtures 14,757 13,823 Vehicles 2,098 1,699 Computer equipment 64,227 58,344 Construction-in-progress 67,665 69,344 Total property, plant, and equipment 955,601 915,786 Less: Accumulated depreciation (508,027) (445,971) Property, plant, and equipment, net $ 447,574 $ 469,815

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Asset Acquisition	The Saol Acquisition was accounted for under the acquisition method of accounting, with Amneal as the accounting acquirer. The purchase price was calculated as follows (in thousands): Cash $ 84,714 Contingent consideration (royalties) (1) 8,796 Fair value of consideration transferred $ 93,510 (1) The estimated fair value of contingent consideration on the acquisition date wa s $8.8 million and was based on significant Level 3 inputs that were not observable in the market. Key assumptions included the discount rate, projected year of payments and expected net product sales. Refer to Note 19. Fair Value Measurements for additional information on the methodology and determination of this liability. The following is a summary of the purchase price allocation for the Saol Acquisition (in thousands): Final F air Values as of February 9, 2022 Inventory $ 2,162 Prepaid expenses and other current assets 98 Goodwill 7,553 Intangible assets 83,815 Total assets acquired 93,628 Accounts payable and accrued expenses 118 Fair value of consideration transferred $ 93,510
Schedule of Acquired Marketed Product Rights Intangible Assets	The acquired intangible assets are being amortized over their estimated useful lives as follows (in thousands): Final Fair Value Weighted-Average Marketed product rights $ 83,815 11.5

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The following table summarizes the percentages of net revenues from each of the Company's customers that individually accounted for 10% or more of its net revenues: For the year ended December 31, 2023 2022 2021 Customer A 24 % 21 % 21 % Customer B 16 % 18 % 20 % Customer C 21 % 22 % 24 % Customer D 9 % 10 % 10 %
Schedule of Disaggregated Revenue	The Company’s significant therapeutic classes for its Generics and Specialty segments and sales channels for its AvKARE segment, as determined based on net revenue for each of the years ended December 31, 2023, 2022 and 2021, are set forth below (in thousands): Year ended December 31, 2023 2022 2021 Generics Anti-infective $ 25,885 $ 23,193 $ 30,501 Hormonal / allergy 451,736 444,909 427,077 Antiviral (1) 39,910 40,601 4,832 Central nervous system 369,201 393,281 381,110 Cardiovascular system 139,942 118,183 141,866 Gastroenterology 67,519 70,796 76,497 Oncology 110,455 64,285 103,327 Metabolic disease / endocrine 45,900 41,128 38,462 Respiratory 42,710 41,085 35,965 Dermatology 70,872 66,553 55,474 Other therapeutic classes 105,106 118,573 69,928 License agreement (2) — 8,018 — International and other 2,165 1,468 1,299 Total Generics net revenue 1,471,401 1,432,073 1,366,338 Specialty Hormonal / allergy 110,486 91,465 68,397 Central nervous system 249,981 255,656 277,196 Other therapeutic classes 29,990 27,000 32,726 Total Specialty net revenue 390,457 374,121 378,319 AvKARE Distribution 347,406 260,560 192,921 Government label 121,829 98,234 118,379 Institutional 38,016 27,742 25,176 Other 24,498 19,574 12,536 Total AvKARE net revenue 531,749 406,110 349,012 Total net revenue $ 2,393,607 $ 2,212,304 $ 2,093,669 (1) Antiviral net revenue for the year ended December 31, 2021 was lower in comparison to the years ended December 31, 2023 and 2022 primarily due to a decline in Oseltamivir (generic Tamiflu®) sales from lower demand and increased returns activity above historical levels as a result of decreased influenza activity during the onset of the COVID-19 pandemic. (2) Refer to Note 5. Alliance and Collaboration for information on revenue recognized under a license agreement.
Schedule of Major Categories of Sales-Related Deductions	A rollforward of the major categories of sales-related deductions for the years ended December 31, 2023, 2022 and 2021 is as follows (in thousands): Contract Charge- Cash Accrued Accrued Balance at December 31, 2020 $ 628,804 $ 22,690 $ 174,984 $ 131,088 Provision related to sales recorded in the period 3,164,331 107,810 105,127 137,452 Credits/payments issued during the period (3,289,233) (106,858) (118,133) (182,803) Balance at December 31, 2021 503,902 23,642 161,978 85,737 Provision related to sales recorded in the period 3,416,149 112,609 84,306 129,203 Credits/payments issued during the period (3,346,459) (108,797) (101,224) (128,910) Balance at December 31, 2022 573,592 27,454 145,060 86,030 Provision related to sales recorded in the period 3,384,360 113,396 73,172 246,608 Credits/payments issued during the period (3,398,618) (116,958) (81,746) (241,948) Balance at December 31, 2023 $ 559,334 $ 23,892 $ 136,486 $ 90,690 The following table summarizes the changes in the Company’s valuation allowance on deferred tax assets (in thousands): Years Ended December 31, 2023 2022 2021 Balance at the beginning of the period $ 434,895 $ 416,588 $ 422,812 Increase (decrease) due to net operating losses and temporary differences 23,078 25,589 (10,828) Increase due to stock-based compensation 1,652 224 5,513 Decrease recorded against goodwill — (1,590) — Increase recorded against additional paid-in capital 96,316 2,720 2,842 Increase (decrease) recorded against other comprehensive income 10,603 (8,636) (3,751) Balance at the end of the period $ 566,544 $ 434,895 $ 416,588

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of (Loss) Income Before Income Taxes	The components of the Company's (loss) income before income taxes were as follows (in thousands): Years Ended December 31, 2023 2022 2021 United States $ (59,781) $ (260,616) $ (10,540) International 19,511 12,489 41,906 Total (loss) income before income taxes $ (40,270) $ (248,127) $ 31,366
Schedule of Provision for (Benefit From) Income Tax Expense	The provision for (benefit from) income taxes was comprised of the following (in thousands): Years Ended December 31, 2023 2022 2021 Current: Domestic $ 2,470 $ (1,073) $ 1,311 Foreign 5,982 7,735 9,885 Total current income tax $ 8,452 $ 6,662 $ 11,196
Schedule of Effective Income Tax Rate	The Company’s effective tax rates were as follows: Years Ended December 31, 2023 2022 2021 Federal income tax at the statutory rate 21.0 % 21.0 % 21.0 % State income tax, net of federal benefit (5.5) (0.8) 4.2 Income not subject to tax 14.5 (10.7) 6.4 Foreign rate differential (19.5) (3.4) 17.3 Permanent book/tax differences (2.1) (0.3) 4.8 Change in prior year estimates 7.7 0.7 (0.3) Deferred tax adjustment (5.7) — 0.1 Valuation allowance (32.3) (10.3) (13.5) Other 0.9 1.1 (4.3) Effective income tax rate (21.0) % (2.7) % 35.7 %
Schedule of Major Categories of Sales-Related Deductions	A rollforward of the major categories of sales-related deductions for the years ended December 31, 2023, 2022 and 2021 is as follows (in thousands): Contract Charge- Cash Accrued Accrued Balance at December 31, 2020 $ 628,804 $ 22,690 $ 174,984 $ 131,088 Provision related to sales recorded in the period 3,164,331 107,810 105,127 137,452 Credits/payments issued during the period (3,289,233) (106,858) (118,133) (182,803) Balance at December 31, 2021 503,902 23,642 161,978 85,737 Provision related to sales recorded in the period 3,416,149 112,609 84,306 129,203 Credits/payments issued during the period (3,346,459) (108,797) (101,224) (128,910) Balance at December 31, 2022 573,592 27,454 145,060 86,030 Provision related to sales recorded in the period 3,384,360 113,396 73,172 246,608 Credits/payments issued during the period (3,398,618) (116,958) (81,746) (241,948) Balance at December 31, 2023 $ 559,334 $ 23,892 $ 136,486 $ 90,690 The following table summarizes the changes in the Company’s valuation allowance on deferred tax assets (in thousands): Years Ended December 31, 2023 2022 2021 Balance at the beginning of the period $ 434,895 $ 416,588 $ 422,812 Increase (decrease) due to net operating losses and temporary differences 23,078 25,589 (10,828) Increase due to stock-based compensation 1,652 224 5,513 Decrease recorded against goodwill — (1,590) — Increase recorded against additional paid-in capital 96,316 2,720 2,842 Increase (decrease) recorded against other comprehensive income 10,603 (8,636) (3,751) Balance at the end of the period $ 566,544 $ 434,895 $ 416,588
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences that give rise to deferred taxes were as follows (in thousands): December 31, December 31, Deferred tax assets: Partnership interest in Amneal $ 318,140 $ 203,336 Projected imputed interest on TRA 22,730 25,255 Net operating loss carryforward 74,340 82,338 IRC Section 163(j) interest carryforward 72,513 54,996 Capitalized costs 2,537 2,505 Accrued expenses 648 431 Stock-based compensation 14,672 5,737 Intangible assets 21,901 23,967 Tax credits and other 39,063 36,330 Total deferred tax assets 566,544 434,895 Valuation allowance (566,544) (434,895) Net deferred tax assets $ — $ —
Schedule of Changes in Unrecognized Tax Benefits	A rollforward of unrecognized tax benefits for the years ended December 31, 2023, 2022 and 2021 is as follows (in thousands): Years Ended December 31, 2023 2022 2021 Unrecognized tax benefits at the beginning of the period $ 3,616 $ 5,489 $ 5,368 Gross change for current period positions 170 110 131 Gross change for prior period positions (51) (1,983) (10) Unrecognized tax benefits at the end of the period $ 3,735 $ 3,616 $ 5,489

(Loss) Earnings per Share (Tabl

(Loss) Earnings per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Schedule of (Loss) Earnings per Share, Basic and Diluted	The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted (loss) earnings per share of Class A common stock (in thousands, except per share amounts): Year Ended December 31, 2023 2022 2021 Numerator: Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (83,993) $ (129,986) $ 10,624 Denominator: Weighted-average shares outstanding - basic 176,136 150,944 148,922 Effect of dilutive securities: Stock options — — 767 Restricted stock units — — 2,132 Weighted-average shares outstanding - diluted 176,136 150,944 151,821 Net loss (income) per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders: Basic $ (0.48) $ (0.86) $ 0.07 Diluted $ (0.48) $ (0.86) $ 0.07
Schedule of Antidilutive Securities Excluded from Computation of (Loss) Earnings per Share	The following table presents potentially dilutive securities excluded from the computations of diluted (loss) earnings per share of Class A common stock (in thousands): Years Ended December 31, 2023 2022 2021 Stock options 2,416 (1) 2,648 (1) 347 (3) Restricted stock units 10,511 (1) 10,755 (1) — Performance stock units 6,944 (1) 7,174 (1) 5,055 (4) Shares of Old PubCo Class B Common Stock — 152,117 (2) 152,117 (2) (1) Excluded from the computation of diluted loss per share of Class A common stock for the years ended December 31, 2023 and 2022 because the effect of their inclusion would have been anti-dilutive since there was a net loss attributable to the Company for the years ended December 31, 2023 and 2022. (2) Shares of Old PubCo Class B Common Stock were considered potentially dilutive shares of Class A common stock. Shares of Old PubCo Class B Common Stock were excluded from the computations of diluted (loss) earnings per share of Class A common stock for each of the years ended December 31, 2022 and 2021 because the effect of their inclusion would have been anti-dilutive under the if-converted method. (3) Excluded from the computation of diluted earnings per share of Class A common stock for the year ended December 31, 2021 because the exercise price of the stock options exceeded the average market price of the Class A common stock during the period (out-of-the-money). (4) Excluded from the computation of diluted earnings per share of Class A common stock for the year ended December 31, 2021 because the performance vesting conditions were not met.

Trade Accounts Receivable, Net

Trade Accounts Receivable, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Receivables [Abstract]
Schedule of Trade Accounts Receivable, Net	Trade accounts receivable, net is comprised of the following (in thousands): December 31, December 31, Gross accounts receivable $ 1,199,980 $ 1,344,959 Allowance for credit losses (3,022) (2,122) Contract charge-backs and sales volume allowances (1) (559,334) (573,592) Cash discount allowances (23,892) (27,454) Subtotal (586,248) (603,168) Trade accounts receivable, net $ 613,732 $ 741,791 (1) Refer to Note 4. Revenue Recognition for additional information.
Schedules of Percent of Gross Trade Receivables	Trade accounts receivables from customers representing 10% or more of the Company’s total trade accounts receivable were as follows: December 31, 2023 December 31, 2022 Customer A 40 % 41 % Customer B 24 % 25 % Customer C 22 % 21 %

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Components of Inventories	Inventories are comprised of the following (in thousands): December 31, December 31, Raw materials $ 217,744 $ 224,607 Work in process 59,563 58,522 Finished goods 304,077 247,606 Total inventories $ 581,384 $ 530,735

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets are comprised of the following (in thousands): December 31, December 31, Deposits and advances $ 2,200 $ 1,821 Prepaid insurance 8,334 8,090 Prepaid regulatory fees 6,331 5,298 Income and other tax receivables 13,168 12,881 Prepaid taxes 11,899 16,593 Other current receivables (1) 9,929 33,133 Chargebacks receivable (2) 7,876 8,605 Other prepaid assets 22,948 17,144 Total prepaid expenses and other current assets $ 82,685 $ 103,565 (1) Other current receivables as of December 31, 2022 included a $21.4 million receivable for an upfront payment associated with the Orion Agreement which was collected in January 2023. Refer to Note 5. Alliance and Collaboration for additional information. (2) When a sale occurs on a contract item, the difference between the cost paid to the manufacturer by the Company and the contract cost that the end customer has with the manufacturer is rebated back to the Company by the manufacturer. The Company establishes a chargeback (rebate) receivable and a reduction to cost of goods sold in the same period as the related sale.

Property, Plant, and Equipmen_2

Property, Plant, and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net Estimated Useful Lives	Depreciation expense is computed primarily using the straight-line method over the estimated useful lives of the assets, which are as follows: Asset Classification Estimated Useful Life Buildings 30 years Computer equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of asset's useful life or remaining life of lease Machinery and equipment 5 - 10 years Vehicles 5 years Property, plant, and equipment, net was comprised of the following (in thousands): December 31, December 31, Land $ 9,024 $ 10,706 Buildings 227,837 225,630 Leasehold improvements 126,461 124,668 Machinery and equipment 443,532 411,572 Furniture and fixtures 14,757 13,823 Vehicles 2,098 1,699 Computer equipment 64,227 58,344 Construction-in-progress 67,665 69,344 Total property, plant, and equipment 955,601 915,786 Less: Accumulated depreciation (508,027) (445,971) Property, plant, and equipment, net $ 447,574 $ 469,815

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in goodwill were as follows (in thousands): Years Ended December 31, 2023 2022 Balance, beginning of period $ 598,853 $ 593,017 Goodwill acquired during the period — 7,553 Adjustment during the period for the Puniska Acquisition — 3,075 Currency translation (224) (4,792) Balance, end of period $ 598,629 $ 598,853
Schedule of Finite-Lived Intangible Assets	Intangible assets were comprised of the following (in thousands): December 31, 2023 December 31, 2022 Weighted- Cost Accumulated Net Cost Accumulated Amortization Net Amortizing intangible assets: Product rights 6.3 $ 1,198,971 $ (703,297) $ 495,674 $ 1,222,762 $ (573,281) $ 649,481 Other intangible assets 3.3 111,800 (72,896) 38,904 133,800 (77,943) 55,857 Total 1,310,771 (776,193) 534,578 1,356,562 (651,224) 705,338 In-process research and development 355,845 — 355,845 390,755 — 390,755 Total intangible assets $ 1,666,616 $ (776,193) $ 890,423 $ 1,747,317 $ (651,224) $ 1,096,093
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The following table presents future amortization expense for the next five years and thereafter, excluding $355.8 million of IPR&D intangible assets (in thousands): Future 2024 $ 159,059 2025 119,404 2026 70,708 2027 50,380 2028 31,656 Thereafter 103,371 Total $ 534,578

Other Assets (Tables)

Other Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Other Assets [Abstract]
Schedule of Other Assets	Other assets were comprised of the following (in thousands): December 31, December 31, Interest rate swap (1) $ 37,089 $ 85,586 Security deposits 3,602 3,523 Long-term prepaid expenses 3,273 3,711 Deferred revolving credit facility costs 4,427 2,206 Other long-term assets 7,126 8,191 Total $ 55,517 $ 103,217 (1) Refer to Note 19. Fair Value Measurements and Note 20. Financial Instruments

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses were comprised of the following (in thousands): December 31, December 31, Accounts payable $ 143,572 $ 165,980 Accrued returns allowance (1) 136,486 145,060 Accrued compensation 71,122 54,038 Accrued Medicaid and commercial rebates (1) 90,690 86,030 Accrued royalties 23,342 19,309 Commercial chargebacks and rebates 10,226 10,226 Accrued professional fees 11,005 11,386 Accrued other 48,219 46,170 Total accounts payable and accrued expenses $ 534,662 $ 538,199 (1) Refer to Note 4. Revenue Recognition for additional information.

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt	The following is a summary of the Company’s term loan indebtedness (in thousands): December 31, December 31, Term Loan Due 2025 $ 191,979 $ 2,563,876 Term Loan Due 2028 2,351,647 — Rondo Term Loan due 2025 — 72,000 Total debt 2,543,626 2,635,876 Less: debt issuance costs (123,497) (13,934) Total debt, net of debt issuance costs 2,420,129 2,621,942 Less: current portion of long-term debt (34,125) (29,961) Total long-term debt, net $ 2,386,004 $ 2,591,981

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Other Liabilities [Abstract]
Schedule of Other Long-Term Liabilities	Other long-term liabilities were comprised of the following (in thousands): December 31, 2023 December 31, 2022 Uncertain tax positions $ 497 $ 563 Long-term portion of liabilities for legal matters (1) 316 49,442 Long-term compensation (2) 21,283 16,737 Contingent consideration (3) 433 11,997 Other long-term liabilities 7,466 8,729 Total other long-term liabilities $ 29,995 $ 87,468 (1) Refer to Note 21. Commitments and Contingencies for additional information. (2) Includes $11.1 million and $7.6 million of long-term liabilities under deferred compensation plans (refer to Note 19. Fair Value Measurements for certain deferred compensation plan liabilities measured at fair value) as of December 31, 2023 and 2022, respectively, and $10.2 million and $9.1 million of long-term employee benefits for the Company’s international employees as of December 31, 2023 and 2022, respectively. (3) Refer to Note 19. Fair Value Measurements for additional information.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Schedule of Components of Lease Costs / Supplemental Cash Flow Information	The components of total lease costs were as follows (in thousands): Years Ended December 31, 2023 2022 2021 Operating lease cost (1) $ 16,734 $ 17,800 $ 15,057 Finance lease cost: Amortization of right-of-use assets 4,972 4,808 4,713 Interest on lease liabilities 4,583 4,508 4,601 Total finance lease cost 9,555 9,316 9,314 Total lease cost $ 26,289 $ 27,116 $ 24,371 (1) Includes variable and short-term lease costs. Supplemental cash flow information related to leases was as follows (in thousands): Years Ended December 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 4,583 $ 4,539 Operating cash flows from operating leases $ 16,036 $ 16,217 Financing cash flows from finance leases $ 3,588 $ 3,484 Non-cash activity: Right-of-use assets obtained in exchange for new operating lease liabilities $ 773 $ 7,504 Right-of-use assets obtained in exchange for new financing lease liabilities $ 856 $ 4,606
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to the Company's leases was as follows (in thousands): Operating leases December 31, 2023 December 31, 2022 Operating lease right-of-use assets $ 30,329 $ 38,211 Operating lease right-of-use assets - related party (1) 12,954 17,910 Total operating lease right-of-use assets $ 43,283 $ 56,121 Operating lease liabilities $ 24,095 $ 32,126 Operating lease liabilities - related party (1) 12,787 15,914 Current portion of operating lease liabilities 9,207 8,321 Current portion of operating lease liabilities - related party (1) 2,825 2,869 Total operating lease liabilities $ 48,914 $ 59,230 Financing leases Financing lease right of use assets $ 59,280 $ 63,424 Financing lease liabilities $ 58,566 $ 60,769 Current portion of financing lease liabilities 2,467 3,488 Total financing lease liabilities $ 61,033 $ 64,257 (1) Refer to Note 24. Related Party Transactions for information about related party leases. The table below reflects the weighted average remaining lease term and weighted average discount rate for the Company's operating and finance leases: December 31, 2023 December 31, 2022 Weighted average remaining lease term - operating leases 5 years 5 years Weighted average remaining lease term - finance leases 18 years 19 years Weighted average discount rate - operating leases 8.9% 8.5% Weighted average discount rate - finance leases 7.3% 7.2%
Schedule of Operating Lease Maturities	Maturities of lease liabilities as of December 31, 2023 were as follow (in thousands): Operating Financing 2024 $ 15,978 $ 6,856 2025 14,544 6,874 2026 10,693 6,140 2027 7,742 5,647 2028 5,467 5,647 Thereafter 6,916 79,573 Total lease payments 61,340 110,737 Less: Imputed interest (12,426) (49,704) Total $ 48,914 $ 61,033 Maturities of lease liabilities as of December 31, 2022 were as follows (in thousands): Operating Financing 2023 $ 15,843 $ 7,976 2024 16,558 6,913 2025 14,264 6,466 2026 10,393 5,989 2027 7,420 5,645 Thereafter 11,550 85,220 Total lease payments 76,028 118,209 Less: Imputed interest (16,798) (53,952) Total $ 59,230 $ 64,257
Schedule of Finance Lease Maturities	Maturities of lease liabilities as of December 31, 2023 were as follow (in thousands): Operating Financing 2024 $ 15,978 $ 6,856 2025 14,544 6,874 2026 10,693 6,140 2027 7,742 5,647 2028 5,467 5,647 Thereafter 6,916 79,573 Total lease payments 61,340 110,737 Less: Imputed interest (12,426) (49,704) Total $ 48,914 $ 61,033 Maturities of lease liabilities as of December 31, 2022 were as follows (in thousands): Operating Financing 2023 $ 15,843 $ 7,976 2024 16,558 6,913 2025 14,264 6,466 2026 10,393 5,989 2027 7,420 5,645 Thereafter 11,550 85,220 Total lease payments 76,028 118,209 Less: Imputed interest (16,798) (53,952) Total $ 59,230 $ 64,257

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table sets forth the Company’s financial assets and liabilities that were measured at fair value on a recurring basis (in thousands): Fair Value Measurement Based on December 31, 2023 Total Quoted Significant Significant Assets Interest Rate Swap (1) $ 37,089 $ — $ 37,089 $ — Liabilities Deferred compensation plan liabilities (2) $ 9,100 $ — $ 9,100 $ — Contingent consideration liability (3) $ 921 $ — $ — $ 921 December 31, 2022 Assets Interest Rate Swap (1) $ 85,586 $ — $ 85,586 $ — Liabilities Deferred compensation plan liabilities (2) $ 9,674 $ — $ 9,674 $ — Contingent consideration liability (3) $ 15,427 $ — $ — $ 15,427 (1) The fair value measurement of the Company’s interest rate swap classified within Level 2 of the fair value hierarchy is a model-derived valuation as of a given date in which all significant inputs are observable in active markets including certain financial information and certain assumptions regarding past, present, and future market conditions. Refer to Note 20. Financial Instruments for information about the Company’s interest rate swap. (2) These liabilities are recorded at the value of the amount owed to the plan participants, with changes in value recognized as compensation expense. The calculation of the deferred compensation plan obligation is derived from observable market data by reference to hypothetical investments selected by the participants. (3) The fair value measurement of contingent consideration liability has been classified as a Level 3 recurring liability as its valuation requires judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for various inputs, the estimated fair value could be higher or lower than what the Company determined. As of December 31, 2023 and 2022, the contingent consideration liability associated with the Saol Acquisition included $0.1 million and $0.1 million, respectively, recorded in accounts payable and accrued expenses and $0.4 million and $12.0 million, respectively, recorded in other-longer term liabilities. As of December 31, 2023 and 2022, the contingent consideration liability associated with the KSP Acquisition included $0.4 million and $3.3 million, respectively, and was recorded within related party payables - long term. Refer to Note 3. Acquisitions for additional about the KSP Acquisition and the Saol Acquisition.
Schedule of Reconciliation of Contingent Consideration Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)	The following table provides a reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): Year Ended December 31, 2023 Year Ended Balance, beginning of period $ 15,427 $ 5,900 Addition due to the Saol Acquisition — 8,796 Net change in fair value during period (14,491) 731 Payments (15) — Balance, end of period $ 921 $ 15,427
Significant Inputs Used in Fair Value Measurements	The following table summarizes the significant unobservable inputs used in the fair value measurement of our contingent consideration liabilities as of December 31, 2022 (the fair value of contingent consideration was immaterial as of December 31, 2023): Contingent Consideration Liability Fair Value as of December 31, 2022 (in thousands) Unobservable input Range Weighted Average (1) Regulatory Milestones (KSP Acquisition) $ 390 Discount rate 7.2% — 8.5% 7.3 % Probability of payment 1.8% — 20.0% 18.6 % Projected year of payment 2024 — 2026 2024 Royalties (KSP Acquisition) $ 2,900 Discount rate 12.5% — 12.5% 12.5 % Probability of payment 1.8% — 20.0% 18.6 % Projected year of payment 2024 — 2033 2028 Royalties (Saol Acquisition) $ 12,137 Discount rate 17.8% — 17.8% 17.8 % Projected year of payment 2023 — 2033 2027 (1) Unobservable inputs were weighted by the relative fair value of each product candidate acquired.

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets	A summary of the fair values of derivative instruments in the consolidated balance sheets was as follows (in thousands): December 31, 2023 December 31, 2022 Derivatives Designated as Hedging Instruments Balance Sheet Fair Value Balance Sheet Fair Value Variable-to-fixed interest rate swap Other Assets $ 37,089 Other Assets $ 85,586

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Charges and Liabilities Related to Legal Matters	Liabilities for legal matters were comprised of the following (in thousands): December 31, Matter 2023 2022 Opana ER® antitrust litigation $ 50,000 $ 83,944 Opana ER® antitrust litigation-accrued interest 2,347 1,423 Civil prescription opioid litigation 21,189 17,993 Other 3,452 4,123 Current portion of liabilities for legal matters $ 76,988 $ 107,483 Opana ER® antitrust litigation $ — $ 50,000 Opana ER ® antitrust litigation-imputed interest — (1,405) Opana ER ® antitrust litigation-accrued interest — 847 Civil prescription opioid litigation 316 — Long-term portion of liabilities for legal matters (included in other long-term liabilities) $ 316 $ 49,442

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss by Component	Changes in Accumulated Other Comprehensive Loss by Component (in thousands): Foreign Unrealized (loss) gain on cash flow hedge, net of tax Accumulated Balance December 31, 2021 $ (18,845) $ (5,982) $ (24,827) Other comprehensive income before reclassification (13,394) 48,270 34,876 Reallocation of ownership interests (143) 33 (110) Balance December 31, 2022 (32,382) 42,321 9,939 Other comprehensive income before reclassification (433) (39,248) (39,681) Reallocation of ownership interests (33,257) 34,016 759 Reclassification of cash flow hedge to earnings, net of tax — (3,366) (3,366) Balance December 31, 2023 $ (66,072) $ 33,723 $ (32,349)

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	The following table summarizes all of the Company’s stock option activity for the years ended December 31, 2023, 2022, and 2021: Stock Options Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2020 3,811,229 $ 4.80 Options exercised (342,350) 2.76 Options forfeited (417,379) 11.09 Outstanding at December 31, 2021 3,051,500 $ 4.17 7.0 $ 5.3 Options exercised (207,452) 2.75 Options forfeited (195,607) 2.77 Outstanding at December 31, 2022 2,648,441 $ 4.38 6.0 $ — Options exercised (163,824) 2.75 Options forfeited (68,252) 2.75 Outstanding at December 31, 2023 2,416,365 $ 4.54 5.0 $ 6.6 Options exercisable at December 31, 2023 2,416,365 $ 4.54 5.0 $ 6.6
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes all of the Company's restricted stock unit activity for the years ended December 31, 2023, 2022, and 2021: Restricted Stock Units Number of Weighted- Weighted- Aggregate Non-vested at December 31, 2020 9,132,552 $ 5.09 Granted 6,870,481 5.86 Vested (1,906,607) 5.97 Forfeited (912,826) 6.68 Non-vested at December 31, 2021 13,183,600 $ 5.25 1.4 $ 63.7 Granted 10,117,037 4.54 Vested (2,697,134) 5.95 Forfeited (2,674,890) 5.07 Non-vested at December 31, 2022 17,928,613 $ 4.77 1.3 $ 35.7 Granted 7,519,565 1.91 Vested (3,888,602) 4.53 Forfeited (4,104,873) 3.41 Non-vested at December 31, 2023 17,454,703 $ 3.92 1.2 $ 105.4
Schedule of Employee Service Share-based Compensation	The amount of stock-based compensation expense recognized by the Company was as follows (in thousands): Year Ended December 31, 2023 2022 2021 Cost of goods sold $ 3,561 $ 4,811 $ 4,688 Selling, general and administrative 18,922 20,746 18,718 Research and development 4,339 6,290 5,006 Total $ 26,822 $ 31,847 $ 28,412

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The following table summarizes the Company’s related party transactions (in thousands): Year ended December 31, Related Party and Nature of Transaction Caption in Balance Sheet and Statement of Operations 2023 2022 2021 A Kashiv Biosciences LLC i. Parking space lease Research and development $ 100 $ 100 $ 99 ii. License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Filgrastim Selling, general and administrative $ — $ 5,000 $ — ii. License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for P egfilgrastim-pbbk Intangible asset $ — $ 15,000 $ — ii. Inventory purchases under license and commercialization agreement - Filgrastim and Pegfilgrastim Inventory and cost of goods sold $ — $ 260 $ — ii. Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko) Cost of goods sold $ 5,114 $ — $ — ii. Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko) Inventory and cost of goods sold $ 1,022 $ — $ — iii. Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate Research and development $ (25) $ 1,761 $ 1,362 iv. Transition services associated with the KSP Acquisition Selling, general and administrative $ — $ — $ 255 v. Development and commercialization - consulting - various products Research and development $ — $ 2 $ 628 vi. Generic development supply agreement - research and development material Research and development $ (2,809) $ — $ — vi. Generic development supply agreement - development activity deferred income Deferred revenue $ (246) $ — $ — vii. K127 development and commercialization agreement* Research and development $ — $ — $ 3,000 viii. Commercial product support for EluRyng and other products* Cost of goods sold and research and development $ — $ — $ 1,239 ix. Profit sharing - various products* Cost of goods sold $ — $ — $ 2,680 x. Development and commercialization agreements - various products* Research and development $ — $ — $ 150 B LAX Hotel, LLC Financing lease Inventory and cost of goods sold $ — $ — $ 217 Interest component of financing lease Interest expense — — 362 Total $ — $ — $ 579 C Kanan, LLC - operating lease Inventory and cost of goods sold $ 2,540 $ 2,104 $ 2,103 D Sutaria Family Realty, LLC - operating lease Inventory and cost of goods sold $ 1,352 $ 1,211 $ 1,179 E PharmaSophia, LLC - research and development services income Research and development $ — $ (45) $ (329) E PharmaSophia, LLC - license and commercialization agreement Research and development $ — $ 1,093 $ — F Fosun International Limited - license and supply agreement Net revenue $ (80) $ — $ — F Fosun International Limited - API co-development agreement Net revenue $ — $ — $ (200) G Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement Inventory and cost of goods sold $ 15,873 $ 2,742 $ 11,380 H Tracy Properties LLC - operating lease Selling, general and administrative $ 625 $ 565 $ 532 I AzaTech Pharma LLC - supply agreement Inventory and cost of goods sold $ 8,746 $ 4,963 $ 5,156 J AvPROP, LLC - operating lease Selling, general and administrative $ 167 $ 178 $ 165 K Tarsadia Investments, LLC - financial consulting services Selling, general and administrative $ — $ — $ — L Avtar Investments, LLC - consulting services Research and development $ 321 $ 216 $ 361 M TPG Operations, LLC - consulting services Selling, general and administrative $ — $ 19 $ 249 N TPG Capital BD, LLC Loss on refinancing $ 3,000 $ — $ — O Alkermes Plc Inventory and cost of goods sold $ 464 $ 235 $ 138 P R&S Solutions LLC - logistics services Selling, general and administrative $ 102 $ 85 $ 183 Q Asana Biosciences, LLC Research and development $ — $ (5) $ (4) S Members - tax receivable agreement Other expense $ 3,126 $ 631 $ — *Agreement between Amneal and Kashiv was acquired with KSP and has become a transaction among Amneal’s consolidated subsidiaries subsequent to the transaction closing on April 2, 2021. The disclosure relates to the historical agreement as a related party transaction through April 2, 2021 (refer to Note 3. Acquisitions for additional information). The following table summarizes the amounts due to or from the Company for related party transactions (in thousands): December 31, 2023 December 31, 2022 R Sellers of AvKARE LLC and R&S - state tax indemnification $ — $ 486 A Kashiv - various agreements 954 12 Q Asana BioSciences, LLC — 2 O Alkermes 1 — Related party receivables - short term $ 955 $ 500 A Kashiv - various agreements $ 3,179 $ 110 G Apace Packaging, LLC - packaging agreement 1,091 756 I AzaTech Pharma LLC - supply agreement 1,958 863 L Avtar Investments LLC - consulting services 100 72 R Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 442 442 S Members - tax receivable agreement 549 201 P R&S Solutions LLC - logistics services — 7 O Alkermes Plc 2 28 Related party payables - short term $ 7,321 $ 2,479 A Kashiv - contingent consideration $ 430 $ 3,290 R Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes 8,139 5,929 S Members - tax receivable agreement 3,207 430 Related party payables - long term $ 11,776 $ 9,649

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The tables below present segment information reconciled to total Company financial results, with segment operating income or loss, including gross profit less direct selling expenses, R&D expenses, and other operating expenses to the extent specifically identified by segment (in thousands): Year Ended December 31, 2023 Generics Specialty AvKARE Corporate Total Net revenue (1) $ 1,471,401 $ 390,457 $ 531,749 $ — $ 2,393,607 Cost of goods sold 913,869 214,277 444,896 — 1,573,042 Gross profit 557,532 176,180 86,853 — 820,565 Selling, general and administrative 119,912 88,137 55,341 166,285 429,675 Research and development 132,233 31,717 — — 163,950 In-process research and development impairment charges 26,500 4,300 — — 30,800 Intellectual property legal development expenses 3,708 120 — — 3,828 Restructuring and other charges 211 1,105 — 433 1,749 Change in fair value of contingent consideration — (14,497) — — (14,497) (Credit) charges related to legal matters, net (64) — — 1,888 1,824 Other operating income (1,138) — — — (1,138) Operating income (loss) $ 276,170 $ 65,298 $ 31,512 $ (168,606) $ 204,374 Year Ended December 31, 2022 Generics Specialty AvKARE Corporate Total Net revenue (1) $ 1,432,073 $ 374,121 $ 406,110 $ — $ 2,212,304 Cost of goods sold 896,031 182,432 349,133 — 1,427,596 Gross profit 536,042 191,689 56,977 — 784,708 Selling, general and administrative 109,781 90,031 53,659 146,229 399,700 Research and development 167,509 28,179 — — 195,688 In-process research and development impairment charges 12,970 — — — 12,970 Intellectual property legal development expenses 4,251 107 — — 4,358 Acquisition, transaction-related and integration expenses 25 49 — 635 709 Restructuring and other charges 821 — — 600 1,421 Change in fair value of contingent consideration — 731 — — 731 Insurance recoveries for property losses and associated expenses, net (1,911) — — — (1,911) Charges related to legal matters, net 22,400 — — 247,530 269,930 Other operating income (3,960) — — — (3,960) Operating income (loss) $ 224,156 $ 72,592 $ 3,318 $ (394,994) $ (94,928) Year Ended December 31, 2021 Generics Specialty AvKARE Corporate Total Net revenue (1) $ 1,366,338 $ 378,319 $ 349,012 $ — $ 2,093,669 Cost of goods sold 848,260 193,562 282,874 — 1,324,696 Gross profit 518,078 184,757 66,138 — 768,973 Selling, general and administrative 64,500 84,481 57,918 158,605 365,504 Research and development 158,365 43,482 — — 201,847 In-process research and development impairment charges 710 — — — 710 Intellectual property legal development expenses 7,562 154 — — 7,716 Acquisition, transaction-related and integration expenses — 16 1,422 6,617 8,055 Restructuring and other charges 80 — — 1,777 1,857 Change in fair value of contingent consideration — 200 — — 200 Charges for property losses and associated expenses, net 5,368 — — — 5,368 Charges related to legal matters, net — — — 25,000 25,000 Operating income (loss) $ 281,493 $ 56,424 $ 6,798 $ (191,999) $ 152,716 (1) Net revenue from external customers is attributed to countries based on the location of the product shipment. For the years ended December 31, 2023, 2022, and 2021, net revenue from external customers attributed to foreign countries was immaterial.
Schedule of Long-Lived Assets, by Geographical Areas	Long-lived assets, which are comprised of property, plant and equipment, net and operating and financing lease right-of-use assets, are attributed based on physical location. Long-lived assets by country were as follows (in thousands): December 31, 2023 December 31, 2022 United States $ 316,947 $ 354,504 India 179,401 180,325 Ireland 53,789 54,531 $ 550,137 $ 589,360

(Insurance Recoveries) Charge_2

(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Unusual or Infrequent Items, or Both [Abstract]
Schedule of Property Losses and Associated Expenses	(Insurance recoveries) charges for property losses and associated expenses was comprised of the following (in thousands): Year Ended December 31, 2023 2022 2021 Impairment of equipment $ — $ — $ 4,202 Impairment of inventory — — 950 Repairs and maintenance expenses — — 3,716 Salaries and benefits — — 1,500 Total property losses and associated expenses $ — $ — $ 10,368 Less: Insurance recoveries received — (1,911) (5,000) (Insurance recoveries) charges for property losses and associated expenses, net $ — $ (1,911) $ 5,368

Nature of Operations (Details)

Nature of Operations (Details)	Dec. 31, 2023 $ / shares	Nov. 07, 2023 $ / shares	Nov. 06, 2023	Dec. 31, 2022 $ / shares
Class A Common Stock
Class of Stock [Line Items]
Common stock, par value (in dollars per share)	$ 0.01			$ 0.01
Class A Common Stock | Old PubCo
Class of Stock [Line Items]
Common stock, par value (in dollars per share)		$ 0.01
Class A Common Stock | New PubCo
Class of Stock [Line Items]
Common stock, par value (in dollars per share)		$ 0.01
Reorganization, common stock conversion ratio		1
Class B Common Stock
Class of Stock [Line Items]
Common stock, par value (in dollars per share)	$ 0.01			$ 0.01
Class B Common Stock | Old PubCo
Class of Stock [Line Items]
Common stock, par value (in dollars per share)		$ 0.01
Amneal Pharmaceuticals, LLC
Class of Stock [Line Items]
Ownership by parent (percent)		100%	50.40%
Amneal Pharmaceuticals, LLC | Amneal Group
Class of Stock [Line Items]
Ownership percentage by noncontrolling owners (percent)			49.60%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Product Information [Line Items]
Restricted cash	$ 7,565	$ 9,251	$ 8,949
Cost of goods sold	1,573,042	1,427,596	1,324,696
Cost of goods sold impairment charges		11,100	22,700
Selling, general and administrative
Product Information [Line Items]
Advertising costs	12,400	16,800	15,100
Shipping Costs
Product Information [Line Items]
Cost of goods sold	$ 21,700	$ 18,700	$ 18,100

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment Estimated Useful Lives (Details)	Dec. 31, 2023
Buildings
Property, Plant and Equipment [Line Items]
Estimated Useful Life	30 years
Computer equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Machinery and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Machinery and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated Useful Life	10 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - USD ($) $ in Thousands				1 Months Ended		2 Months Ended	9 Months Ended	11 Months Ended	12 Months Ended
	Feb. 09, 2022	Nov. 02, 2021	Apr. 02, 2021	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jan. 11, 2021	Jan. 31, 2020
Business Acquisition [Line Items]
Goodwill					$ 593,017	$ 593,017	$ 593,017	$ 598,853	$ 598,629	$ 598,853	$ 593,017
Net revenue									2,393,607	2,212,304	2,093,669
Operating loss									204,374	(94,928)	152,716
Acquisition, transaction-related and integration expenses										700	8,100
Contingent consideration (up to)								15,427	921	15,427
Specialty
Business Acquisition [Line Items]
Goodwill								366,300	366,300	366,300
Net revenue									$ 390,457	374,121	378,319
Saol Baclofen Franchise Acquisition | Generic
Business Acquisition [Line Items]
Goodwill	$ 5,200
Goodwill deductible for tax purposes	4,900
Saol Baclofen Franchise Acquisition | Specialty
Business Acquisition [Line Items]
Goodwill	2,400
Puniska Healthcare Pvt Ltd
Business Acquisition [Line Items]
Definitive acquisition agreement amount		$ 93,000
Consideration paid in cash on hand		$ 72,900		$ 1,700
Voting interest acquired (percent)		74%		26%					26%
Other payments to acquire businesses				$ 14,200
Acquired non-controlling interest, non-public subsidiary					$ 4,300
Acquisition, transaction-related and integration expenses											1,000
Loss of acquiree since date of acquisition						$ 1,800
Kashiv Specialty Pharmaceuticals, LLC
Business Acquisition [Line Items]
Consideration paid in cash on hand			$ 100,100
Voting interest acquired (percent)			98%									98%
Acquisition, transaction-related and integration expenses											$ 3,100
Loss of acquiree since date of acquisition							21,300
Total consideration, net of cash acquired			$ 104,500
Deferred consideration			30,500
Working capital costs			4,400
Contingent consideration (up to)			$ 8,000					3,300	$ 400	3,300
Amortization							$ 5,800
AvKARE and R&S Acquisitions
Business Acquisition [Line Items]
Voting interest acquired (percent)													65.10%
Saol Baclofen Franchise Acquisition
Business Acquisition [Line Items]
Cash	84,714
Asset acquisition, inventory acquired	$ 1,100
Asset acquisition, transaction cost										$ 100
Net revenue								19,800
Operating loss								$ 7,100

Acquisitions - Payments to Acqu

Acquisitions - Payments to Acquire Business (Details) - Saol Baclofen Franchise Acquisition $ in Thousands	Feb. 09, 2022 USD ($)
Business Acquisition [Line Items]
Cash	$ 84,714
Contingent consideration (royalties)	8,796
Fair value of consideration transferred	$ 93,510

Acquisitions - Purchase Price A

Acquisitions - Purchase Price Allocation for Acquisitions (Details) - Saol Baclofen Franchise Acquisition $ in Thousands	Feb. 09, 2022 USD ($)
Asset Acquisition [Line Items]
Inventory	$ 2,162
Prepaid expenses and other current assets	98
Goodwill	7,553
Intangible assets	83,815
Total assets acquired	93,628
Accounts payable and accrued expenses	118
Fair value of consideration transferred	$ 93,510

Acquisitions - Acquired Markete

Acquisitions - Acquired Marketed Product Rights Intangible Assets (Details) - Marketed product rights $ in Thousands	Feb. 09, 2022 USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 83,815
Weighted-Average Useful Life (in years)	11 years 6 months

Revenue Recognition - Concentra

Revenue Recognition - Concentration of Revenue (Details) - Revenue from Contract with Customer Benchmark - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Customer A
Concentration Risk [Line Items]
Concentration risk (percent)	24%	21%	21%
Customer B
Concentration Risk [Line Items]
Concentration risk (percent)	16%	18%	20%
Customer C
Concentration Risk [Line Items]
Concentration risk (percent)	21%	22%	24%
Customer D
Concentration Risk [Line Items]
Concentration risk (percent)	9%	10%	10%

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Disaggregated Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Net revenue	$ 2,393,607	$ 2,212,304	$ 2,093,669
Generics
Disaggregation of Revenue [Line Items]
Net revenue	1,471,401	1,432,073	1,366,338
Specialty
Disaggregation of Revenue [Line Items]
Net revenue	390,457	374,121	378,319
AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	531,749	406,110	349,012
International and other | Generics
Disaggregation of Revenue [Line Items]
Net revenue	2,165	1,468	1,299
Anti-infective | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	25,885	23,193	30,501
Hormonal / allergy | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	451,736	444,909	427,077
Hormonal / allergy | United States | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	110,486	91,465	68,397
Antiviral | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	39,910	40,601	4,832
Central nervous system | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	369,201	393,281	381,110
Central nervous system | United States | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	249,981	255,656	277,196
Cardiovascular system | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	139,942	118,183	141,866
Gastroenterology | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	67,519	70,796	76,497
Oncology | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	110,455	64,285	103,327
Metabolic disease / endocrine | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	45,900	41,128	38,462
Respiratory | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	42,710	41,085	35,965
Dermatology | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	70,872	66,553	55,474
Other therapeutic classes | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	105,106	118,573	69,928
Other therapeutic classes | United States | Specialty
Disaggregation of Revenue [Line Items]
Net revenue	29,990	27,000	32,726
License agreement | United States | Generics
Disaggregation of Revenue [Line Items]
Net revenue	0	8,018	0
Distribution | United States | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	347,406	260,560	192,921
Government label | United States | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	121,829	98,234	118,379
Institutional | United States | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	38,016	27,742	25,176
Other | United States | AvKARE
Disaggregation of Revenue [Line Items]
Net revenue	$ 24,498	$ 19,574	$ 12,536

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Major Categories of Sales-Related Deductions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Contract Charge- backs and Sales Volume Allowances
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	$ 573,592	$ 503,902	$ 628,804
Provision related to sales recorded in the period	3,384,360	3,416,149	3,164,331
Credits/payments issued during the period	(3,398,618)	(3,346,459)	(3,289,233)
Balance, end of period	559,334	573,592	503,902
Cash Discount Allowances
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	27,454	23,642	22,690
Provision related to sales recorded in the period	113,396	112,609	107,810
Credits/payments issued during the period	(116,958)	(108,797)	(106,858)
Balance, end of period	23,892	27,454	23,642
Accrued Returns Allowance
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	145,060	161,978	174,984
Provision related to sales recorded in the period	73,172	84,306	105,127
Credits/payments issued during the period	(81,746)	(101,224)	(118,133)
Balance, end of period	136,486	145,060	161,978
Accrued Medicaid and Commercial Rebates
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance, beginning of period	86,030	85,737	131,088
Provision related to sales recorded in the period	246,608	129,203	137,452
Credits/payments issued during the period	(241,948)	(128,910)	(182,803)
Balance, end of period	$ 90,690	$ 86,030	$ 85,737

Alliance and Collaboration - Or

Alliance and Collaboration - Orion Corporation License Agreement (Details) - License Agreement with Orion Corporation € in Millions, $ in Millions			12 Months Ended
	Dec. 28, 2022 EUR (€)	Dec. 28, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term	8 years	8 years
Collaborative arrangement renew for successive term	2 years	2 years
Collaborative arrangement upfront payment	€ 20	$ 21.4
Collaborative arrangement aggregate sales-based milestone payment	€ 45	$ 49.7
Collaborative arrangement, reimbursable research and development expense			$ 0.5
Collaborative arrangement license revenue agreement			0.9	$ 8
Collaborative arrangement remaining upfront amount				13.4
Prepaid Expenses and Other Current Assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement upfront payment receivable				21.4
Accounts Payable and Accrued Expenses
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred income			7.8	6.7
Other long-term liabilities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred income			$ 4.7	$ 6.7

Alliance and Collaboration - ON

Alliance and Collaboration - ONGENTYS® License Agreement (Details) - ONGENTYS® License Agreement - USD ($) $ in Millions	1 Months Ended
	Dec. 31, 2023	Dec. 05, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, medical and marketing activities		$ 6
Collaborative arrangement non-refundable license fee	$ 12.5
Collaborative arrangement non-refundable license fee, amortization period	8 years
License supply agreement, potential future milestone payments	$ 22.5

Alliance and Collaboration - Le

Alliance and Collaboration - Levothyroxine License and Supply Agreement; Transition Agreement (Details) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Aug. 16, 2018	Apr. 30, 2019	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of goods sold			$ 1,573,042	$ 1,427,596	$ 1,324,696
JSP License And Commercialization Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement term	10 years
Payment of up-front license contingent payment		$ 50,000
Accrued up-front license contingent payment		$ 50,000
JSP And Lannett Company Transition Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of goods sold					$ 17,700

Alliance and Collaboration - Bi

Alliance and Collaboration - Biosimilar Licensing and Supply Agreement (Details)			12 Months Ended
	Oct. 12, 2023 product	May 07, 2018 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reduction of R&D expense			$ (163,950,000)	$ (195,688,000)	$ (201,847,000)
Biosimilar Licensing and Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement maximum contingent payments amount		$ 78,300,000
Reduction of R&D expense			0	0	$ (11,700,000)
Collaborative arrangement, milestone payment			2,500,000	$ 26,500,000
Weighted- Average Amortization Period (in years)				7 years
Collaborative arrangement, number of products | product	2
Collaborative arrangement upfront payment			2,500,000
License supply agreement, potential future milestone payments			69,000,000
Biosimilar Licensing and Supply Agreement | Development Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments			6,500,000
Biosimilar Licensing and Supply Agreement | Regulatory Approval
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments			15,000,000
Biosimilar Licensing and Supply Agreement | Achievement Of Cumulative Net Sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License supply agreement, potential future milestone payments			$ 47,500,000

Alliance and Collaboration - Di

Alliance and Collaboration - Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited (Details) - USD ($)	12 Months Ended			54 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of goods sold	$ 1,573,042,000	$ 1,427,596,000	$ 1,324,696,000
Astra Zeneca
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement reduced royalty				$ 30,000,000	$ 30,000,000
Astra Zeneca | Royalty
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cost of goods sold	$ 900,000	$ 1,400,000	$ 12,500,000

Government Grants (Details)

Government Grants (Details) $ in Thousands, ₨ in Billions	1 Months Ended	12 Months Ended
	Nov. 30, 2021 INR (₨) company	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other operating income		$ 1,200	$ 4,000
Prepaid expenses and other current assets		82,685	103,565
Government of India
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of companies | company	55
Grants receivable	₨ 10	120,200
Government grant eligible term	6 years
Prepaid expenses and other current assets		$ 1,300	$ 4,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)		10 Months Ended	12 Months Ended
	Nov. 07, 2023	Nov. 06, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Valuation allowance			$ 566,544,000	$ 434,895,000	$ 416,588,000		$ 422,812,000
Percentage of tax receivable agreement paid to other holders of Amneal common units	75%	85%
Reversal of accrued tax receivable agreement liability						$ 192,800,000
Liabilities under tax receivable agreement			185,200,000
Tax receivable agreement liability			3,700,000	600,000
Tax receivable agreement expense			3,100,000	600,000
Income tax (benefit) provision			$ 8,452,000	$ 6,662,000	$ 11,196,000
Effective tax rate, percent			(21.00%)	(2.70%)	35.70%
Income tax examination, CARES Act carryback amount sustained			$ 345,000,000
Income tax returns subject to examination period			3 years
Provision for deferred income taxes			$ 0	$ 0	$ 0
Unrecognized tax benefits			3,735,000	3,616,000	5,489,000		$ 5,368,000
Unrecognized tax benefits that would impact the effective tax rate			3,600,000	3,500,000	5,400,000
Unrecognized tax benefits, net interest expense			0	(700,000)	100,000
Unrecognized tax benefits, accrued interest expense			100,000	$ 100,000	$ 800,000
Undistributed earnings of foreign subsidiaries			$ 130,800,000
Ministry of Finance, India
Operating Loss Carryforwards [Line Items]
Effective tax rate, percent			25.17%
Foreign
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards			$ 145,600,000
Foreign | Ministry of Finance, India
Operating Loss Carryforwards [Line Items]
Income tax returns subject to examination period			3 years
Foreign | Swiss Federal Tax Administration (FTA) , Switzerland
Operating Loss Carryforwards [Line Items]
Income tax returns subject to examination period			5 years
Foreign | Revenue Commissioners, Ireland
Operating Loss Carryforwards [Line Items]
Income tax returns subject to examination period			4 years
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards			$ 216,600,000
Federal | R&D Credit Carryforwards
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards			13,400,000
Federal | Capital Loss Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards			5,000,000
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards			174,900,000
State | R&D Credit Carryforwards
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards			$ 12,300,000

Income Taxes - Components of (L

Income Taxes - Components of (Loss) Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Total (loss) income before income taxes	$ (40,270)	$ (248,127)	$ 31,366
United States
Operating Loss Carryforwards [Line Items]
Total (loss) income before income taxes	(59,781)	(260,616)	(10,540)
International
Operating Loss Carryforwards [Line Items]
Total (loss) income before income taxes	$ 19,511	$ 12,489	$ 41,906

Income Taxes - Provision for (B

Income Taxes - Provision for (Benefit From) Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current:
Domestic	$ 2,470	$ (1,073)	$ 1,311
Foreign	5,982	7,735	9,885
Total current income tax	$ 8,452	$ 6,662	$ 11,196

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal income tax at the statutory rate	21%	21%	21%
State income tax, net of federal benefit	(5.50%)	(0.80%)	4.20%
Income not subject to tax	14.50%	(10.70%)	6.40%
Foreign rate differential	(19.50%)	(3.40%)	17.30%
Permanent book/tax differences	(2.10%)	(0.30%)	4.80%
Change in prior year estimates	7.70%	0.70%	(0.30%)
Deferred tax adjustment	(5.70%)	0%	0.10%
Valuation allowance	(32.30%)	(10.30%)	(13.50%)
Other	0.90%	1.10%	(4.30%)
Effective income tax rate	(21.00%)	(2.70%)	35.70%

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets, Changes in Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Assets, Valuation Allowance [Roll Forward]
Balance at the beginning of the period	$ 434,895	$ 416,588	$ 422,812
Increase (decrease) due to net operating losses and temporary differences	23,078	25,589	(10,828)
Increase due to stock-based compensation	1,652	224	5,513
Decrease recorded against goodwill	0	(1,590)	0
Increase recorded against additional paid-in capital	96,316	2,720	2,842
Increase (decrease) recorded against other comprehensive income	10,603	(8,636)	(3,751)
Balance at the end of the period	$ 566,544	$ 434,895	$ 416,588

Income Taxes - Deferred Tax A_2

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Partnership interest in Amneal	$ 318,140	$ 203,336
Projected imputed interest on TRA	22,730	25,255
Net operating loss carryforward	74,340	82,338
IRC Section 163(j) interest carryforward	72,513	54,996
Capitalized costs	2,537	2,505
Accrued expenses	648	431
Stock-based compensation	14,672	5,737
Intangible assets	21,901	23,967
Tax credits and other	39,063	36,330
Total deferred tax assets	566,544	434,895
Valuation allowance	(566,544)	(434,895)	$ (416,588)	$ (422,812)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits at the beginning of the period	$ 3,616	$ 5,489	$ 5,368
Gross change for current period positions	170	110	131
Gross change for prior period positions	(51)	(1,983)	(10)
Unrecognized tax benefits at the end of the period	$ 3,735	$ 3,616	$ 5,489

(Loss) Earnings per Share - Com

(Loss) Earnings per Share - Computation of Basic and Diluted (Loss) Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net (loss) income attributable to Amneal Pharmaceuticals, Inc.	$ (83,993)	$ (129,986)	$ 10,624
Denominator:
Weighted-average shares outstanding - basic (in shares)	176,136	150,944	148,922
Effect of dilutive securities:
Weighted-average shares outstanding - diluted (in shares)	176,136	150,944	151,821
Net loss (income) per share attributable to Amneal Pharmaceuticals, Inc.'s Class A common stockholders:
Basic (in dollars per share)	$ (0.48)	$ (0.86)	$ 0.07
Diluted (in dollars per share)	$ (0.48)	$ (0.86)	$ 0.07
Stock options
Effect of dilutive securities:
Effect of dilutive securities (in shares)	0	0	767
Restricted Stock Units
Effect of dilutive securities:
Effect of dilutive securities (in shares)	0	0	2,132

(Loss) Earnings per Share - Sec

(Loss) Earnings per Share - Securities Excluded from Diluted (Loss) Earnings per Share Computation (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Common Class B | Old PubCo
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	0	152,117	152,117
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	2,416	2,648	347
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	10,511	10,755	0
Performance stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from earnings per share (in shares)	6,944	7,174	5,055

Trade Accounts Receivable, Ne_2

Trade Accounts Receivable, Net - Schedule of Trade Accounts Receivable, Net (Details) - Nonrelated Party - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Gross accounts receivable	$ 1,199,980	$ 1,344,959
Allowance for credit losses	(3,022)	(2,122)
Contract charge-backs and sales volume allowances	(559,334)	(573,592)
Cash discount allowances	(23,892)	(27,454)
Subtotal	(586,248)	(603,168)
Trade accounts receivable, net	$ 613,732	$ 741,791

Trade Accounts Receivable, Ne_3

Trade Accounts Receivable, Net - Concentration of Receivables (Details) - Customer Concentration Risk - Accounts Receivable	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Customer A
Concentration Risk [Line Items]
Concentration risk (percent)	40%	41%
Customer B
Concentration Risk [Line Items]
Concentration risk (percent)	24%	25%
Customer C
Concentration Risk [Line Items]
Concentration risk (percent)	22%	21%

Inventories - Components of Inv

Inventories - Components of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 217,744	$ 224,607
Work in process	59,563	58,522
Finished goods	304,077	247,606
Total inventories	$ 581,384	$ 530,735

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Gain Contingencies [Line Items]
Deposits and advances	$ 2,200	$ 1,821
Prepaid insurance	8,334	8,090
Prepaid regulatory fees	6,331	5,298
Income and other tax receivables	13,168	12,881
Prepaid taxes	11,899	16,593
Other current receivables	9,929	33,133
Chargebacks receivable	7,876	8,605
Other prepaid assets	22,948	17,144
Total prepaid expenses and other current assets	$ 82,685	103,565
Prepaid Expenses and Other Current Assets | License Agreement with Orion Corporation
Gain Contingencies [Line Items]
Collaborative arrangement upfront payment receivable		$ 21,400

Property, Plant, and Equipmen_3

Property, Plant, and Equipment, Net - Summary of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	$ 955,601	$ 915,786
Less: Accumulated depreciation	(508,027)	(445,971)
Property, plant, and equipment, net	447,574	469,815
Land
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	9,024	10,706
Buildings
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	227,837	225,630
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	126,461	124,668
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	443,532	411,572
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	14,757	13,823
Vehicles
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	2,098	1,699
Computer equipment
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	64,227	58,344
Construction-in-progress
Property, Plant and Equipment [Line Items]
Total property, plant, and equipment	$ 67,665	$ 69,344

Property, Plant, and Equipmen_4

Property, Plant, and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 66.2	$ 68.1	$ 60.7

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Roll Forward]
Balance, beginning of period	$ 598,853	$ 593,017
Goodwill acquired during the period	0	7,553
Adjustment during the period for the Puniska Acquisition	0	3,075
Currency translation	(224)	(4,792)
Balance, end of period	$ 598,629	$ 598,853

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Additional Information (Details)	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 31, 2023 USD ($) asset	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($) product	Dec. 31, 2021 USD ($) product	Oct. 01, 2023
Goodwill [Line Items]
Goodwill	$ 598,629,000		$ 598,629,000	$ 598,853,000	$ 593,017,000
Goodwill impairment			$ 0
Goodwill impairment test, increase of assumed discount rates			5%
Intangible asset impairment charges			$ 66,932,000	$ 24,081,000	$ 23,402,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]			In-process research and development impairment charges, Cost of goods sold	In-process research and development impairment charges, Cost of goods sold	In-process research and development impairment charges, Cost of goods sold
Amortization			$ 163,200,000	$ 172,100,000	$ 172,700,000
Cost Of Goods Sold
Goodwill [Line Items]
Intangible asset impairment charges			36,100,000	11,100,000	22,700,000
In-Process Research And Development Impairment Charges
Goodwill [Line Items]
Intangible asset impairment charges			$ 30,800,000	$ 13,000,000	700,000
Levothyroxine
Goodwill [Line Items]
Intangible asset impairment charges					$ 17,700,000
Marketed Products
Goodwill [Line Items]
Intangible assets impairment, number of products experiencing price erosion | product				1	5
Number of products contract terminated | product				1	2
Number of products not expected to be sold | product				1
In-Process Research and Development
Goodwill [Line Items]
Intangible assets impairment, number of products experiencing price erosion | product				1
Number of products experienced delay in expected launch date | product				1	1
Discount rate
Goodwill [Line Items]
Goodwill inputs, percentage			13%
Minimum | Long-term Revenue Growth Rate
Goodwill [Line Items]
Goodwill inputs, percentage			0%
Maximum | Long-term Revenue Growth Rate
Goodwill [Line Items]
Goodwill inputs, percentage			1%
Specialty
Goodwill [Line Items]
Goodwill impairment		$ 0
Percentage of fair value in excess of carrying amount						88%
Generics
Goodwill [Line Items]
Percentage of fair value in excess of carrying amount						46%
Specialty
Goodwill [Line Items]
Goodwill	$ 366,300,000		$ 366,300,000	$ 366,300,000
Specialty | In-Process Research and Development
Goodwill [Line Items]
Number of assets experienced adverse clinical trials | asset	1
Generics
Goodwill [Line Items]
Goodwill	$ 162,800,000		162,800,000	163,100,000
Generics | In-Process Research and Development
Goodwill [Line Items]
Number of assets experienced adverse clinical trials | asset	1
AvKARE
Goodwill [Line Items]
Goodwill	$ 69,500,000		$ 69,500,000	$ 69,500,000

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Cost	$ 1,310,771	$ 1,356,562
Accumulated Amortization	(776,193)	(651,224)
Net	534,578	705,338
In-process research and development	355,845	390,755
Intangible assets, cost	1,666,616	1,747,317
Intangible assets, net	$ 890,423	1,096,093
Product rights
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Amortization Period (in years)	6 years 3 months 18 days
Cost	$ 1,198,971	1,222,762
Accumulated Amortization	(703,297)	(573,281)
Net	$ 495,674	649,481
Other intangible assets
Finite-Lived Intangible Assets [Line Items]
Weighted- Average Amortization Period (in years)	3 years 3 months 18 days
Cost	$ 111,800	133,800
Accumulated Amortization	(72,896)	(77,943)
Net	$ 38,904	$ 55,857

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
In-process research and development	$ 355,845	$ 390,755
Future Amortization
2024	159,059
2025	119,404
2026	70,708
2027	50,380
2028	31,656
Thereafter	103,371
Net	$ 534,578	$ 705,338

Other Assets - Schedule of Othe

Other Assets - Schedule of Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Other Assets [Line Items]
Other assets	$ 55,517	$ 103,217
Interest rate swap
Other Assets [Line Items]
Other assets	37,089	85,586
Security deposits
Other Assets [Line Items]
Other assets	3,602	3,523
Long-term prepaid expenses
Other Assets [Line Items]
Other assets	3,273	3,711
Deferred revolving credit facility costs
Other Assets [Line Items]
Other assets	4,427	2,206
Other long-term assets
Other Assets [Line Items]
Other assets	$ 7,126	$ 8,191

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Details) - Nonrelated Party - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Accounts payable	$ 143,572	$ 165,980
Accrued returns allowance	136,486	145,060
Accrued compensation	71,122	54,038
Accrued Medicaid and commercial rebates	90,690	86,030
Accrued royalties	23,342	19,309
Commercial chargebacks and rebates	10,226	10,226
Accrued professional fees	11,005	11,386
Accrued other	48,219	46,170
Total accounts payable and accrued expenses	$ 534,662	$ 538,199

Debt - Summary of Long-term Deb

Debt - Summary of Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Long-term debt	$ 2,543,626	$ 2,635,876
Less: debt issuance costs	(123,497)	(13,934)
Total debt, net of debt issuance costs	2,420,129	2,621,942
Less: current portion of long-term debt	(34,125)	(29,961)
Total long-term debt, net	2,386,004	2,591,981
Term Loan Due 2025
Debt Instrument [Line Items]
Long-term debt	191,979	2,563,876
Term Loan Due 2028
Debt Instrument [Line Items]
Long-term debt	2,351,647	0
Rondo Term Loan due 2025
Debt Instrument [Line Items]
Long-term debt	$ 0	$ 72,000

Debt - Overview of Amneal Credi

Debt - Overview of Amneal Credit Facilities (Details) - USD ($)		2 Months Ended
	May 04, 2018	Dec. 31, 2023	Nov. 14, 2023	Nov. 13, 2023	Dec. 31, 2022	Jun. 02, 2022	Oct. 31, 2019
Debt Instrument [Line Items]
Long-term debt		$ 2,543,626,000			$ 2,635,876,000
Senior Secured Credit Facility, Term Loan Due May 2025 | Senior Secured Credit Facility
Debt Instrument [Line Items]
Principal amount of debt	$ 2,700,000,000
Senior Secured Credit Facility, Asset Backed Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	500,000,000
Senior Secured Credit Facility, Asset Backed Revolving Credit Facility | Line of Credit | Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 25,000,000
Remaining borrowing capacity	25,000,000
Senior Secured Credit Facility, Asset Backed Revolving Credit Facility | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity						350,000,000
Line of credit facility, increase limit						150,000,000
Senior Secured Credit Facility, Asset Backed Revolving Credit Facility | Line of Credit | Bridge Loan
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 35,000,000
Term Loan Due 2028
Debt Instrument [Line Items]
Long-term debt		2,351,647,000			0
Term Loan Due 2028 | Senior Secured Credit Facility
Debt Instrument [Line Items]
Principal amount of debt			$ 2,350,000,000
Repayments of debt		0
Term Loan Due 2025
Debt Instrument [Line Items]
Long-term debt		191,979,000			$ 2,563,876,000
Term Loan Due 2025 | Interest Rate Lock Commitments
Debt Instrument [Line Items]
Notional amount							$ 1,300,000,000
Term Loan Due 2025 | Senior Secured Credit Facility
Debt Instrument [Line Items]
Long-term debt			192,000,000	$ 2,540,000,000
Repayments of debt	$ 192,000,000	0
Amended New Revolving Credit Agreement | Line of Credit | Letter of Credit
Debt Instrument [Line Items]
Remaining borrowing capacity		20,900,000
Amended New Revolving Credit Agreement | Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 600,000,000
Remaining borrowing capacity		$ 225,200,000

Debt - Amneal Term Loans - Term

Debt - Amneal Term Loans - Term Loan Due 2025 (Details) - Senior Secured Credit Facility - USD ($)				2 Months Ended	12 Months Ended
	Nov. 14, 2023	May 31, 2023	May 04, 2018	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018
Term Loan Due 2025
Debt Instrument [Line Items]
Quarterly installment rate			1%
Repayments of debt			$ 192,000,000	$ 0
Effective interest rate				9%	9%
Debt issuance costs, gross								$ 38,100,000
Unamortized debt issuance costs	$ 7,300,000							600,000
Amortization of debt issuance costs					$ 4,700,000	$ 5,400,000	$ 5,500,000
Term Loan Due 2025 | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate		3.50%
Term Loan Due 2025 | SOFR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		0.11448%
Term Loan Due 2025 | SOFR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		3.50%
Term Loan Due 2028
Debt Instrument [Line Items]
Quarterly installment rate	2.50%
Repayments of debt				$ 0
Effective interest rate				10.90%	10.90%
Unamortized debt issuance costs	$ 118,600,000							$ 7,300,000
Amortization of debt issuance costs					$ 2,900,000
Term Loan Due 2028 | SOFR
Debt Instrument [Line Items]
Basis spread on variable rate	5.50%

Debt - Amneal Term Loans - Refi

Debt - Amneal Term Loans - Refinancing and Term Loan Due 2028 (Details) - USD ($) $ in Thousands		12 Months Ended
	Nov. 14, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018
Debt Instrument [Line Items]
Loss on refinancing		$ 40,805	$ 291	$ 0
Term Loan Due 2028
Debt Instrument [Line Items]
Voting interest acquired (percent)	0.65
Term Loan Due 2028 | Senior Secured Credit Facility
Debt Instrument [Line Items]
Quarterly installment rate	2.50%
Effective interest rate		10.90%
Debt, percentage of lenders included in refinancing considered modified	99%
Unamortized debt issuance costs	$ 118,600				$ 7,300
Loss on refinancing		$ 40,800
Amortization of debt issuance costs		$ 2,900
Term Loan Due 2028 | Senior Secured Credit Facility | SOFR
Debt Instrument [Line Items]
Debt instrument, interest rate floor (percent)	0%
Basis spread on variable rate	5.50%
Term Loan Due 2028 | Senior Secured Credit Facility | ABR
Debt Instrument [Line Items]
Debt instrument, interest rate floor (percent)	1%
Basis spread on variable rate	4.50%

Debt - New Credit Agreement, Ne

Debt - New Credit Agreement, New Revolving Credit Facility and Amended New Credit Facility (Details) - USD ($)			1 Months Ended	10 Months Ended	12 Months Ended			24 Months Ended
	Nov. 14, 2023	Jun. 02, 2022	Jan. 31, 2023	Nov. 13, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2023	May 04, 2018
Debt Instrument [Line Items]
Borrowings on revolving credit facility					$ 219,000,000	$ 85,000,000	$ 0
Opana ER® antitrust litigation
Debt Instrument [Line Items]
Amount Due			$ 83,900,000					$ 215,000,000
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Commitment fee percentage on unused capacity		0.25%
Debt issuance costs, gross		$ 1,600,000							$ 4,600,000
Write off of deferred debt issuance cost						300,000
Change in fair value of contingent consideration					500,000	700,000	$ 900,000
Borrowings on revolving credit facility			$ 80,000,000
Repayments of lines of credit				$ 70,000,000
Outstanding borrowings on credit facility						$ 60,000,000
Revolving Credit Facility | Line of Credit | Amended New Revolving Credit Agreement
Debt Instrument [Line Items]
Debt issuance costs, gross	$ 2,400,000
Borrowings on revolving credit facility	$ 109,000,000
Outstanding borrowings on credit facility					179,000,000			179,000,000
Remaining borrowing capacity					225,200,000			225,200,000
Revolving Credit Facility | Line of Credit | ABR
Debt Instrument [Line Items]
Debt instrument, interest rate floor (percent)		1%
Basis spread on variable rate		0.25%
Revolving Credit Facility | Line of Credit | ABR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		0.25%
Revolving Credit Facility | Line of Credit | ABR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		0.50%
Revolving Credit Facility | Line of Credit | SOFR
Debt Instrument [Line Items]
Debt instrument, interest rate floor (percent)		0%
Basis spread on variable rate		1.25%
Revolving Credit Facility | Line of Credit | SOFR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate		1.25%
Revolving Credit Facility | Line of Credit | SOFR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate		1.50%
Letter of Credit | Line of Credit | Amended New Revolving Credit Agreement
Debt Instrument [Line Items]
Remaining borrowing capacity					$ 20,900,000			$ 20,900,000

Debt - Rondo Acquisitions Finan

Debt - Rondo Acquisitions Financing - Revolving Credit and Term Loan Agreement (Details) - USD ($)					12 Months Ended
	Dec. 31, 2023	Sep. 21, 2023	Apr. 30, 2023	Jan. 31, 2020	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 26, 2023
Debt Instrument [Line Items]
Borrowings on revolving credit facility					$ 219,000,000	$ 85,000,000	$ 0
Long-term debt	$ 2,543,626,000				2,543,626,000	2,635,876,000
Rondo Term Loan
Debt Instrument [Line Items]
Principal amount of debt				$ 180,000,000
Quarterly installment rate				5%
Prepayment of outstanding principal					63,000,000
Debt issuance costs, gross				$ 3,500,000
Long-term debt	$ 0				$ 0	$ 72,000,000
Rondo Revolving Credit Facility | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate				3%
Rondo Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 30,000,000		$ 30,000,000
Rondo Revolving Credit Facility | Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity		10,000,000
Amended Rondo Revolving Credit Facility
Debt Instrument [Line Items]
Basis spread on variable rate	2.50%
Commitment fee, as a percent				0.25%
Commitment fee percentage on unused capacity					0.25%
Debt issuance costs, gross		$ 600,000
Borrowings on revolving credit facility					$ 30,000,000
Repayments of lines of credit					30,000,000
Amended Rondo Revolving Credit Facility | SOFR
Debt Instrument [Line Items]
Basis spread on variable rate		2.25%	2.25%
Debt instrument, interest rate floor (percent)		0.10%	0.10%
Amended Rondo Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 70,000,000
Amended Rondo Revolving Credit Facility | Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 60,000,000
Long-term debt	$ 0				0
Outstanding letters of credit amount	42,000,000				42,000,000
Amended Rondo Revolving Credit Facility | Standby Letters of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity								$ 42,000,000
Remaining borrowing capacity	$ 28,000,000				$ 28,000,000
Amended Rondo Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Commitment fee percentage on unused capacity					0.25%
Amended Rondo Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Commitment fee percentage on unused capacity					0.50%
Rondo Term Loan And Amended Rondo Revolving Credit Facility
Debt Instrument [Line Items]
Amortization of debt issuance costs					$ 1,600,000

Debt - Rondo Acquisitions Fin_2

Debt - Rondo Acquisitions Financing – Notes Payable-Related Party (Details) - Rondo Partners LLC - USD ($) $ in Millions		12 Months Ended
	Jan. 31, 2020	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Feb. 28, 2021
Long Term Promissory Notes
Debt Instrument [Line Items]
Liabilities incurred	$ 44.2
Interest rate	5%
Liabilities incurred, fair value	$ 35
Unamortized discount	9.2
Amortization of debt issuance costs		$ 1.7	$ 1.7	$ 1.6
Short Term Promissory Notes
Debt Instrument [Line Items]
Liabilities incurred	1
Interest rate					1.60%
Liabilities incurred, fair value	$ 1

Other Long-Term Liabilities - S

Other Long-Term Liabilities - Schedule of Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Deferred compensation plan liabilities	$ 11,100	$ 7,600
Long-term employee benefit	10,200	9,100
Nonrelated Party
Related Party Transaction [Line Items]
Uncertain tax positions	497	563
Long-term portion of liabilities for legal matters	316	49,442
Long-term compensation	21,283	16,737
Contingent consideration	433	11,997
Other long-term liabilities	7,466	8,729
Total other long-term liabilities	$ 29,995	$ 87,468

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Operating and finance lease, rent expense	$ 21.7	$ 22.6	$ 19.8
Minimum
Lessee, Lease, Description [Line Items]
Operating and finance lease term	1 year
Minimum | International Land Easements
Lessee, Lease, Description [Line Items]
Operating and finance lease term	27 years
Maximum
Lessee, Lease, Description [Line Items]
Operating and finance lease term	21 years
Maximum | International Land Easements
Lessee, Lease, Description [Line Items]
Operating and finance lease term	96 years

Leases - Components of Total Le

Leases - Components of Total Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease cost	$ 16,734	$ 17,800	$ 15,057
Finance lease cost:
Amortization of right-of-use assets	4,972	4,808	4,713
Interest on lease liabilities	4,583	4,508	4,601
Total finance lease cost	9,555	9,316	9,314
Total lease cost	$ 26,289	$ 27,116	$ 24,371

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating leases
Operating lease right-of-use assets	$ 43,283	$ 56,121
Total operating lease liabilities	48,914	59,230
Financing leases
Total financing lease liabilities	61,033	64,257
Nonrelated Party
Operating leases
Operating lease right-of-use assets	30,329	38,211
Operating lease liabilities	24,095	32,126
Current portion of operating lease liabilities	9,207	8,321
Financing leases
Financing lease right of use assets	59,280	63,424
Financing lease liabilities	58,566	60,769
Current portion of financing lease liabilities	2,467	3,488
Related Party
Operating leases
Operating lease right-of-use assets	12,954	17,910
Operating lease liabilities	12,787	15,914
Current portion of operating lease liabilities	2,825	2,869
Excluding Related Party
Financing leases
Financing lease right of use assets	59,280	63,424
Financing lease liabilities	58,566	60,769
Current portion of financing lease liabilities	2,467	3,488
Affiliated Entity
Operating leases
Current portion of operating lease liabilities	$ 2,825	$ 2,869

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from finance leases	$ 4,583	$ 4,539
Operating cash flows from operating leases	16,036	16,217
Financing cash flows from finance leases	3,588	3,484
Non-cash activity:
Right-of-use assets obtained in exchange for new operating lease liabilities	773	7,504
Right-of-use assets obtained in exchange for new financing lease liabilities	$ 856	$ 4,606

Leases - Term and Discount Rate

Leases - Term and Discount Rate Information (Details)	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Weighted average remaining lease term - operating leases	5 years	5 years
Weighted average remaining lease term - finance leases	18 years	19 years
Weighted average discount rate - operating leases	8.90%	8.50%
Weighted average discount rate - finance leases	7.30%	7.20%

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Operating Leases
Year one	$ 15,978	$ 15,843
Year two	14,544	16,558
Year three	10,693	14,264
Year four	7,742	10,393
Year five	5,467	7,420
Thereafter	6,916	11,550
Total lease payments	61,340	76,028
Less: Imputed interest	(12,426)	(16,798)
Total	48,914	59,230
Financing Leases
Year one	6,856	7,976
Year two	6,874	6,913
Year three	6,140	6,466
Year four	5,647	5,989
Year five	5,647	5,645
Thereafter	79,573	85,220
Total lease payments	110,737	118,209
Less: Imputed interest	(49,704)	(53,952)
Total	$ 61,033	$ 64,257

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Apr. 02, 2021
Assets
Interest rate swap	$ 37,089	$ 85,586
Liabilities
Deferred compensation plan liabilities	9,100	9,674
Contingent consideration liability	921	15,427
Kashiv Specialty Pharmaceuticals, LLC
Liabilities
Contingent consideration liability	400	3,300	$ 8,000
Accounts Payable And Accrued Expenses | Saol Baclofen Franchise Acquisition
Liabilities
Contingent consideration liability	100	100
Other long-term liabilities | Saol Baclofen Franchise Acquisition
Liabilities
Contingent consideration liability	400	12,000
Quoted Prices in Active Markets (Level 1)
Assets
Interest rate swap	0	0
Liabilities
Deferred compensation plan liabilities	0	0
Contingent consideration liability	0	0
Significant Other Observable Inputs (Level 2)
Assets
Interest rate swap	37,089	85,586
Liabilities
Deferred compensation plan liabilities	9,100	9,674
Contingent consideration liability	0	0
Significant Unobservable Inputs (Level 3)
Assets
Interest rate swap	0	0
Liabilities
Deferred compensation plan liabilities	0	0
Contingent consideration liability	$ 921	$ 15,427

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Apr. 02, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt	$ 2,420,129	$ 2,621,942
Significant Other Observable Inputs (Level 2) | Rondo Term Loan due 2025
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt fair value		70,900
Senior Secured Credit Facility | Significant Other Observable Inputs (Level 2) | Senior Secured Credit Facility, Term Loan Due May 2025
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt fair value	190,800	2,300,000
Senior Secured Credit Facility | Significant Other Observable Inputs (Level 2) | Term Loan Due 2028
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt fair value	2,300,000
Promissory Notes | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt	$ 41,000	$ 39,100
Kashiv Specialty Pharmaceuticals, LLC
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, maximum liability			$ 8,000

Fair Value Measurements - Recon

Fair Value Measurements - Reconciliation of Contingent Consideration Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Net change in fair value during period	$ 14,497	$ (731)	$ (200)
Kashiv Specialty Pharmaceuticals, LLC
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	15,427	5,900
Net change in fair value during period	(14,491)	731
Payments	(15)	0
Balance, end of period	921	15,427	$ 5,900
Saol Baclofen Franchise Acquisition
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Addition due to the Saol Acquisition	$ 0	$ 8,796

Fair Value Measurements - Signi

Fair Value Measurements - Significant Inputs Used in Fair Value Measurements (Details) $ in Thousands	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Apr. 02, 2021 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 921	$ 15,427
Kashiv Specialty Pharmaceuticals, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value	$ 400	3,300	$ 8,000
Regulatory Milestones (KSP Acquisition)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value		$ 390
Regulatory Milestones (KSP Acquisition) | Minimum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.072
Regulatory Milestones (KSP Acquisition) | Minimum | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.018
Regulatory Milestones (KSP Acquisition) | Maximum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.085
Regulatory Milestones (KSP Acquisition) | Maximum | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.200
Regulatory Milestones (KSP Acquisition) | Weighted Average | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.073
Regulatory Milestones (KSP Acquisition) | Weighted Average | Probability of payment
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.186
Royalties | Kashiv Specialty Pharmaceuticals, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value		$ 2,900
Royalties | Saol Baclofen Franchise Acquisition
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value		$ 12,137
Royalties | Minimum | Discount rate | Kashiv Specialty Pharmaceuticals, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.125
Royalties | Minimum | Discount rate | Saol Baclofen Franchise Acquisition
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.178
Royalties | Minimum | Probability of payment | Kashiv Specialty Pharmaceuticals, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.018
Royalties | Maximum | Discount rate | Kashiv Specialty Pharmaceuticals, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.125
Royalties | Maximum | Discount rate | Saol Baclofen Franchise Acquisition
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.178
Royalties | Maximum | Probability of payment | Kashiv Specialty Pharmaceuticals, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.200
Royalties | Weighted Average | Discount rate | Kashiv Specialty Pharmaceuticals, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.125
Royalties | Weighted Average | Discount rate | Saol Baclofen Franchise Acquisition
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.178
Royalties | Weighted Average | Probability of payment | Kashiv Specialty Pharmaceuticals, LLC
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.186

Financial Instruments - Additio

Financial Instruments - Additional Information (Details) - USD ($)		12 Months Ended
	Nov. 14, 2023	Dec. 31, 2023	Dec. 31, 2022	Oct. 31, 2019
Derivative [Line Items]
Fair Value		$ 37,089,000	$ 85,586,000
Derivative gain reclassified from accumulated OCI into income (loss)		3,400,000
Cash flow hedge gain (loss) to be reclassified within 12 months		26,200,000
Total gain, net of income taxes, recognized in accumulated other comprehensive (loss) income		$ 33,700,000	85,600,000
Accumulated Other Comprehensive Income (Loss)
Derivative [Line Items]
Total gain, net of income taxes, recognized in accumulated other comprehensive (loss) income			42,300,000
Non- Controlling Interests
Derivative [Line Items]
Total gain, net of income taxes, recognized in accumulated other comprehensive (loss) income			$ 43,300,000
Interest Rate Lock Agreement
Derivative [Line Items]
Notional amount				$ 1,300,000,000
November 2023 Swap
Derivative [Line Items]
Notional amount	$ 1,300,000,000
Derivative, fixed interest rate	2.7877%
Fair Value	$ 66,700,000
Amended October 2019 Swap
Derivative [Line Items]
Derivative, fixed interest rate	1.366%
Unrealized gain recorded within accumulated other comprehensive income (loss)	$ 66,700,000

Financial Instruments - Summary

Financial Instruments - Summary of Fair Values of Derivative Instruments in Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Fair Value	$ 37,089	$ 85,586
Derivatives Designated as Hedging Instruments | Variable-to-fixed interest rate swap | Other Assets
Derivative [Line Items]
Fair Value	$ 37,089	$ 85,586

Commitments and Contingencies -

Commitments and Contingencies - Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Charges related to legal matters, net	$ (1,824)	$ (269,930)	$ (25,000)
Insurance recoveries		1,911	$ 5,000
Long-term portion of liabilities for legal matters (included in other long-term liabilities)	316	49,442
Litigation settlement, initial discount, amount	$ 2,200
January 2023
Loss Contingencies [Line Items]
Litigation settlement, interest rate	3%
January 2024
Loss Contingencies [Line Items]
Litigation settlement, interest rate	3%
Additional interest rate	2.70%
Long-term portion of liabilities for legal matters (included in other long-term liabilities)	$ 50,000
Civil prescription opioid litigation
Loss Contingencies [Line Items]
Charges related to legal matters, net	(3,900)	(18,000)
Customer Claim
Loss Contingencies [Line Items]
Charges related to legal matters, net	(3,000)
Antitrust Litigation
Loss Contingencies [Line Items]
Charges related to legal matters, net	(3,000)
Stockholder Derivative Lawsuit
Loss Contingencies [Line Items]
Charges related to legal matters, net	(1,900)
Patent Infringement Matters
Loss Contingencies [Line Items]
Charges related to legal matters, net	(10,000)
Opana ER® antitrust litigation
Loss Contingencies [Line Items]
Charges related to legal matters, net		$ (262,800)
Insurance recoveries	$ 15,500
Litigation settlement, interest rate	3%

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Liabilities For Legal Matters (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters	$ 76,988	$ 107,483
Long-term portion of liabilities for legal matters (included in other long-term liabilities)	316	49,442
Opana ER® antitrust litigation
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters, excluding interest	50,000	83,944
Current portion of liabilities for legal matters, interest	2,347	1,423
Long-term portion of liabilities for legal matters, excluding interest	0	50,000
Long-term portion of liabilities for legal matters, imputed interest	0	(1,405)
Long-term portion of liabilities for legal matters, accrued interest	0	847
Civil prescription opioid litigation
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters, excluding interest	21,189	17,993
Long-term portion of liabilities for legal matters, excluding interest	316	0
Other
Loss Contingencies [Line Items]
Current portion of liabilities for legal matters, excluding interest	$ 3,452	$ 4,123

Commitments and Contingencies_3

Commitments and Contingencies - Other Litigation Related to the Company’s Business (Details) $ in Thousands

1 Months Ended

12 Months Ended

24 Months Ended

Feb. 28, 2024

Feb. 22, 2024

Dec. 18, 2023 USD ($)

Sep. 05, 2023

May 31, 2023 case

Feb. 28, 2023 USD ($)

Mar. 22, 2022 lawsuit

Jun. 10, 2020 state action

Mar. 13, 2015 medication

Nov. 06, 2014 representative

Jan. 31, 2023 USD ($)

Dec. 31, 2023 USD ($) state case lawsuit

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Jan. 15, 2024 USD ($)

Dec. 31, 2023 USD ($) case state

Apr. 10, 2023 plaintiff

Nov. 01, 2019 state

May 10, 2019 state

Loss Contingencies [Line Items]

Charges related to legal matters, net

$ (1,824)

$ (269,930)

$ (25,000)

Opana ER® antitrust litigation

Loss Contingencies [Line Items]

Amount Due

$ 83,900

$ 215,000

Loss contingency accrual

$ 50,000

$ 50,000

Litigation settlement, interest rate

3%

3%

Charges related to legal matters, net

(262,800)

Opana ER® antitrust litigation | Forecast

Loss Contingencies [Line Items]

Litigation settlement amount

$ 265,000

United States Department of Justice Investigations

Loss Contingencies [Line Items]

Number of sales representatives | representative

1

Number of generic prescription medications | medication

4

Generic Digoxin and Doxycycline Antitrust Litigation

Loss Contingencies [Line Items]

Number of states, filed civil lawsuit | state

46

43

Loss contingency civil lawsuit filed number of additional states | state

9

Number of actions | action

2

Civil prescription opioid litigation

Loss Contingencies [Line Items]

Number of cases | case

900

900

Number of states with cases | state

7

7

Number of claims dismissed | case

2

Charges related to legal matters, net

$ (3,900)

(18,000)

Ranitidine Litigation

Loss Contingencies [Line Items]

Number of states with cases | state

5

5

Metformin Litigation

Loss Contingencies [Line Items]

Number of settlement demands | lawsuit

2

Metformin Litigation | Subsequent Event

Loss Contingencies [Line Items]

Stipulation period

45 days

Xyrem® (Sodium Oxybate) Antitrust Litigation

Loss Contingencies [Line Items]

Charges related to legal matters, net

$ 4,000

$ 1,900

$ 3,000

$ 2,900

Value Drug Company v. Takeda Pharmaceuticals U.S.A., Inc.

Loss Contingencies [Line Items]

Litigation settlement amount

3,000

Number of former absent members added as plaintiffs | plaintiff

18

Length of jury trial

22 days

UFCW Local 1500 Welfare Fund v. Takeda Pharmaceuticals U.S.A., Inc. | Subsequent Event

Loss Contingencies [Line Items]

Loss contingency, deadline period for defendants to respond to complaint

45 days

Russell Thiele, et al. v. Kashiv Biosciences, LLC, et al.

Loss Contingencies [Line Items]

Litigation settlement amount

$ 1,900

Number of settlement demands | lawsuit

2

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)			1 Months Ended	12 Months Ended
	Nov. 02, 2021 USD ($)	Apr. 02, 2021 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2023 USD ($) vote shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	Jan. 11, 2021	Jan. 31, 2020
Class of Stock [Line Items]
Preferred stock, shares issued (in shares) | shares				0	0
Tax distribution				$ 56,700,000	$ 10,600,000	$ 53,500,000
Liability for tax distributions payable to Members				0	0
Kashiv Specialty Pharmaceuticals, LLC
Class of Stock [Line Items]
Voting interest acquired (percent)		98%					98%
Consideration paid in cash on hand		$ 100,100,000
Kashiv Specialty Pharmaceuticals, LLC | Sellers of KSP
Class of Stock [Line Items]
Ownership percentage by noncontrolling owners (percent)		2%
AvKare and R&S
Class of Stock [Line Items]
Voting interest acquired (percent)								65.10%
Tax distribution recorded as a reduction to redeemable non-controlling interest				14,200,000	6,900,000	$ 3,600,000
Amounts due to tax distributions related to redeemable non-controlling interests				$ 0	0
AvKare and R&S | Rondo Partners LLC
Class of Stock [Line Items]
Ownership percentage by noncontrolling owners (percent)								34.90%
Puniska Healthcare Pvt Ltd
Class of Stock [Line Items]
Voting interest acquired (percent)	74%		26%	26%
Consideration paid in cash on hand	$ 72,900,000		$ 1,700,000
Increase in redeemable non-controlling interest to redemption value					$ 900,000
Class B Common Stock
Class of Stock [Line Items]
Common stock, shares outstanding (in shares) | shares				0
Class A Common Stock
Class of Stock [Line Items]
Number of votes per share | vote				1

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	$ 183,979	$ 366,973
Other comprehensive income before reclassification	(39,681)	34,876
Reallocation of ownership interests	759	(110)
Reclassification of cash flow hedge to earnings, net of tax	(3,366)
Stockholders' equity ending balance	20,011	183,979
Foreign currency translation adjustment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	(32,382)	(18,845)
Other comprehensive income before reclassification	(433)	(13,394)
Reallocation of ownership interests	(33,257)	(143)
Reclassification of cash flow hedge to earnings, net of tax	0
Stockholders' equity ending balance	(66,072)	(32,382)
Unrealized (loss) gain on cash flow hedge, net of tax
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	42,321	(5,982)
Other comprehensive income before reclassification	(39,248)	48,270
Reallocation of ownership interests	34,016	33
Reclassification of cash flow hedge to earnings, net of tax	(3,366)
Stockholders' equity ending balance	33,723	42,321
Accumulated other comprehensive (loss) income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Stockholders' equity beginning balance	9,939	(24,827)
Stockholders' equity ending balance	$ (32,349)	$ 9,939

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions			2 Months Ended	12 Months Ended
	May 09, 2023	May 05, 2020	Apr. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, exercises in period, intrinsic value				$ 0.2
Options granted (in shares)				0	0	0
Compensation cost not yet recognized				$ 32.3
Compensation cost not yet recognized, period for recognition				1 year 6 months
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				4 years
Expiration period				10 years
MPRSUs | Granted in 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				3 years
Awards granted to executives (in shares)			2,431,521
Awards vesting, percentage				200%
Award exercisable (in shares)				4,863,042
Shares outstanding and unvested (in shares)				2,375,711
MPRSUs | Granted in 2023 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair value per share (in dollars per share)				$ 1.81
MPRSUs | Granted in 2023 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair value per share (in dollars per share)				$ 2.17
MPRSUs | Granted in 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				3 years
Awards granted to executives (in shares)					3,053,738
Awards vesting, percentage				200%
Award exercisable (in shares)				6,107,476
Estimated fair value per share (in dollars per share)				$ 6.22
Shares outstanding and unvested (in shares)				2,627,349
MPRSUs | Granted in 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				3 years
Awards granted to executives (in shares)						2,331,211
Awards vesting, percentage				200%
Award exercisable (in shares)				4,662,422
Shares outstanding and unvested (in shares)				1,940,739
MPRSUs | Granted in 2021 | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair value per share (in dollars per share)				$ 5.31
MPRSUs | Granted in 2021 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated fair value per share (in dollars per share)				$ 8.58
Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)	20,000,000	14,000,000
Shares reserved (in shares)	57,000,000
Number of shares available for grant (in shares)				26,764,218

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Options (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Number of Shares Under Option
Beginning balance (in shares)	2,648,441	3,051,500	3,811,229
Options exercised (in shares)	(163,824)	(207,452)	(342,350)
Options forfeited (in shares)	(68,252)	(195,607)	(417,379)
Ending balance (in shares)	2,416,365	2,648,441	3,051,500
Options exercisable ending balance (in shares)	2,416,365
Weighted- Average Exercise Price per Share
Beginning balance (in dollars per share)	$ 4.38	$ 4.17	$ 4.80
Options exercised (in dollars per share)	2.75	2.75	2.76
Options forfeited (in dollars per share)	2.75	2.77	11.09
Ending balance (in dollars per share)	4.54	$ 4.38	$ 4.17
Options exercisable ending balance (in dollars per share)	$ 4.54
Weighted- Average Remaining Contractual Life, Outstanding	5 years	6 years	7 years
Weighted- Average Remaining Contractual Life, Exercisable	5 years
Aggregate Intrinsic Value, Outstanding	$ 6.6	$ 0	$ 5.3
Aggregate Intrinsic Value, Exercisable	$ 6.6

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Stock Units (Details) - Restricted Stock Units - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Number of Restricted Stock Units
Non-vested beginning balance (in shares)	17,928,613	13,183,600	9,132,552
Granted (in shares)	7,519,565	10,117,037	6,870,481
Vested (in shares)	(3,888,602)	(2,697,134)	(1,906,607)
Forfeited (in shares)	(4,104,873)	(2,674,890)	(912,826)
Non-vested ending balance (in shares)	17,454,703	17,928,613	13,183,600
Weighted- Average Grant Date Fair Value
Non-vested beginning balance (in dollars per share)	$ 4.77	$ 5.25	$ 5.09
Granted (in dollars per share)	1.91	4.54	5.86
Vested (in dollars per share)	4.53	5.95	5.97
Forfeited (in dollars per share)	3.41	5.07	6.68
Non-vested ending balance (in dollars per share)	$ 3.92	$ 4.77	$ 5.25
Weighted- Average Remaining Years	1 year 2 months 12 days	1 year 3 months 18 days	1 year 4 months 24 days
Aggregate Intrinsic Value, Non-vested	$ 105.4	$ 35.7	$ 63.7

Stock-Based Compensation - Shar

Stock-Based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	$ 26,822	$ 31,847	$ 28,412
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	3,561	4,811	4,688
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	18,922	20,746	18,718
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total	$ 4,339	$ 6,290	$ 5,006

Related Party Transactions - Re

Related Party Transactions - Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Kashiv Biosciences LLC | Parking space lease, Research and development
Related Party Transaction [Line Items]
Amounts of transaction with related party	$ 100	$ 100	$ 99
Kashiv Biosciences LLC | License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Filgrastim, Selling, general and administrative
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	5,000	0
Kashiv Biosciences LLC | License and commercialization agreement - Filgrastim and Pegfilgrastim - regulatory approval milestone for Pegfilgrastim-pbbk, Intangible asset
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	15,000	0
Kashiv Biosciences LLC | Inventory Purchases Under License and Commercialization Agreement - Filgrastim and Pegfilgrastim - Inventory and Cost of Goods Sold
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	260	0
Kashiv Biosciences LLC | Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko), Cost of goods sold
Related Party Transaction [Line Items]
Amounts of transaction with related party	5,114	0	0
Kashiv Biosciences LLC | Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko), Inventory and cost of goods sold
Related Party Transaction [Line Items]
Amounts of transaction with related party	1,022	0	0
Kashiv Biosciences LLC | Development and commercialization agreement - Ganirelix Acetate and Cetrorelix Acetate, Research and development
Related Party Transaction [Line Items]
Amounts of transaction with related party	(25)	1,761	1,362
Kashiv Biosciences LLC | Transition services associated with the KSP Acquisition, Selling, general and administrative
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	255
Kashiv Biosciences LLC | Development and commercialization - consulting - various products, Research and development
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	2	628
Kashiv Biosciences LLC | Generic development supply agreement - research and development material, Research and development
Related Party Transaction [Line Items]
Amounts of transaction with related party	(2,809)	0	0
Kashiv Biosciences LLC | Generic development supply agreement - development activity deferred income, Deferred revenue
Related Party Transaction [Line Items]
Amounts of transaction with related party	(246)	0	0
Kashiv Biosciences LLC | K127 development and commercialization agreement, Research and development
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	3,000
Kashiv Biosciences LLC | Commercial product support for EluRyng and other products, Cost of goods sold and research and development
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	1,239
Kashiv Biosciences LLC | Profit sharing - various products, Cost of goods sold
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	2,680
Kashiv Biosciences LLC | Development and commercialization agreements - various products, Research and development
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	150
LAX Hotel, LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	579
LAX Hotel, LLC | Financing lease, Inventory and cost of goods sold
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	217
LAX Hotel, LLC | Interest component of financing lease, Interest expense
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	362
Kanan, LLC - operating lease
Related Party Transaction [Line Items]
Amounts of transaction with related party	2,540	2,104	2,103
Sutaria Family Realty, LLC - operating lease
Related Party Transaction [Line Items]
Amounts of transaction with related party	1,352	1,211	1,179
PharmaSophia, LLC - research and development services income
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	(45)	(329)
PharmaSophia, LLC - license and commercialization agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	1,093	0
Fosun International Limited - license and supply agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party	(80)	0	0
Fosun International Limited - API co-development agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	(200)
Alkermes
Related Party Transaction [Line Items]
Amounts of transaction with related party	15,873	2,742	11,380
Tracy Properties LLC - operating lease
Related Party Transaction [Line Items]
Amounts of transaction with related party	625	565	532
AzaTech Pharma LLC - supply agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party	8,746	4,963	5,156
AvPROP, LLC - operating lease
Related Party Transaction [Line Items]
Amounts of transaction with related party	167	178	165
Tarsadia Investments, LLC - financial consulting services
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	0	0
Avtar Investments LLC - consulting services
Related Party Transaction [Line Items]
Amounts of transaction with related party	321	216	361
TPG Operations, LLC - consulting services
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	19	249
TPG Capital BD, LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	3,000	0	0
Alkermes Plc
Related Party Transaction [Line Items]
Amounts of transaction with related party	464	235	138
R&S Solutions LLC - logistics services
Related Party Transaction [Line Items]
Amounts of transaction with related party	102	85	183
Asana Biosciences, LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party	0	(5)	(4)
Members - tax receivable agreement
Related Party Transaction [Line Items]
Amounts of transaction with related party	$ 3,126	$ 631	$ 0

Related Party Transactions - Du

Related Party Transactions - Due to or From the Company for Related Party Transactions (Details) - Related Party - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Trade accounts receivable, net	$ 955	$ 500
Accounts payable and accrued expenses	7,321	2,479
Other long-term liabilities	11,776	9,649
Sellers of AvKARE LLC and R&S - state tax indemnification
Related Party Transaction [Line Items]
Trade accounts receivable, net	0	486
Kashiv - various agreements
Related Party Transaction [Line Items]
Trade accounts receivable, net	954	12
Accounts payable and accrued expenses	3,179	110
Asana BioSciences, LLC
Related Party Transaction [Line Items]
Trade accounts receivable, net	0	2
Alkermes
Related Party Transaction [Line Items]
Trade accounts receivable, net	1	0
Apace Packaging, LLC - packaging agreement
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	1,091	756
AzaTech Pharma LLC - supply agreement
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	1,958	863
Avtar Investments LLC - consulting services
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	100	72
Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	442	442
Other long-term liabilities	8,139	5,929
Members - tax receivable agreement
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	549	201
Other long-term liabilities	3,207	430
R&S Solutions LLC - logistics services
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	0	7
Alkermes Plc
Related Party Transaction [Line Items]
Accounts payable and accrued expenses	2	28
Kashiv - contingent consideration
Related Party Transaction [Line Items]
Other long-term liabilities	$ 430	$ 3,290

Related Party Transactions - _2

Related Party Transactions - Related Party Descriptions 1 (Details) $ in Thousands		1 Months Ended			12 Months Ended
	Jan. 11, 2021 USD ($)	Aug. 31, 2022 USD ($)	Jul. 31, 2022 USD ($)	Feb. 28, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2017 USD ($) product	May 27, 2022	Apr. 02, 2021
Related Party Transaction [Line Items]
Annual lease cost					$ 26,289	$ 27,116	$ 24,371
Selling, general and administrative					$ 429,675	399,700	$ 365,504
Kashiv Bio Sciences License And Commercialization Agreement
Related Party Transaction [Line Items]
Number of products in agreement | product									2
Collaborative arrangement term									10 years
Collaborative arrangement, profit share (percent)									50%
Kashiv Bio Sciences License And Commercialization Agreement | Regulatory Approval
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount									$ 22,500
Kashiv Bio Sciences License And Commercialization Agreement | Successful Delivery Of Commercial Launch Inventory
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount									43,000
Kashiv Bio Sciences License And Commercialization Agreement | Number Of Competitors For Launch Of One Product | Maximum
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount									50,000
Kashiv Bio Sciences License And Commercialization Agreement | Achievement Of Cumulative Net Sales | Maximum
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount									67,500
Kashiv Bio Sciences License And Commercialization Agreement | Achievement Of Cumulative Net Sales | Minimum
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount									15,000
K127 | Kashiv Biosciences LLC | R&D Reimbursement | Affiliated Entity
Related Party Transaction [Line Items]
Collaborative arrangement upfront payment								$ 1,500
K127 | Regulatory Approval | Kashiv Biosciences LLC | R&D Reimbursement | Affiliated Entity
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount								$ 16,500
Kashiv Specialty Pharmaceuticals, LLC
Related Party Transaction [Line Items]
Voting interest acquired (percent)	98%										98%
Kashiv Biosciences LLC
Related Party Transaction [Line Items]
Annual lease cost	$ 100
Collaborative arrangement upfront payment									$ 183,000
Collaborative arrangement maximum milestone incurred						$ 15,000
Weighted- Average Amortization Period (in years)										8 years 3 months 18 days
Collaborative arrangement, milestone payment		$ 15,000
Kashiv Biosciences LLC | Maximum
Related Party Transaction [Line Items]
Collaborative arrangement upfront payment			$ 37,500
Filgrastim
Related Party Transaction [Line Items]
Selling, general and administrative				$ 5,000

Related Party Transactions - _3

Related Party Transactions - Related Party Descriptions 2 (Details)	1 Months Ended		12 Months Ended
	Dec. 31, 2022 USD ($) candidate	Aug. 31, 2020 USD ($) product	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2019 USD ($)	Apr. 02, 2021 USD ($)
Related Party Transaction [Line Items]
Contingent consideration (up to)	$ 15,427,000		$ 921,000	$ 15,427,000
Kashiv Specialty Pharmaceuticals, LLC
Related Party Transaction [Line Items]
Contingent consideration (up to)	3,300,000		400,000	3,300,000			$ 8,000,000
Transition Services
Related Party Transaction [Line Items]
Amounts of transaction with related party					$ 300,000
Kashiv Biosciences LLC | R&D Reimbursement | Affiliated Entity
Related Party Transaction [Line Items]
Amounts of transaction with related party	$ 2,400,000		0	0	0
Number of generic product candidates | candidate	4
Kashiv Biosciences LLC | R&D Reimbursement | Affiliated Entity | Ganirelix Acetate and Cetrorelix acetate
Related Party Transaction [Line Items]
Number of products in agreement | product		2
Collaborative arrangement upfront payment		$ 1,100,000
Kashiv Biosciences LLC | R&D Reimbursement | Affiliated Entity | Ganirelix Acetate and Cetrorelix acetate | Development Milestones
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount		2,100,000
Kashiv Biosciences LLC | R&D Reimbursement | Affiliated Entity | Ganirelix Acetate and Cetrorelix acetate | Regulatory Approval
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount		300,000
Kashiv Biosciences LLC | R&D Reimbursement | Affiliated Entity | Ganirelix Acetate and Cetrorelix acetate | Development Fees
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount		$ 2,600,000
Kashiv Biosciences LLC | R&D Reimbursement | Affiliated Entity | K127
Related Party Transaction [Line Items]
Collaborative arrangement upfront payment						$ 1,500,000
Kashiv Biosciences LLC | R&D Reimbursement | Affiliated Entity | K127 | Regulatory Approval
Related Party Transaction [Line Items]
Collaborative arrangement maximum contingent payments amount						$ 16,500,000
LAX Hotel, LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party			$ 0	$ 0	$ 579,000

Related Party Transactions - _4

Related Party Transactions - Related Party Descriptions 3 (Details) $ in Thousands		1 Months Ended		12 Months Ended
	Jun. 01, 2020 USD ($)	Oct. 31, 2022 USD ($)	Jul. 31, 2019 USD ($)	Dec. 31, 2023 USD ($) building	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) product	Aug. 11, 2023 USD ($) product	Aug. 10, 2023 product	Aug. 12, 2021 product	Jun. 06, 2019 USD ($) product
Fosun International Limited
Related Party Transaction [Line Items]
Number of products in agreement | product							10	8
First commercial sales milestone							$ 300
Pharma Sophia L L C | Affiliated Entity
Related Party Transaction [Line Items]
Ownership interest (percent)		50%		50%
Pharma Sophia L L C | Development Costs | Affiliated Entity
Related Party Transaction [Line Items]
Amounts of transaction with related party		$ 6,000			$ 1,100
Pharma Sophia L L C | Development Costs | Affiliated Entity | Minimum
Related Party Transaction [Line Items]
Trade accounts receivable, net		1,100
Pharma Sophia L L C | Development Costs | Affiliated Entity | Maximum
Related Party Transaction [Line Items]
Trade accounts receivable, net		$ 4,900
Fosun International Limited | Non-Refundable Fee, Net of Tax | Affiliated Entity
Related Party Transaction [Line Items]
Amounts of transaction with related party			$ 1,000
Fosun International Limited | Fee Due Upon First Commercial Sale Of Products | Affiliated Entity
Related Party Transaction [Line Items]
Additional amount due from related parties upon sale of each product										$ 300
Additional amount due from related parties upon sale of each product, number of products | product										8
Subsidiary of Fosun International Limited | Affiliated Entity
Related Party Transaction [Line Items]
Number of products in agreement | product									2
Subsidiary of Fosun International Limited | Non-Refundable Fee, Net of Tax | Affiliated Entity
Related Party Transaction [Line Items]
Amounts of transaction with related party						$ 200
Subsidiary of Fosun International Limited | Fee Due Upon First Commercial Sale Of Products | Affiliated Entity
Related Party Transaction [Line Items]
Additional amount due from related parties upon sale of each product						$ 100
Number of products in agreement | product						2
LAX Hotel, LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party				$ 0	$ 0	$ 579
LAX Hotel, LLC | Affiliated Entity
Related Party Transaction [Line Items]
Number of buildings | building				2
Kanan, LLC | Affiliated Entity
Related Party Transaction [Line Items]
Number of buildings | building				2
Kanan, LLC | Annual Rental Cost | Affiliated Entity
Related Party Transaction [Line Items]
Amounts of transaction with related party				$ 2,000
Industrial Real Estate Holdings NY, LLC
Related Party Transaction [Line Items]
Lease renewal term	5 years
Industrial Real Estate Holdings NY, LLC | Rent Renewal Fee
Related Party Transaction [Line Items]
Amounts of transaction with related party	$ 100
Industrial Real Estate Holdings NY, LLC | Rent Expense
Related Party Transaction [Line Items]
Amounts of transaction with related party	$ 100
Annual rent increase (percent)	3%

Related Party Transactions - _5

Related Party Transactions - Related Party Descriptions 4 (Details) - USD ($) $ in Thousands			1 Months Ended		10 Months Ended	12 Months Ended
	Nov. 07, 2023	Nov. 02, 2021	Mar. 31, 2022	Mar. 31, 2020	Nov. 06, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Percentage of tax receivable agreement paid to other holders of Amneal common units	75%				85%
Puniska Healthcare Pvt Ltd
Related Party Transaction [Line Items]
Due to sellers								$ 14,200
Consideration paid in cash on hand		$ 72,900	$ 1,700
Voting interest acquired (percent)		74%	26%			26%
TPG Capital BD, LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party						$ 3,000	$ 0	$ 0
TPG Operations, LLC
Related Party Transaction [Line Items]
Consulting agreement, term				7 months
Affiliated Entity | TPG Capital BD, LLC
Related Party Transaction [Line Items]
Amounts of transaction with related party						$ 3,000
Affiliated Entity | Sellers of AvKARE LLC and R&S - accrued interest on Sellers Notes | Rondo Partners LLC
Related Party Transaction [Line Items]
Tax indemnification amount							500
Trade accounts receivable, net							$ 500

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Contributions to defined contribution plan		$ 9,900,000	$ 9,500,000	$ 8,900,000
Deferred compensation plan, employer contributions	$ 0

Segment Information - Additiona

Segment Information - Additional Information (Details)	12 Months Ended
	Dec. 31, 2023 segment product
Segment Reporting [Abstract]
Number of reportable segments | segment	3
Number of product families | product	260

Segment Information - Schedules

Segment Information - Schedules of Segment Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Net revenue	$ 2,393,607	$ 2,212,304	$ 2,093,669
Cost of goods sold	1,573,042	1,427,596	1,324,696
Gross profit	820,565	784,708	768,973
Selling, general and administrative	429,675	399,700	365,504
Research and development	163,950	195,688	201,847
In-process research and development impairment charges	30,800	12,970	710
Intellectual property legal development expenses	3,828	4,358	7,716
Acquisition, transaction-related and integration expenses	0	709	8,055
Restructuring and other charges	1,749	1,421	1,857
Change in fair value of contingent consideration	(14,497)	731	200
Insurance recoveries for property losses and associated expenses, net		(1,911)	(5,000)
Charges related to legal matters, net	1,824	269,930	25,000
Other operating income	(1,138)	(3,960)	0
Charges for property losses and associated expenses, net			5,368
Operating income (loss)	204,374	(94,928)	152,716
Generics
Segment Reporting Information [Line Items]
Net revenue	1,471,401	1,432,073	1,366,338
Specialty
Segment Reporting Information [Line Items]
Net revenue	390,457	374,121	378,319
AvKARE
Segment Reporting Information [Line Items]
Net revenue	531,749	406,110	349,012
Operating Segments | Generics
Segment Reporting Information [Line Items]
Net revenue	1,471,401	1,432,073	1,366,338
Cost of goods sold	913,869	896,031	848,260
Gross profit	557,532	536,042	518,078
Selling, general and administrative	119,912	109,781	64,500
Research and development	132,233	167,509	158,365
In-process research and development impairment charges	26,500	12,970	710
Intellectual property legal development expenses	3,708	4,251	7,562
Acquisition, transaction-related and integration expenses		25	0
Restructuring and other charges	211	821	80
Change in fair value of contingent consideration	0	0	0
Insurance recoveries for property losses and associated expenses, net		(1,911)
Charges related to legal matters, net	(64)	22,400	0
Other operating income	(1,138)	(3,960)
Charges for property losses and associated expenses, net			5,368
Operating income (loss)	276,170	224,156	281,493
Operating Segments | Specialty
Segment Reporting Information [Line Items]
Net revenue	390,457	374,121	378,319
Cost of goods sold	214,277	182,432	193,562
Gross profit	176,180	191,689	184,757
Selling, general and administrative	88,137	90,031	84,481
Research and development	31,717	28,179	43,482
In-process research and development impairment charges	4,300	0	0
Intellectual property legal development expenses	120	107	154
Acquisition, transaction-related and integration expenses		49	16
Restructuring and other charges	1,105	0	0
Change in fair value of contingent consideration	(14,497)	731	200
Insurance recoveries for property losses and associated expenses, net		0
Charges related to legal matters, net	0	0	0
Other operating income	0	0
Charges for property losses and associated expenses, net			0
Operating income (loss)	65,298	72,592	56,424
Operating Segments | AvKARE
Segment Reporting Information [Line Items]
Net revenue	531,749	406,110	349,012
Cost of goods sold	444,896	349,133	282,874
Gross profit	86,853	56,977	66,138
Selling, general and administrative	55,341	53,659	57,918
Research and development	0	0	0
In-process research and development impairment charges	0	0	0
Intellectual property legal development expenses	0	0	0
Acquisition, transaction-related and integration expenses		0	1,422
Restructuring and other charges	0	0	0
Change in fair value of contingent consideration	0	0	0
Insurance recoveries for property losses and associated expenses, net		0
Charges related to legal matters, net	0	0	0
Other operating income	0	0
Charges for property losses and associated expenses, net			0
Operating income (loss)	31,512	3,318	6,798
Corporate and Other
Segment Reporting Information [Line Items]
Net revenue	0	0	0
Cost of goods sold	0	0	0
Gross profit	0	0	0
Selling, general and administrative	166,285	146,229	158,605
Research and development	0	0	0
In-process research and development impairment charges	0	0	0
Intellectual property legal development expenses	0	0	0
Acquisition, transaction-related and integration expenses		635	6,617
Restructuring and other charges	433	600	1,777
Change in fair value of contingent consideration	0	0	0
Insurance recoveries for property losses and associated expenses, net		0
Charges related to legal matters, net	1,888	247,530	25,000
Other operating income	0	0
Charges for property losses and associated expenses, net			0
Operating income (loss)	$ (168,606)	$ (394,994)	$ (191,999)

Segment Information - Schedule

Segment Information - Schedule of Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 550,137	$ 589,360
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	316,947	354,504
India
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	179,401	180,325
Ireland
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 53,789	$ 54,531

(Insurance Recoveries) Charge_3

(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net - Narrative (Details) $ in Thousands		12 Months Ended
	Sep. 01, 2021 facility	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Unusual or Infrequent Items, or Both [Abstract]
Number of facilities damaged | facility	2
Total property losses and associated expenses		$ 0	$ 0	$ 10,368
Charges (insurance recoveries) for property losses and associated expenses			$ 1,911	$ 5,000

(Insurance Recoveries) Charge_4

(Insurance Recoveries) Charges for Property Losses and Associated Expenses, Net - Charges (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Unusual or Infrequent Item, or Both [Line Items]
Total property losses and associated expenses	$ 0	$ 0	$ 10,368
Less: Insurance recoveries received	0	(1,911)	(5,000)
(Insurance recoveries) charges for property losses and associated expenses, net	0	(1,911)	5,368
Impairment of equipment
Unusual or Infrequent Item, or Both [Line Items]
Total property losses and associated expenses	0	0	4,202
Impairment of inventory
Unusual or Infrequent Item, or Both [Line Items]
Total property losses and associated expenses	0	0	950
Repairs and maintenance expenses
Unusual or Infrequent Item, or Both [Line Items]
Total property losses and associated expenses	0	0	3,716
Salaries and benefits
Unusual or Infrequent Item, or Both [Line Items]
Total property losses and associated expenses	$ 0	$ 0	$ 1,500

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event € in Millions, $ in Millions	Feb. 26, 2024 USD ($)	Feb. 23, 2024 EUR (€)	Jan. 24, 2024
Knight Therapeutics International S.A. License Agreement
Subsequent Event [Line Items]
Collaborative arrangement term			15 years
Collaborative arrangement renew for successive term			2 years
Collaborative arrangement, renewal decline notice period			1 year
Collaborative arrangement, nonrefundable license fee received, amount | $	$ 1
License supply agreement, potential future milestone payments | $	$ 10.5
License Agreement with Zambon Biotech
Subsequent Event [Line Items]
Collaborative arrangement term		15 years
Collaborative arrangement renew for successive term		2 years
Collaborative arrangement, renewal decline notice period		1 year
Collaborative arrangement, nonrefundable license fee received, amount | €		€ 5
License supply agreement, potential future milestone payments | €		€ 71.5